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Systemic lupus erythematosus and nephritis Systemic lupus
erythematosus (SLE) is an autoimmune disease in which
many organs can be involved (1). The disease mainly affects
young women. Both the disease itself and the installed the-
rapy have an enormous impact on the patient's daily life (2).
Involvement of the kidneys (lupus nephritis) occurs fre-
quently and can range from mild to severe (3). Patients with
the proliferative forms of lupus nephritis are at highest risk
of developing end-stage renal disease (4). Therefore, these
patients should be treated adequately. Since the publication
of some keynote studies, performed at the National
Institutes of Health (NIH), the treatment of proliferative
lupus nephritis changed from therapy with glucocorticoids
alone to a combination of corticosteroids and cytotoxic
immunosuppressive drugs (5). The choice of immunosup-
pressive drugs, however, is still under research.
Pathogenesis of lupus nephritis Nucleosomes are thought to
play a key role in the pathogenesis of lupus nephritis (6). For a
long time autoantibodies against anti-double stranded (ds) DNA
have been regarded as the serological hallmark of the disease.
However, dsDNA itself is not immunogenic, while nucleosomes
are. Nucleosomes are formed during apoptosis by the cleavage
of chromatin. Due to a disturbed removal of apoptotic cells,
(modified) nucleosomes are released and can induce an autoim-
mune response (7). Indeed, nucleosomes and anti-nucleosome
autoantibodies can be found in the circulation of SLE patients
(8). Complexes of anti-chromatin autoantibodies/nucleosome
antigens can bind to the glomerular basement membrane
(GBM) (9) and were shown to be deposited in the GBM in both
murine (10) and human (11) lupus nephritis. Since basement
membranes are present throughout the body, the deposition
of these complexes probably occurs at more sites. Apart from
producing nucleosome-specific autoantibodies, the identified
nucleosome-specific T-helper cells can also induce anti-dsDNA
and anti-histone autoantibodies. A rise in anti-dsDNA and anti-
nucleosome autoantibody titres was shown to precede renal
flares in mice (12) and to be associated with disease activity in
humans (13,14). Whereas in daily clinical practice anti-dsDNA
autoantibodies are measured regularly, assessment of other
autoantibodies are mainly studied in research settings (15).
Whether or not these assessments can also be used for diagno-
sing the disease and for monitoring the effects of therapy is 
largely unknown.
Classification and histopathology of lupus nephritis The classi-
fication systems for lupus nephritis have changed over the
years. The most recent versions are the WHO1995 and the
ISN/RPS2003 classification systems (3,16). In Table 1 these
classification systems are summarised. The proliferative
forms of lupus nephritis are divided in class III (focal) and
class IV (diffuse). In the ISN/RPS2003 classification system
class IV is subdivided into segmental and global proliferative
lupus nephritis, with further subclasses based on the presence
of active or chronic lesions or a combination of both active
and chronic lesions. The division for renal biopsies classi-
fied as class III is limited to active, chronic or a combination
of these. The findings in renal biopsies taken from patients
with lupus nephritis are diverse. Some examples of light
microscopic abnormalities found in renal biopsies from
patients with proliferative lupus nephritis are given in
Figure 1. Prognostic histopathological factors have been
searched for for a long time. Moreover, repeat biopsies
might be of (more) prognostic value (17).
Treatment options for proliferative lupus nephritis Until the
seventies the only treatment option for patients with proli-
ferative lupus nephritis was therapy with corticosteroids. In
1984 a metaanalysis by Felson et al. showed that patients
with diffuse proliferative lupus nephritis (class IV) who
were treated with a combination of corticosteroids and
immunosuppressive drugs had a significantly better renal
survival than those who were treated with corticosteroids
only (18). It was also shown that the progression of chronic,
irreversible lesions was better delayed by combination treat-
ment than by corticosteroids alone (19). Since the studies
in which comparisons of combination regimens with corti-
costeroids alone were performed in rather small groups of
patients, the immunosuppressive drug of choice for
patients with proliferative lupus nephritis is not known. 
In the early studies published by the NIH (5,20) it was 
suggested that the treatment with intravenous cyclophos-
phamide in combination with corticosteroids was most
effective in reducing the number of patients reaching end-
stage renal disease. However, the other combination regi-
mens (e.g. azathioprine plus corticosteroids) were statisti-
cally not inferior to intravenous cyclophosphamide. But,
due to the enormous worldwide impact of these studies,
patients with proliferative lupus nephritis have been treated
with pulses of cyclophosphamide ever since. Cyclophos-
phamide has many side effects, especially a chance of prema-
ture menopause and infertility. Therefore, alternatives for
cyclophosphamide therapy are warranted.
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Outline of this thesis  Most of the studies described in this
thesis are based on the initiatives of the Dutch Working
Party on SLE to start a multicentre randomised controlled
trial in patients with proliferative lupus nephritis (21). In
this 'first Dutch lupus nephritis study' a regimen consisting
of intravenous pulses of cyclophosphamide plus prednisone
was compared with a regimen consisting of intravenous
methylprednisolone, prednisone and azathioprine, a strate-
gy that was extensively studied in a Dutch cohort (22). The
study aimed at a long-term follow-up of at least five years,
and the protocol included skin biopsies at study entry and
a repeat kidney biopsy after two years of treatment.
The major objective of the study was to find an alternative treat-
ment for cyclophosphamide pulse therapy. The alternative
regimen should have a comparable effect on renal function,
but less side effects. In this thesis the clinical outcome, and
the prognostic value of kidney biopsies taken at study entry
and after two years, are described. Furthermore, we evaluated
the role of nucleosomes and anti-nucleosome autoantibodies 
in both plasma and skin of the patients who entered the study.
-Part I Pathogenesis
First, an overview of the hypothesis of disturbed apoptosis
and inefficient removal of apoptotic cells, which is thought
to play a role in the development of lupus nephritis, is
given (Chapter II).
To analyse whether anti-chromatin/nucleosome complexes
are deposited in the basement membranes of the skin in
lupus nephritis, we studied skin biopsies from patients with
active lupus nephritis, and compared these with skin biop-
sies from patients with inactive SLE, diabetes patients and
patients with parapemphigus (Chapter III).
Furthermore, to study the impact of both treatment regi-
mens of the first Dutch lupus nephritis study, we measured
the reactivity of several autoantibodies in plasma during
the first year of treatment (Chapter IV).
-Part II Clinical aspects
A total of 87 patients were included in the first Dutch lupus
nephritis study between September 1995 and September
Introduction
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Figure 1 Several examples of glomerular changes present in renal biopsies from patients with proliferative lupus nephritis.
(A) endocapillary and mesangial proliferation with hyaline thrombi, (B) extensive mesangial proliferation, (C) segmental necro-
tising lesion with extracapillary proliferation, and (D) circumferential recent extracapillary proliferation. (Photographs by cour-
tesy of dr E.J. Steenbergen, Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen)
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2001. The analyses of the effects on disease course of the two
treatment arms, after a minimum follow-up of three years,
are discussed in Chapter V. To be able to evaluate the effect of
treatment, not only on laboratory parameters, but also on the
quality of life, a disease-specific questionnaire (the SLE
Symptom Checklist, SSC) was developed. Its development and
validation are described in Chapter VI, and the results of the
clinical studies with this questionnaire and other quality of
life instruments are presented in Chapter VII. Most studies in
patients with proliferative lupus nephritis focus on induction
treatment. The question whether or not it is possible to with-
draw therapy after this period is discussed in Chapter VIII. 
-Part III Renal histopathology
A total of 128 renal biopsies were performed in the patients
enrolled in the first Dutch lupus nephritis study, among
which 39 protocolised repeat biopsies after two years of the-
rapy. Five nephropathologists scored the biopsies according
to a newly developed scoring form, and they classified the
biopsies. The analyses on inter- and intraobserver agree-
ment and the comparison between the two classification
systems for lupus nephritis, namely the WHO1995 and
ISN/RPS2003 classification, are described in Chapter IX.
Furthermore, the effect of the two treatment regimens was
studied in the protocolised repeat renal biopsies. The
results are presented in Chapter X.
-Part IV Considerations
In Chapter XI the results of the various studies are summari-
sed and proposals for future studies are given.
Acknowledgements
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Table 1 WHO1995 and ISN/RPS2003 classification systems for lupus nephritis.
WHO1995 classification ISN/RPS2003 classification
I normal glomeruli I minimal mesangial LN
a) nil (by all techniques) normal glomeruli by LM, but mesangial immune deposits by IF
b) normal by LM, but deposits by EM or IF
II pure mesangial alterations (mesangiopathy) II mesangial proliferative lupus nephritis
a) mesangial widening and/or mild hypercellularity (+) - purely mesangial hypercellularity of any degree or mesangial matrix
b) moderate hypercellularity (++) expansion by LM, with mesangial immune deposits
- few isolated subepithelial or subendothelial deposits may be visible
by IF or EM, but not by LM
III focal segmental GN III focal LN
(associated with mild or moderate mesangial alterations) active or inactive focal, segmental or global endo- or extracapillary GN
a) with 'active' necrotising lesions involving <50% of all glomeruli, typically with focal subendothelial 
b) with 'active' and sclerosing lesions immune deposits, with or without mesangial alterations
c) with sclerosing lesions A active lesions
A/C active and chronic lesions
C chronic inactive lesions with glomerular scars
IV diffuse GN IV diffuse LN
(severe mesangial, endocapillary, or mesangio-capillary proliferation active or inactive diffuse, segmental or global endo- or extracapillary GN
and/or extensive subendothelial deposits) involving ≥50% of all glomeruli, typically with diffuse subendothelial
a) without segmental lesions immune deposits, with or without mesangial alterations
b) with 'active' necrotising lesions Divided into segmental (IV-S) and global (IV-G), when ≥50% of the 
c) with 'active' and sclerosing lesions involved glomeruli have segmental lesions, or global lesions, 
d) with sclerosing lesions respectively. Segmental: a glomerular lesion that involves less than
half of the glomerular tuft.
A active lesions
A/C active and chronic lesions
C chronic inactive lesions with glomerular scars
V diffuse membranous GN V membranous LN
a) pure membranous GN global or segmental subepithelial immune deposits or their 
b) associated with lesions of category II (a or b) morphologic sequelae by LM and by IF or EM, with or without
mesangial alterations
- if in combination with class III or IV both will be diagnosed
- may show advanced sclerosis
VI advanced sclerosing glomerulonephritis VI advanced sclerotic LN
≥90% of glomeruli sclerosed without residual activity
LM: light microscopy, EM: electron microscopy, IF: immunofluorescence microscopy, LN: lupus nephritis, GN: glomerulonephritis
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deling van proliferatieve glomerulonefritis bij SLE-patiën-
ten: een nationale, prospectieve, gerandomiseerde studie.';
- The Dutch Arthritis Association, grant 735 'De behandeling
van proliferatieve glomerulonefritis bij SLE-patiënten: een
nationale, prospectieve, gerandomiseerde studie.';
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- The Dutch Kidney Foundation, grant C99.1826 'Diagnostic
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nucleosome-specific autoantibodies in SLE.';
- The Dutch Kidney Foundation, grant C02.2023 'Stan-
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ratieve lupusnefritis: inter- en intraobservervariabiliteit,
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The autoimmune response in systemic lupus erythemato-
sus (SLE) is autoantigen-driven and T cell-dependent. The
nucleosome, the exclusive product of apoptosis, has been
proposed as major autoantigen (1,2). Defective removal of
apoptotic cells leads to the release of (modified) nucleoso-
mes, which can induce an autoimmune response. Indeed,
nucleosomes can be found in the circulation of SLE patients
(3,4). Moreover, histone-specific and nucleosome-specific T
cells were identified (5-7). Anti-chromatin autoantibodies
can be divided into antibodies that recognise a component
of the nucleosome, i.e. DNA or histones, and autoantibodies
that preferentially recognise the intact nucleosome (nucle-
osome-specific antibodies). Anti-nucleosome antibodies are
found in most SLE patients (40-90%), especially in patients
with lupus nephritis (LN) (8). Anti-nucleosome and also anti-
dsDNA reactivity have been associated with disease activity
and flares of LN (9-15). 12-40% of SLE patients show anti-
nucleosome reactivity without anti-dsDNA reactivity, indi-
cating the presence of nucleosome-specific antibodies
(13,14,16,17). Anti-nucleosome autoantibodies are rather
specific for SLE, although some studies also report anti-
nucleosome autoantibodies in patients with mixed connec-
tive tissue disease and scleroderma (10,18). However, the
nucleosome preparations used in these studies were proba-
bly contaminated with topoisomerase I, which might
explain the findings (19). Anti-histone autoantibodies are
less frequently found in SLE patients. Their clinical relevan-
ce is still not clear (20). The binding of anti-chromatin/
nucleosome complexes to the glomerular basement mem-
brane (GBM) is considered a major event in the initiation of
LN (21). These complexes can bind to negatively charged
heparan sulfate in the GBM via the positively charged histo-
ne tails, especially when anti-dsDNA or nucleosome-specific
autoantibodies mask the negative charges on the nucleo-
somes (22).
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(464), Radboud University Nijmegen Medical Centre, PO Box 9101, 6500
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A prospective study of anti-chromatin and 
anti-C1q autoantibodies and MBL concentrations
in patients with proliferative lupus nephritis
treated with cyclophosphamide pulses or
azathioprine/methylprednisolone
Cecile Grootscholten*, Jürgen W.C. Dieker*, Fabian D. McGrath, Anja Roos, Ronald H.W.M. Derksen, Johan van der Vlag,
Mohamed R. Daha and Jo H.M. Berden, on behalf of the Dutch Working Party on SLE
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key words: lupus nephritis, autoantibodies, nucleosome, C1q, mannose binding lectin
Objective. To study the prevalence and course of anti-chromatin (anti-nucleosome, anti-dsDNA and anti-histone)
autoantibodies and anti-C1q autoantibodies in patients with proliferative lupus nephritis (LN), treated in a rando-
mised controlled trial, with cyclophosphamide, or azathioprine with methylprednisolone. And, to investigate the
relationship between mannose-binding lectin (MBL) concentrations and disease activity.
Methods. Autoantibody levels and MBL concentrations were measured in 52 patients with proliferative LN, during
their first year of treatment. Values were compared with each other and between both treatment arms. Moreover,
associations with entering remission and experiencing renal relapses were studied.
Results. At study entry, prevalences for anti-nucleosome, anti-dsDNA, anti-histone and anti-C1q autoantibodies were
81%, 96%, 23% and 65%, respectively. Anti-chromatin autoantibodies correlated with each other, but not with anti-
C1q levels. If patients were divided for their autoantibody titre at start of treatment above or below the median, the
only significant differences were higher SLEDAI with higher anti-nucleosome, and higher creatinine and lower fre-
quency of class III LN with higher anti-C1q autoantibodies. During the first year a comparable rapid decline in the
levels of anti-nucleosome, anti-dsDNA and anti-C1q autoantibodies was seen in both treatment arms. Anti-histone
autoantibodies did not change. Renal flares were not preceded by rises in autoantibody titres. Low MBL levels were
not associated with higher autoantibody titres, and MBL levels were not influenced by treatment.
Conclusion. These results indicate that measurement of anti-chromatin and anti-C1q autoantibodies is useful for 
diagnosing LN, but not for monitoring disease course.
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Deficiency of components of the classical pathway, like C1q,
is associated with the development of anti-nuclear autoimmu-
nity and glomerulonephritis in mice (23,24). In patients defi-
cient for C1q, lupus-like disorders are commonly found and
about 30% develop glomerulonephritis (25,26). Paradoxically,
anti-C1q autoantibodies are also frequently found (30-45%) in
SLE patients (27), especially in LN. They prognosticate renal
flares (28,29). Binding of anti-C1q/C1q complexes can induce
glomerulonephritis in mice, if IgG is present in the GBM (30).
Moreover, anti-C1q autoantibodies might interfere with the
function of C1q and thereby amplify disease. C1q is also invol-
ved in removing apoptotic cells. Mice with a targeted disrup-
tion of C1q were shown to defectively remove apoptotic cells,
and develop anti-nucleosome reactivity and lupus-like glome-
rulonephritis (23). Reduced serum concentrations of manno-
se-binding lectin (MBL) are associated with susceptibility for
SLE (31). There is contradictory evidence that deficiency of
MBL correlates with disease activity (31,32).
Cyclophosphamide pulses combined with corticosteroids
has been the standard treatment of proliferative LN for
many years. In a search for an effective therapy, with a redu-
ced risk of infertility, in 1995 a randomised controlled trial
comparing cyclophosphamide pulses with azathioprine/
methylprednisolone started. Recently the first results were
published (33). The aim of the current study was to assess
the levels of anti-nucleosome, anti-dsDNA, anti-histone and
anti-C1q autoantibodies in the included patients during
their first year of treatment. Autoantibody titres were ana-
lysed for their association with several serological, clinical,
renal, biopsy and outcome parameters. In addition, MBL
concentrations were studied.
Methods
Patients Eighty-seven patients with biopsy-proven proliferati-
ve LN were enrolled in the first Dutch Lupus Nephritis Study.
Patients in the cyclophosphamide arm (CY) were given thir-
teen pulses of cyclophosphamide (750 mg/m2) during 24
months, combined with oral prednisone. The patients in the
azathioprine arm (AZA) started with azathioprine (2 mg/
kg/day) and oral prednisone at day one, combined with a
total of nine methylprednisolone pulses. Levels of comple-
ment components C3 and C4, and anti-dsDNA titres (Farr
assay and/or Crithidia test (34)) were measured locally.
Disease activity was measured with the SLE Disease Activity
Index (SLEDAI) (35). Plasma samples were collected and stored
at -80°C until use. Plasma samples at study entry and after 4,
12, 26 and 52 weeks were available from 52 patients.
Definitions Renal relapse: doubling of the lowest serum cre-
atinine so far and/or development of either a nephrotic syn-
drome, while the lowest protein excretion so far had been
≤ 2.0 g/day repeatedly, or proteinuria >1.5 g/day without
other causes in a previously non-proteinuric patient.
Complete remission: serum creatinine <130% of lowest
serum creatinine since study entry, proteinuria <0.5 g/day,
and <10 erythrocytes/hpf.
Autoantibody flare: increase of anti-nucleosome and/or anti-
dsDNA titres of more than 100%.
ELISAs All ELISA tests were performed in a central laborato-
ry; 96-well Maxisorb® plates (Nunc, Roskilde, DK) were used.
-Anti-dsDNA, anti-histone and anti-nucleosome
The anti-dsDNA, anti-histone and anti-nucleosome ELISAs
were performed as described before (36). For the anti-nucleo-
some ELISA H1-stripped chromatin (kindly provided by dr. R.
Burlingame, INOVA Diagnostics Inc., San Diego, USA), diluted
in PBS (5 µg/ml), was used. In the DNA ELISA calf thymus
dsDNA (Roche, Almere, The Netherlands) was coated over-
night at a concentration of 20 µg/ml in PBS. In the histone
ELISA calf thymus histones (Roche) were coated overnight
(concentration 2.5 mg/ml) in 0.1 M glycine buffer at pH 9. The
titre (in arbitrary units (AU)) was defined as the dilution of
the patients' plasma yielding an absorbance of 0.5. The day-
to-day variation of the assay was corrected by using the titre
of a standardised positive plasma in each measurement. For
the analyses the cut-off value was set at the value of the nega-
tive control plasmas plus three times the standard deviation.
-Anti-C1q
The anti-C1q ELISA was performed as described before (37).
A sample positive for anti-C1q was used as a calibration
standard in each assay, plate reactivity was assessed as rela-
tive to the standard serum. Values >75 AU, compared with
the standard serum, were regarded positive.
-MBL concentrations
MBL concentrations were measured as described before (38).
A calibration line was produced using pooled human serum
from healthy donors with a known concentration of MBL.
Statistical analysis Statistical analysis was performed using
SPSS 12.0.1 (Chicago, IL, USA). Clinical events (complete
remission, occurrence of relapse and occurrence of doub-
ling of serum creatinine) were analysed with Kaplan Meier
survival curves and log-rank statistics. Relative risk ratios
(RR) and 95% confidence intervals (95%CI) were calculated
for these events using Cox regression analysis. Correlations
between the autoantibody levels were studied with non-
parametric Spearman's rank correlation. Mann-Whitney U
or Chi square tests were used to analyse differences be-
tween groups. Differences between the two treatment arms
and the course of laboratory parameters and SLEDAI were
studied with repeated measurements mixed model tests. A
p value <0.05 was regarded statistically significant, except
for correlation coefficients, where a p value of <0.01 was
used, to correct for the effect of multiple comparisons
(according to Bonferroni).
Results
Disease course The achievement of complete remission did
not differ between the two treatment groups. Also, after 
a median follow-up of 5.7 years (interquartile range (IQR)
4.1-7.2 years), reaching the study endpoint (doubling of
serum creatinine) did not differ between AZA and CY.
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However, more relapses occurred in the AZA group (Figure 1).
More details on clinical data were published before (33).
Characteristics of study patients There were no differences
in baseline characteristics between the subgroup of
patients for whom five consecutive plasma samples were
available (n=52) and those for whom this was not the case
(n=35). Subnormal levels of complement C3 and C4 were
present in most patients (92% and 69%, respectively). The
median C3 values were 0.50 g/l (IQR 0.37-0.64), and for C4
these were 0.10 g/l (IQR 0.08-0.15)). The occurrence of renal
relapses and reaching complete remission did not differ 
between the two groups.
Autoantibodies
-At study entry
At study entry, anti-nucleosome reactivity above the cut-off
value (18.5 AU) was present in 81% of the patients, while anti-
dsDNA and anti-histone reactivity above cut-off values (26.5
AU and 17.5 AU) were found in 96% and 23% of the patients,
respectively (no differences between CY and AZA). Anti-C1q
reactivity (above 75 AU) was present in 65% of all patients.
The median anti-nucleosome titre was 200 AU (IQR 41-600).
For anti-dsDNA, anti-histone and anti-C1q the median titres
were 145 (IQR 72-400), 9 (IQR 8-16) and 123 AU (IQR 60-188),
respectively. There were no differences between CY and AZA.
-During first year of treatment
Although the anti-nucleosome and anti-dsDNA reactivity
declined during the first year of treatment (Figure 2A/B),
reactivity at 52 weeks stayed above the cut-off value in most
patients. There were no significant differences between
both treatment groups. Anti-histone reactivity was initially
low and did not change during treatment (Figure 2C). Anti-
C1q reactivity decreased significantly and became negative
within 12 weeks, without differences between CY and AZA
(Figure 2D). To analyse whether the two treatment regimens
had a different effect on the kinetics of the autoantibody
titres, we compared the decrease of anti-nucleosome anti-
body titres during the first 4 weeks of treatment in both
arms (Figure 3). No significant difference in the rate of decline
was found. Comparable results were found for the decline
of anti-dsDNA and anti-C1q titres (data not shown).
Correlations Since no significant differences were observed
in titres and time course of the autoantibodies between the
treatment arms, all patients were analysed as one group. At
study entry, a significant positive correlation between anti-
nucleosome reactivity and anti-dsDNA reactivity was seen
(r=0.629, p<0.001 Table 1). There was also a significant cor-
relation of anti-nucleosome and anti-dsDNA reactivity with
anti-histone reactivity (r=0.583, p<0.001, and r=0.495,
p<0.001, respectively). This underlines the fact that chro-
matin is the driving autoantigen in the formation of these
autoantibodies. In contrast, neither anti-C1q reactivity, nor
MBL concentration showed a significant correlation with
any of the anti-chromatin autoantibodies. It has been sug-
gested that patients positive for anti-C1q antibodies more
frequently have antiphospholipid (aPL) antibodies (32). In
our patients 91% positive for aPL antibodies also had anti-
C1q antibodies, while 43% of the anti-C1q positive patients
had aPL antibodies (p=0.06).
Correlation with serological markers and disease activity
Since the Farr assay is often used as the standard assay to
determine anti-dsDNA autoantibodies in lupus patients, a
comparison was made of the autoantibody titres as measured
by ELISA with the results of the locally performed Farr assays.
Whereas the Farr assay showed a strong correlation with
autoantibody levels obtained in the anti-dsDNA ELISA
(p<0.001)  and with anti-nucleosome autoantibodies
(p<0.001), no correlation with anti-histone and anti-C1q
autoantibodies was observed (Table 1).
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Figure 1 Kaplan-Meier estimates of the proportion of
patients with relapse after a median follow-up of 5.7 years.
All 87 patients who were included in the first Dutch Lupus
Nephritis Study were used for this analysis.
Table 1 Correlation coefficients at study entry in 52 patients
with proliferative lupus nephritis.
anti-nucleosome anti-dsDNA anti-histone anti-C1q
anti-nucleosome 0.629* 0.583* 0.110
anti-dsDNA 0.495* 0.270
anti-histone 0.115
Farr 0.491* 0.531* 0.361 0.203
C3 -0.241 -0.418* -0.231 -0.180
C4 -0.057 -0.227 -0.088 0.023
MBL 0.177 0.240 0.287 0.074
SLEDAI 0.288 0.420* 0.358 0.159
C3: complement C3, C4: complement C4, MBL: mannose-binding lectin, 
SLEDAI: SLE disease activity index; *p<0.01 
No correlation was found for C4 levels with any of the auto-
antibodies, while C3 showed a significant negative correla-
tion with anti-dsDNA autoantibody levels. Finally, the SLEDAI
correlated with anti-dsDNA reactivity only. An autoantibody
flare was present in 8 out of 52 patients. Three of these
patients experienced a renal relapse at some point during
follow-up, varying from 24 to 120 weeks after rise of the
autoantibody titre(s). Notably, although these patients were
treated with reinduction therapy, all three had a second
renal relapse. The other patients with a doubling of autoan-
tibody titre(s) did not have a renal relapse. Three of the
eight patients doubled their titres after having reached CR,
while one patient even fulfilled the criteria for CR and auto-
antibody flare at the same time.
Association with clinical and histological parameters To ana-
lyse the relation between autoantibody titres and various disease
parameters the patients were divided in high and low activity
(above and below the median) for each autoantibody specificity
(Table 2). No significant differences existed between patients
with high or low anti-chromatin antibody levels for GFR,
serum creatinine or proteinuria. The only finding was that
patients with high anti-C1q levels had a higher serum creati-
nine. By comparing patients positive for one autoantibody
specificity (either anti-nucleosome or anti-dsDNA) with those
positive for both specificities, no differences in clinical para-
meters were found (data not shown). The course of disease 
in patients with high versus low autoantibody titres at study
entry did not differ with regard to the occurrence of renal
relapses, or complete remission, except for patients with ini-
tial high anti-dsDNA reactivity, who attained a complete
remission more often (p=0.046). For all autoantibody specifici-
ties, there were no differences in time to reach complete
remission (data not shown). Comparing the patients with 
a first episode of lupus nephritis with those who had been 
diagnosed with lupus nephritis in the past, no significant dif-
ferences in antibody levels were found (data not shown).
Patients with high anti-chromatin titres had a significantly
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Figure 2 Autoantibody reactivity in the two treatment arms during the first year of treatment. (A) anti-nucleosome, (B) anti-
dsDNA, (C) anti-histone, and (D) anti-C1q reactivity. Results are expressed as medians, AU: arbitrary units. The cut-off value for
the different assays is indicated by a dashed line. CY: treatment with cyclophosphamide pulses, AZA: treatment with azathio-
prine/methylprednisolone.
higher SLEDAI. This was not observed for anti-C1q (see Table
2). Analysis of the renal biopsies showed no differences for
the activity or chronicity indices for LN (39) between
patients with high or low reactivity for any of the autoanti-
body specificities. Since both patients with LN WHO class III
and IV were included in the study, we analysed whether
class III was associated with a certain autoantibody specifici-
ty. This was not the case for the anti-chromatin antibodies,
but all patients with class III (n=5) had low anti-C1q titres
(p=0.028). It should be noted that at inclusion all patients
with LN class III were obliged to have renal function distur-
bances, whereas patients with LN class IV were not.
MBL If patients were categorised for high or low MBL concen-
trations (higher or lower than 300 ng/ml), no differences were
found for renal, serological, or histological parameters (data
not shown). Furthermore, the disease course was not different
for these groups. In addition, the frequency of anti-C1q anti-
bodies in patients with low MBL concentrations was not hig-
her, as was reported before (32). In contrast to complement C3
levels, MBL concentrations did not change during treatment
(initial 355 versus 365 ng/ml after 6 months) (Figure 4).
Discussion
In our patients with proliferative lupus nephritis, included
in a randomised controlled trial, a high prevalence of anti-
dsDNA (96%) and anti-nucleosome (81%) autoantibodies was
found, higher than is found on average in unselected SLE
patients. A possible explanation is that the presence of
these autoantibodies correlates with the occurrence of LN
(8,17). Remarkably, in our cohort the prevalence of anti-
dsDNA autoantibodies was higher than the presence of
anti-nucleosome autoantibodies, while in the majority of
studies this was the other way around. The latter can be
expected since all anti-chromatin antibodies (nucleosome-
specific, anti-dsDNA, anti-histone) can bind to the nucleo-
some. The higher prevalence of anti-dsDNA antibodies
found in our patient group, might be due to the use of an
anti-dsDNA ELISA, which also detects low avidity antibo-
dies in contrast to the Farr assay (40). Indeed, the Farr assay
was positive in 81% of our patients. Based on our results we
cannot support the anticipated superiority of anti-nucleo-
some testing. A correlation between anti-dsDNA and anti-
nucleosome reactivity was found, comparable with values
found in unselected SLE patients (11-13,41,42). The preva-
lence of anti-histone autoantibodies was low (23%), with
also low reactivity. Indeed, anti-histone autoantibodies are
more often found in drug-induced lupus (20), and do not
correlate with renal disease (8). Studies in mice showed
that complexes of monoclonal anti-histone autoantibo-
dies/nucleosomes bound less efficiently to the GBM, which
might be due to masking of the positive histone charges
involved in the GBM binding (22). Positive anti-C1q reacti-
vity was present in 65%, comparable with reported preva-
lences in other patients with LN ((27): 50-83% (28): 74%). At
study entry we found no correlation between anti-chroma-
tin and anti-C1q autoantibodies, while anti-chromatin anti-
bodies correlated with each other. This corresponds with
the fact that the inducing autoantigen is different: nucleo-
some versus C1q. No differences between the two treat-
ment regimens on the course of autoantibody titres during
the first year of treatment were found. In both groups, the
autoantibody titres declined very fast. No differences were
found between AZA and CY.
Anti-nucleosome and anti-dsDNA autoantibodies have been
associated with disease activity and renal function in SLE
patients (8,11). Anti-nucleosome, anti-dsDNA and anti-histone
autoantibodies showed a positive correlation with the SLEDAI,
comparable with the literature (11,13,14). Remarkable was
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Figure 3 Decrease of anti-nucleosome autoantibody titres in patients treated with (A) cyclophosphamide pulses (CY) and (B)
azathioprine/methylprednisolone (AZA), during the first 4 weeks of treatment. No statistically significant differences in the rate
of decline of autoantibody titres were found between the two treatment groups. AU=arbitrary units.
the absence of such a correlation with anti-C1q reactivity.
Furthermore, the presence of anti-dsDNA autoantibodies
seems to be associated with complement consumption, as
shown by the negative correlation with C3 levels. Others
have shown that anti-nucleosome and anti-C1q autoantibo-
dies correlated with the presence of LN (8,10,13,28),
although these correlations were investigated in lupus
patients with or without renal involvement. In our patient
cohort a direct correlation between anti-nucleosome and
anti-C1q autoantibody titres and renal function parameters
was not found. In addition, no differences in renal function
parameters between patients with high or low anti-nucleo-
some titres were present. The absence of these correlations
might be due to the fact that all our patients had a biopsy-
proven LN with more or less comparable disease manifesta-
tions. In contrast, patients with higher anti-C1q reactivity
had a higher serum creatinine, and presented with class IV
but not class III LN. Renal flares were not associated with
significant increases in anti-nucleosome and/or anti-dsDNA
titres during the first treatment year. This is consistent with
the only prospective analysis available so far (42). Although it
has been claimed that renal flares are associated with signifi-
cant increases of anti-dsDNA (15) or anti-C1q titres (43), we
could not confirm this. MBL concentrations were not associ-
ated with disease activity or disease course. In time MBL
concentrations did not change, suggesting that MBL, in
contrast to C3 and C4, is not significantly consumed during
active disease. This supports the suggestion that MBL
might play a role in the susceptibility for SLE, but not in
disease severity or response to treatment (32).
In conclusion, the majority of our LN patients was positive
for anti-nucleosome, anti-dsDNA and/or anti-C1q autoantibo-
dies. Titres of anti-chromatin autoantibodies correlated with
disease activity, but there was no association with renal
function parameters. In contrast, high levels of anti-C1q
autoantibodies were associated with increased renal injury.
Except for a higher proportion of patients with high anti-
dsDNA reactivity reaching complete remission, the autoanti-
bodies were not associated with outcome parameters.
Treatment with AZA did not result in significant differences
in anti-chromatin or anti-C1q autoantibody kinetics compa-
red to treatment with CY. These findings imply that measu-
ring the autoantibody specificities serves as an important
tool for diagnosis of LN but not for monitoring disease cour-
se or treatment.
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Table 2 Characteristics of patients with low (below median) or high (above median) autoantibody levels measured at study
entry. Number, or median and interquartile range are given.
anti-DNA anti-nucleosome anti-histone anti-C1q
low high low high low high low high
n 26 26 27 25 27 25 26 25
CY/AZA (n) 16/10 14/12 17/10 13/12 17/10 13/12 15/11 14/11
Renal parameters
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CY: treatment with cyclophosphamide and prednisone, AZA: treatment with azathioprine, methylprednisolone and prednisone, GFR: glomerular filtration rate
(Cockcroft-Gault formula), Screat: serum creatinine (to convert values of creatinine to mg/dl, divide by 88.4), Uprot: proteinuria, SLEDAI: SLE disease activity index,
CR: complete remission
School, Fukushima, JP). Nicole Schlagwein (Department of
Nephrology, Leiden University Medical Centre, Leiden, NL)
is acknowledged for excellent technical support.
This study was supported by grants from the Dutch Kidney
Foundation (C94.1363, C99.1826 and C02.2023) and the
Dutch League against Rheumatism (No. 735). CG is a reci-
pient of a Netherlands Organisation for Scientific Research
Fellowship for Clinical Investigators (NWO No. 920-03-115).
References
1. Dieker JW, van der Vlag J, Berden JH. Triggers for anti-
chromatin autoantibody production in SLE. Lupus
2002;11:856-64.444
2. Burlingame RW, Boey ML, Starkebaum G, Rubin RL.
The central role of chromatin in autoimmune respon-
ses to histones and DNA in systemic lupus erythema-
tosus. J Clin Invest 1994;94:184-92.
3. Rumore PM, Steinman CR. Endogenous circulating
DNA in systemic lupus erythematosus. Occurrence as
multimeric complexes bound to histone. J Clin Invest
1990;86:69-74.
4. Amoura Z, Piette JC, Chabre H, Cacoub P, Papo T,
Wechsler B, et al. Circulating plasma levels of nucleos-
omes in patients with systemic lupus erythematosus:
correlation with serum antinucleosome antibody
titers and absence of clear association with disease
activity. Arthritis Rheum 1997;40:2217-25.
5. Voll RE, Roth EA, Girkontaite I, Fehr H, Herrmann M,
Lorenz HM, et al. Histone-specific Th0 and Th1 clones
derived from systemic lupus erythematosus patients
induce double-stranded DNA antibody production.
Arthritis Rheum 1997;40:2162-71.
6. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major
peptide autoepitopes for nucleosome-specific T cells of
human lupus. J Clin Invest 1999;104:345-55.
7. Fournel S, Neichel S, Dali H, Farci S, Maillere B, Briand
JP, et al. CD4+ T cells from (New Zealand Black x New
Zealand White)F1 lupus mice and normal mice immu-
nized against apoptotic nucleosomes recognise similar
Th cell epitopes in the C terminus of histone H3. J
Immunol 2003;171:636-44.
8. Burlingame RW, Cervera R. Anti-chromatin (anti-nucle-
osome) autoantibodies. Autoimmun Rev 2002;1:321-8.
9. Burlingame RW. Recent advances in understanding
the clinical utility and underlying cause of antinucleo-
some (antichromatin) autoantibodies. Clin Applied
Immunol Rev 2004;4:351-66.
10. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura
I, Musset L, et al. Presence of antinucleosome autoan-
tibodies in a restricted set of connective tissue disea-
ses: antinucleosome antibodies of the IgG3 subclass
are markers of renal pathogenicity in systemic lupus
erythematosus. Arthritis Rheum 2000;43:76-84.
11. Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F.
Nucleosomes are major T and B cell autoantigens in
systemic lupus erythematosus. Arthritis Rheum
2000;43:2307-15.
12. Horak P, Scudla V, Hermanovo Z, Pospisil Z, Faltynek
L, Budikova M, et al. Clinical utility of selected disease
activity markers in patients with systemic lupus
erythematosus. Clin Rheumatol 2001;20:337-44.
13. Min DJ, Kim SJ, Park SH, Seo YI, Kang HJ, Kim WU, et
al. Anti-nucleosome antibody: significance in lupus
patients lacking anti-double-stranded DNA antibody.
Clin Exp Rheumatol 2002;20:13-8.
14. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-
Guerrero J. Anti-nucleosome antibodies in patients
with systemic lupus erythematosus of recent onset.
Potential utility as a diagnostic tool and disease activi-
ty marker. Rheumatology (Oxford) 2004;43:220-4.
15. ter Borg EJ, Horst G, Hummel EJ, Limburg PC,
Kallenberg CG. Measurement of increases in anti-dou-
ble-stranded DNA antibody levels as a predictor of
disease exacerbation in systemic lupus erythematosus.
A long-term, prospective study. Arthritis Rheum
1990;33:634-43.
16. Cairns AP, McMillan SA, Crockard AD, Meenagh GK,
Duffy EM, Armstrong DJ, et al. Antinucleosome antibo-
dies in the diagnosis of systemic lupus erythematosus.
Ann Rheum Dis 2003;62:272-3.
17. Cervera R, Vinas O, Ramos-Casals M, Font J, Garcia-
Carrasco M, Siso A, et al. Anti-chromatin antibodies in
systemic lupus erythematosus: a useful marker for
lupus nephropathy. Ann Rheum Dis 2003;62:431-4.
18. Sato S, Kodera M, Hasegawa M, Fujimoto M, Takehara
K. Antinucleosome antibody is a major autoantibody in
localized scleroderma. Br J Dermatol 2004;151:1182-8.
19. Suer W, Dahnrich C, Schlumberger W, Stocker W.
Autoantibodies in SLE but not in scleroderma react
with protein-stripped nucleosomes. J Autoimmun
2004;22:325-34.
20. Burlingame RW. The clinical utility of antihistone anti-
bodies. Autoantibodies reactive with chromatin in
34
before treatment after 6 m of treatment
400
350
300
250
200
150
100
50
0
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0M
B
L 
co
n
ce
n
tr
at
io
n
 (
n
g/
m
l)
Co
m
p
le
m
en
t 
C3
 (
g/
l)
MBL C3
Figure 4 Change in MBL and C3 levels during treatment. The
second sample was taken after 6 months of treatment.
Medians are given.
systemic lupus erythematosus and drug-induced
lupus. Clin Lab Med 1997;17:367-78.
21. Tax WJ, Kramers C, van Bruggen MC, Berden JH.
Apoptosis, nucleosomes, and nephritis in systemic
lupus erythematosus. Kidney Int 1995;48:666-73.
22. van Bruggen MC, Walgreen B, Rijke TP, Tamboer W,
Kramers K, Smeenk RJ, et al. Antigen specificity of
anti-nuclear antibodies complexed to nucleosomes
determines glomerular basement membrane binding
in vivo. Eur J Immunol 1997;27:1564-9.
23. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM,
Cook HT, Petry F, et al. Homozygous C1q deficiency
causes glomerulonephritis associated with multiple
apoptotic bodies. Nat Genet 1998;19:56-9.
24. Chen Z, Koralov SB, Kelsoe G. Complement C4 inhibits
systemic autoimmunity through a mechanism inde-
pendent of complement receptors CR1 and CR2. J Exp
Med 2000;192:1339-52.
25. Walport MJ. Complement and systemic lupus erythe-
matosus. Arthritis Res 2002;4 Suppl 3:S279-S293.
26. Bowness P, Davies KA, Norsworthy PJ, Athanassiou P,
Taylor-Wiedeman J, Borysiewicz LK, et al. Hereditary
C1q deficiency and systemic lupus erythematosus.
QJM 1994;87:455-64.
27. Seelen MA, Trouw LA, Daha MR. Diagnostic and prog-
nostic significance of anti-C1q antibodies in systemic
lupus erythematosus. Curr Opin Nephrol Hypertens
2003;12:619-24.
28. Marto N, Bertolaccini ML, Calabuig E, Hughes GR,
Khamashta MA. Anti-C1q antibodies in nephritis: cor-
relation between titres and renal disease activity and
positive predictive value in systemic lupus erythema-
tosus. Ann Rheum Dis 2005;64:444-8.
29. Moroni G, Trendelenburg M, Del PN, Quaglini S,
Raschi E, Panzeri P, et al. Anti-C1q antibodies may
help in diagnosing a renal flare in lupus nephritis. Am
J Kidney Dis 2001;37:490-8.
30. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM,
Bajema IM, Prins FA, et al. Anti-C1q autoantibodies
deposit in glomeruli but are only pathogenic in com-
bination with glomerular C1q-containing immune
complexes. J Clin Invest 2004;114:679-88.
31. Garred P, Voss A, Madsen HO, Junker P. Association of
mannose-binding lectin gene variation with disease
severity and infections in a population-based cohort of
systemic lupus erythematosus patients. Genes Immun
2001;2:442-50.
32. Seelen MA, van der Bijl EA, Trouw LA, Zuiverloon TC,
Munoz JR, Fallaux-van den Houten FC, et al. A role for
mannose-binding lectin dysfunction in generation of
autoantibodies in systemic lupus erythematosus.
Rheumatology (Oxford) 2005;44:111-9.
33. Grootscholten C, Ligtenberg G, Hagen EC, van den
Wall Bake A, de Glas-Vos JW, Bijl M, et al.
Azathioprine/methylprednisolone versus cyclophos-
phamide in proliferative lupus nephritis. A randomi-
zed controlled trial. Kidney Int 2006;70:732-42.
34. Aarden LA, de Groot ER, Feltkamp TE. Immunology of
DNA. III. Crithidia luciliae, a simple substrate for the
determination of anti-dsDNA with the immunofluore-
scence technique. Ann N Y Acad Sci 1975;254:505-15.
35. Bombardier C, Gladman DD, Urowitz MB, Caron D,
Chang CH. Derivation of the SLEDAI. A disease activi-
ty index for lupus patients. The Committee on
Prognosis Studies in SLE. Arthritis Rheum
1992;35:630-40.
36. Dieker JW, Sun YJ, Jacobs CW, Putterman C, Monestier
M, Muller S, et al. Mimotopes for lupus-derived anti-
DNA and nucleosome-specific autoantibodies selected
from random peptide phage display libraries: facts
and follies. J Immunol Methods 2005;296:83-93.
37. Siegert C, Daha M, Westedt ML, van der Voort E,
Breedveld F. IgG autoantibodies against C1q are corre-
lated with nephritis, hypocomplementemia, and
dsDNA antibodies in systemic lupus erythematosus. J
Rheumatol 1991;18:230-4.
38. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-
Krol MC, Stahl GL, Daha MR. Human IgA activates the
complement system via the mannan-binding lectin
pathway. J Immunol 2001;167:2861-8.
39. Austin HA III, Muenz LR, Joyce KM, Antonovych TT,
Balow JE. Diffuse proliferative lupus nephritis: identi-
fication of specific pathologic features affecting renal
outcome. Kidney Int 1984;25:689-95.
40. Smeenk RJ, van den Brink HG, Brinkman K, Termaat
RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in
relation to clinical value. Rheumatol Int 1991;11:101-7.
41. Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An
analysis of clinical disease activity and nephritis-asso-
ciated serum autoantibody profiles in patients with
systemic lupus erythematosus: a cross-sectional study.
Rheumatology (Oxford) 2001;40:1405-12.
42. Ghirardello A, Doria A, Zampieri S, Tarricone E,
Tozzoli R, Villalta D, et al. Antinucleosome antibodies
in SLE: a two-year follow-up study of 101 patients. J
Autoimmun 2004;22:235-40.
43. Coremans IE, Spronk PE, Bootsma H, Daha MR, van
der Voort EA, Kater L, et al. Changes in antibodies to
C1q predict renal relapses in systemic lupus erythema-
tosus. Am J Kidney Dis 1995;26:595-601.
35
autoantibodies in lupus nephritis
36 Kidney Int 2006;70:732-42
Chapter V Clinical Aspects
37
azathioprine in proliferative lupus nephritis
38
39
azathioprine in proliferative lupus nephritis
40
41
azathioprine in proliferative lupus nephritis
42
43
azathioprine in proliferative lupus nephritis
44
45
azathioprine in proliferative lupus nephritis
46
47Qual Life Res 2003;12:635-44
Chapter VI Clinical Aspects
48
49
lupus patients and quality of life
50
51
lupus patients and quality of life
52
53
lupus patients and quality of life
54
55
lupus patients and quality of life
56
57
Quality of life (QoL) is a critical issue in the care of SLE
patients (1,2), since both the disease itself and the treatment
have a significant impact on the well-being of the patient.
Particularly fatigue is known to have a disabling effect on
the daily functioning of SLE patients (3), not necessarily cor-
related with objective measures of disease activity (4-7).
One of the most serious manifestations of SLE is prolifera-
tive lupus nephritis (LN) (8,9). The treatment of patients
with proliferative LN consists of both cytotoxic drugs and
corticosteroids. Cyclophosphamide pulse therapy has been
regarded the standard treatment for a long period, and is
known to cause serious negative side effects, such as infer-
tility and malignancies (10). In a search for an alternative,
less toxic therapy, azathioprine could be considered (11). In
a randomised controlled trial we compared the efficacy of
cyclophosphamide pulse treatment with azathioprine
combined with methylprednisolone The treatment was dif-
ferent in the first two years only. Although more relapses
occurred in the azathioprine-treated patients, no signifi-
cant differences regarding the occurrence of doubling of
serum creatinine or renal function at last visit were found
after a median follow-up of 5.7 years (12). Here we report
on the quality of life outcomes from this trial. We anticipa-
ted less side effects with azathioprine/methylprednisolone
compared to cyclophosphamide, impacting positively on
perceived life quality and reducing treatment burden.
Patients & Methods
Design & patients Details of the first Dutch Lupus Nephritis
Study have been described elsewhere (12). In short, this
study is a randomised controlled trial with repeated measu-
rements, including clinical parameters and patient-repor-
ted outcomes. All 87 study patients met the following crite-
ria: presence of ≥4 American College of Rheumatology cri-
teria for SLE (13), age 18 to 60 years, creatinine clearance
(Cockcroft-Gault (14)) >25 ml/min, and biopsy-proven proli-
ferative LN (15). Patients with WHO-class IV LN were eligible
when they had signs of active nephritis or a deterioration of
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Objective. To study prospectively the impact of treatment with cyclophosphamide pulses (CY) versus azathioprine
with methylprednisolone (AZA), both during 24 months, on health-related quality of life (HRQoL) in patients with
proliferative lupus nephritis (LN) in a randomised controlled trial. We expected better HRQoL during AZA.
Methods. HRQoL and disease activity were measured at start, after 12 and after 24 months. Generic questionnaires
(patient's visual analogue scale (VAS), MOS-SF36, Profile of Mood States), and a disease-specific measure (SLE
Symptom Checklist) were used. Treatment burden was assessed at 24 months. Disease activity was measured with
the SLE Disease Activity Index (SLEDAI) and physician's VAS.
Results. Complete questionnaire data were available from 47 of the 87 patients included in the trial. These patients
were representative of the whole group, except for the fact that completers were more often Caucasian. HRQoL sco-
res improved significantly during treatment, particularly during the first year, both on generic and disease-specific
outcomes. No differences were found in HRQoL between the CY and AZA group, except for the MOS-SF36 Mental
Component Summary Scale, showing more favourable scores in the AZA group. The mean reported treatment bur-
den at 24 months was significantly higher in the CY group. HRQoL scores did not correlate with the SLEDAI and
physician's VAS. The disease activity measures correlated positively with each other.
Conclusion. Treatment of patients with proliferative LN with immunosuppressive drugs and corticosteroids impro-
ves HRQoL, particularly in the first year. Unexpectedly, only minor differences were observed between AZA or CY
treatment, after two years.
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renal function. Patients with WHO-class III LN had to meet
both criteria. For the detailed study protocol see our prior
publication (12). The study was approved by the ethics com-
mittees of all participating hospitals and written informed
consent was obtained from all patients.
Treatments Patients in the cyclophosphamide arm (CY) were
given six pulses of cyclophosphamide (750 mg/m2) every 4
weeks, followed by seven pulses every 12 weeks, combined
with oral prednisone, initially 1 mg/kg/day, tapered to a
final dose of 10 mg daily after six months. Patients in the
azathioprine arm (AZA) started with azathioprine (2 mg/
kg/day) at day one, combined with methylprednisolone
intravenously (1000 mg) on three consecutive days. This
cycle of three pulses was repeated after two and six weeks.
In addition, oral prednisone (20 mg/day) was given for five
months and then tapered to 10 mg/day. After two years of
treatment, both groups continued on azathioprine (2 mg/
kg/day) and prednisone (10 mg/day) for two more years,
after which both drugs were successively tapered over a year
(to 1 mg/kg/day and 10 mg every other day, respectively),
and continued for another two years. 
Disease activity measures The overall disease activity was
measured at each visit using the SLE Disease Activity Index
(SLEDAI), ranging from 0 to 105 (16). Physicians were also
asked to rate the disease activity on a visual analogue scale
score (VAS) (physician's VAS), ranging from 0 to 10. For both
activity measures a lower score denotes less disease activity.
Quality of life Patients were invited to complete a booklet
of questionnaires at study entry and at 12 and 24 months.
The questionnaires were filled out at home and returned to
a central office, using a prepaid and pre-addressed envelope.
Biographical data and socio-demographics were gathered
using sixteen questions on the duration of lupus, marital
status, ethnicity, employment etc. Health-related quality of
life (HRQoL) was operationalised as a multi-dimensional
concept, including generic measures of perceived health
status, mood, impact on daily life, and disease-specific
symptom distress. 
-Generic QoL measures
Perceived general health status was measured by a visual
analogue scale with the following question: 'Everything
considered, how do you feel at this moment?'. The scale ran-
ges from 1 to 10, a higher number representing a higher
degree of general well-being (patient's VAS).
The widely-used MOS-SF-36, or SF-36, was used as generic
measure of QoL (17-20). The SF-36 has been tested and
recommended to be used in SLE patients (21,22). It contains
eight domains, including fatigue, and one question relating
to change in health. After recoding, all eight scales can
reach a maximum of 100, with a higher number represen-
ting better functioning and/or less limitations. Summary
health scores (Physical Component Summary and Mental
Component Summary) are calculated (23). These standardi-
sed scores (with a mean of 50 and a standard deviation of 10
in the general population) make international comparisons
possible.
The Dutch shortened version of the Profile of Mood States
(POMS) was used to measure emotional well-being (24-26). It
consists of 32 items with a five-point response format, ran-
ging from 'not at all' to 'extremely', covering four negative
mood states (depression, anger, fatigue, and tension), and
one positive affect (vigour), referring to 'the past few days,
including today'.  
-Treatment burden
The experienced treatment burden was measured at 24
months using two questions: 'The treatment so far was ….',
on a five-point Likert scale ranging from 'not burdensome
(1)' to 'extremely burdensome (5)' and 'What aspect of the
treatment did you experience as most burdensome?', as an
open-end question.
-Impact on activities of daily life
The impact of SLE on activities of daily life was assessed by
using an adapted version of the IRGL (Influence of
Rheumatic diseases on General health and Lifestyle) questi-
onnaire (27), based on the AIMS (Arthritis Impact
Measurement Scales)(28). The IRGL has been validated in
the Netherlands for Rheumatoid Arthritis patients (27). 
For the present study only the IRGL subscales 'mobility' and
'impact of disease' were applied. The mobility part consists
of 6 items measuring activities such as walking stairs. The
impact of disease on daily life is evaluated by 10 items. For
all questions, the answers range from 'almost never' to
'almost always' on a four-point Likert scale. Scores range
from 6 to 24 for mobility, and from 10 to 40 for impact of
disease, a higher score denoting better mobility and more
impact of disease, respectively.
-Disease-specific 
To study the presence and perceived burden of both disea-
se-related and treatment-related symptoms, we used the
SLE Symptom Checklist (SSC) (29). The SSC refers to the
month preceding the day of completing the questionnaire.
It consists of 38 symptoms. Each item is scored on a fre-
quency scale, and if a symptom is present, also on a discom-
fort scale. The total distress score is calculated by summa-
tion of the perceived burden of each symptom as given on
a four-point Likert scale (either 'not present' (=0), 'present,
but not burdensome' (=1), 'a little burdensome' (=2), 'quite
burdensome' (=3) or 'extremely burdensome' (=4)). In a dif-
ferent cohort of 87 stable SLE patients (with a median disease
duration of 8 years) a mean number of symptoms of 12.9,
with a total distress level of 30.1, was found (29). The SSC
was shown to have a satisfactory reliability (Cronbach's
alpha 0.89 for both number of symptoms and total distress
level) and reproducibility. Furthermore, it was proved sensi-
tive to change (29).
Statistical analysis
For the analyses SPSS 12.0.1 was used. Descriptive statistics
included frequency tables of the patients' characteristics.
Values are expressed as means and standard deviation for
normally distributed data, or as median with interquartile
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range (IQR) for skewed data. Comparisons between the dif-
ferent instruments and the two treatment groups were stu-
died with Chi square or non-parametric tests. Changes of
the diverse scales and activity measurements during the
first two years of treatment were studied with mixed model
analyses. The mixed model module in SPSS is an extension
of the well-known analysis of variance technique for repea-
ted measures that allows to test for treatment and time
effects and the interaction of treatment and time, in the
presence of missing data. For all analyses a p value <0.05
was regarded statistically significant.
Results
Baseline characteristics At study entry, 70 out of the 87
included patients (80%) had completed the questionnaire
booklet. Questionnaire data on all three time points were
available from 47 patients, due to loss of follow-up or death
or loss of interest during follow-up. Of these 47 patients, 27
were randomised to CY and 20 to AZA. In Table 1 baseline
characteristics are summarised. As can be seen completers
more often were Caucasian and they had a lower comple-
ment C3 at study entry, but no differences for the other para-
meters of disease activity were present. Socio-demographics
of the 47 patients are shown in Table 2.
Clinical outcomes Whereas more renal relapses were pre-
sent in the AZA group, so far no statistically significant dif-
ferences in the primary study end point (doubling of serum
creatinine), or parameters at last visit (creatinine and pro-
teinuria) have been found (12). Partial remission was rea-
ched by most patients within the first year of treatment,
and after two years approximately half of the patients had
reached complete remission. Remission criteria did not
include subjective variables. The time course of disease acti-
vity as measured by the SLEDAI and physician's VAS is depic-
ted in Figures 1A and 1B. There were no differences between
the two treatment groups, or for the total group of patients
as compared with the completers. The SLEDAI and the phy-
sician's VAS significantly correlated with each other (R =
0.670, p<0.001).
Health-related quality of life
-Generic
General well-being, measured with the patient's VAS,
improved over time, but was not different between the two
treatment groups. After two years of treatment the median
patient's VAS had increased from 6 to 7 (see also Figure 1C).
As to be expected relatively low scores (compared to norm
data) of most subscales of the SF36 were present at study
entry. A significantly lower score for perceived general
health was found in the AZA group compared with the CY
group. In Figure 2 the SF-36 scores are compared with those
in Dutch lupus patients with stable disease (29) and in the
general Dutch population (30). The scores were comparable
with results from most other studies in lupus patients,
except for role-emotional, which was scored higher in our
population (80.1) than in other SLE populations (ranging
from 52 to 65) (2,31-34). Across both treatment regimens,
the physical and social functioning, and mental health
domains at study entry were significantly lower in those
patients who presented with LN as their first symptom of
SLE (n=22) compared to those who had been diagnosed with
SLE in the past (n=25) (45.6 versus 64.5, 39.8 versus 63.1, and
Table 1 Baseline characteristics of all included patients 
and of those of whom three questionnaires were available.
Data are given as medians and interquartile ranges, or 
as percentages.
characteristic all patients three questionnaires
n=87 n=47 p*
CY/AZA 50/37 27/20 ns
Caucasian (%) 76 87 0.007
nephritis in the past 23 21 ns
LN first symptom of disease 41 47 ns
age (years) 33 (25-33) 31 (25-40) ns
SLEDAI 20 (14-24) 21 (17-26) ns
biopsy parameters
- WHO class IV (%) 91 91 ns
- activity index 9.3 (6.7-11.7) 10.3 (6.7-12.3) ns
- chronicity index 2.7 (2.0-3.7) 2.3 (1.7-3.3) ns
laboratory parameters
- serum creatinine (µmol/l)** 111 (85-156) 105 (83-140) ns
- serum C3 (g/l) 0.50 (0.37-0.64) 0.45 (0.32-0.55) 0.035
- serum C4 (g/l) 0.10 (0.08-0.15) 0.10 (0.07-0.12) ns
- anti-dsDNA (IU/ml) 158 (26-545) 142 (28-516) ns
- proteinuria (g/24h) 3.9 (2.1-6.5) 4.2 (2.8-7.1) ns
CY: cyclophosphamide/prednisone, AZA: azathioprine/methylprednisolone/
prednisone, LN: proliferative lupus nephritis, SLEDAI: SLE disease activity index,
C3: complement C3, C4: complement C4, anti-dsDNA: anti-double stranded
DNA antibodies.
*p value applies to the comparison of patients who completed three 
questionnaires and those who did not
**to convert values of creatinine to milligrams per decilitre, divide by 88.4
Table 2 Socio-demographic characteristics at study entry, of
the 47 patients who completed three questionnaires. Number
and percentage, or median and interquartile range are given.
characteristic
female 42 (89)
Caucasian 41 (87)
age (years) 31 (25-40)
disease duration (months) 8 (1-66)
currently employed 21 (45)
marital status
- married/living together 30 (64)
- divorced 1 (2)
- never married 16 (34)
one or more children 22 (47)
education >9 years 40 (85)
member of lupus association 21 (45)
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60.0 versus 70.7, respectively). Mixed model analyses revea-
led a significant effect of time on all subscales, but no diffe-
rences between the two treatment groups, except for the
Mental Component Summary Scores. The latter showed a
significantly larger improvement in the AZA group, sug-
gesting better mental functioning. Overall, all scores impro-
ved during treatment, with the largest changes during the
first year of treatment (see Table 3 for data of all 47
patients).
Results for the different POMS mood scales are also summa-
rised in Table 3. During treatment the subscales vigour, fati-
gue and tension improved significantly, without differences
between AZA and CY. If patients for whom LN was the first
symptom of SLE were compared with those who had been
diagnosed with SLE before, no differences in the POMS sub-
scales were found (data not shown).
-Treatment burden
After two years of therapy the patients reported to have
experienced their treatment as rather troublesome (mean
2.9). In the CY group the reported treatment burden was
higher than in the AZA group (3.6 versus 2.2, p<0.001).
Patients in the CY group mentioned the hospital admissions
for the cyclophosphamide pulses as most burdensome,
while in the AZA group having to take medication and expe-
riencing side effects of the corticosteroids was rated most
burdensome. The latter group also more often mentioned
admission for renal biopsy and collecting urine during 24
hours as burdensome.
-Impact on activities of daily life
Mobility improved during treatment, while the impact on
daily life did not change. There were no differences between
the CY and AZA group on IRGL scores. The IRGL scores at all
time points were comparable with means found in Dutch
patients with Rheumatoid Arthritis (27). Newly diagnosed
lupus patients scored lower on the mobility subscale, indi-
cating that they were less mobile.
-Disease-specific
The mean number of complaints (SSC) did not change signi-
ficantly during treatment, while the mean reported symp-
tom distress decreased significantly (p=0.009) from 34.6 to
28.4 after one year of therapy, to stabilise at two years (29.3)
(see also Table 3). There were no differences between the
two treatment groups. Fatigue was reported most frequent-
ly, and rated as most distressing symptom. At study entry
94% of the patients mentioned to be fatigued, with a mean
distress level of 3.2. After two years of therapy fatigue was
still present in most patients (87%), while the distress had
decreased to 2.7. With regard to nausea and vomiting,
symptoms which are more often thought to be caused 
by cyclophosphamide than by azathioprine, no differences
between the two treatment arms, at all three time points,
were present. Comparing the patients for whom nephritis
was the presenting symptom of SLE with those who had
been diagnosed with SLE before, the number of complaints
was significantly higher at study entry (15 versus 12,
p=0.029) in the newly diagnosed patients. At the other time
points no differences were present anymore. Although the
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Figure 1 Time course of activity measures during the first
two years of treatment in 47 patients treated with either 
CY or AZA. (A) SLEDAI, (B) physician's VAS and (C) patient's VAS.
To enhance readability of the figures the confidence intervals
are omitted. There were no statistically significant differences
between the two treatment groups.
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total distress score in the newly diagnosed patients was also
higher at study entry (40 versus 30) and after one year of the-
rapy (32 versus 25), this did not reach statistical significance.
Discussion
In this randomised controlled trial in patients with prolife-
rative lupus nephritis, we showed that treatment with
immunosuppressive drugs improved QoL across different
domains during the first year, although most (mainly physi-
cal) QoL scores were lower than in other Dutch patient
groups (19). In contrast to our expectations, no substantial
differences were observed between patients treated with
cyclophosphamide or azathioprine with methylprednisolo-
ne. The latter group did report more favourable Mental
Summary Scores and less treatment burden. We had expec-
ted to find a difference with respect to the symptom 'nau-
sea/vomiting'. The absence of a difference between AZA and
CY might be explained by the fact that the nausea/vomiting
due to cyclophosphamide did not occur within the period
referred to in the SSC (i.e. one month), since after six
months the cyclophosphamide pulses were given quarterly.
Another explication is that nausea and vomiting can also be
caused by other drugs than cyclophosphamide, or that nau-
sea increases with the number of pills that are prescribed.
Alternatively, the drugs prescribed to prevent nausea and
vomiting during cyclophosphamide proved to be effective. 
While other symptoms either disappeared or emerged, fati-
gue remained present in most patients and was regarded
the most burdensome symptom. This is in line with previ-
ous studies (4,6,29). Fatigue was significantly correlated
with all subscales of the SSC, IRGL and SF-36. Interestingly,
no correlation existed between fatigue and disease activity
as measured with the physician's VAS and SLEDAI, under-
scoring the importance of using patient-reported outcomes
when evaluating treatment effects.
This report focuses on HRQoL in patients with proliferative LN,
who were included in a prospective study, using a randomi-
sed controlled design. In contrast to most HRQoL studies in
patients with SLE (2,32,34-37), our population consisted of
Table 3 Time course of diverse QoL scales and activity measures during the first two years of treatment in 47 patients with
proliferative lupus nephritis, treated in the first Dutch Lupus Nephritis Study. Means (SD) or medians (IQR) are given.
at study after after
item range entry 1 year 2 years p
MOS-SF36
physical functioning 0-100 56.1 (23.5) 71.9 (18.9) 73.9 (21.4) 0.000
role-physical 0-100 15.0 (27.3) 43.8 (40.8) 47.3 (43.1) 0.000
bodily pain 0-100 53.4 (26.6) 71.0 (21.5) 70.0 (21.3) 0.000
general health* 0-100 38.4 (17.5) 44.3 (21.2) 48.5 (20.8) 0.003
vitality 0-100 36.1 (20.6) 55.5 (18.6) 57.3 (18.4) 0.000
social functioning 0-100 52.8 (30.0) 72.4 (23.6) 74.2 (22.6) 0.000
role-emotional 0-100 54.9 (44.1) 75.8 (35.5) 80.1 (34.5) 0.002
mental health 0-100 65.8 (15.0) 72.6 (17.0) 74.2 (16.7) 0.016
physical summary score 3-78 35.4 (8.1) 41.8 (9.2) 43.1 (10.7) 0.000
mental summary score 6-72 43.8 (10.0) 49.5 (9.6) 50.0 (8.4) 0.000**
POMS
depression 0-32 4 (1-8) 2 (0-4) 2 (0-6) ns
vigour 0-20 7.5 (5-11) 8 (5-12) 9 (6-13) 0.036
fatigue 0-24 8 (3-12) 5 (2-9) 6.5 (2-11) 0.007
anger 0-28 2 (1-6) 4 (1-6.3) 3.5 (1-7) ns
tension 0-24 5 (3-8) 3 (1-6) 2 (0-6) 0.001
IRGL
mobility 6-24 16.0 (5.7) 18.1 (5.4) 18.8 (5.3) 0.000
impact on daily life 10-40 21.6 (7.3) 20.5 (6.9) 20.2 (7.9) ns
SSC
total distress level 0-152 34.6 (15.9) 28.4 (14.5) 29.3 (17.7) 0.009
number of complaints 0-38 13.6 (4.9) 12.0 (5.5) 12.5 (6.4) ns
patient's VAS 0-10 6 (5-7) 7 (6-8) 7 (6.5-8) 0.000
physician's VAS 0-10 6 (4-8) 1 (0-2) 1 (0-2) 0.000
SLEDAI 0-105 21 (17-26) 4 (2-6.5) 2.5 (2-6) 0.000
p value refers to the differences between the values at the three time points (time effect)
* value at t=0 in AZA group was significantly lower than in CY group (29.4 vs 45.6)
** the increase of the mental summary score in time was different between the two treatment arms (larger in the AZA group)
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patients with active proliferative LN only, and patients had
comparable characteristics at study entry. Although there
was a significant loss to follow-up, the studied patients were
representative of the total group of patients included in the
trial. Moreover, if all patients who completed the question-
naires at study entry and either after one or after two years
(n=16) were added to the analyses, the results did not chan-
ge much. We therefore have little reason to question the
external validity of our findings.
Unfortunately, no follow-up data on the QoL after two years
of treatment are available, as it would have been interesting
to know whether or not the QoL improvement that we
noted at 12 and 24 months sustained over time. Future stu-
dies with longer follow-up should be able to clarify this
issue. Nevertheless, after 4 years, the patient's VAS as mea-
sured during the outpatient visits was available for 67% of
the patients. This VAS was comparable with the observed
score at 2 years and showed a median of 7.5 (IQR 6.5-8.0).
There were no differences between the CY and AZA group.
We can conclude that in proliferative LN successful treat-
ment significantly improves HRQoL within a period of 12
months, and this effect sustains in the second year of treat-
ment. Treatment with either pulse cyclophosphamide or
azathioprine with methylprednisolone does not appear to
make much difference in terms of HRQoL, although pulse
cyclophosphamide-treatment was reported as significantly
more burdensome. It remains to be determined whether
current alternative treatments like mycophenolate mofetil
(MMF) have a more favourable effect on HRQoL. In this res-
pect it is noteworthy to mention that, in a limited number
of patients with LN, treatment with MMF resulted in better
scores on several QoL domains compared to treatment with
oral cyclophosphamide (38). When azathioprine/methyl-
prednisolone is considered as initial therapy for proliferative
lupus nephritis, one should take into account that there is
a higher chance of developing a renal relapse, and that
HRQoL was not proven to be better than during treatment
with cyclophosphamide pulses for two years. Furthermore,
MMF or low doses of cyclophosphamide should also be con-
sidered as an alternative for two years of cyclophosphamide
treatment.
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Figure 2 Comparison of SF-36 scale scores between study patients, stable lupus patients (n=33) (29) and the general Dutch
population (n=1742) (30). Because there were no differences between the CY and AZA patients (except for mental component
summary scores), data of all patients in this study were used. 
pf: physical functioning, rp: role-physical, bp: bodily pain, gh: general health, vt: vitality, sf: social functioning, 
re: role-emotional, mh: mental health, pcs: physical component summary, mcs: mental component summary.
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Systemic Lupus Erythematosus (SLE) is an autoimmune
disease in which virtually any organ can be affected (1).
Involvement of the kidney occurs frequently (2) and the
morphologic changes observed in the kidney have the
same diversity as the character of the disease (3). Attempts
have been made to categorise the morphologic changes in
order to recognise certain patterns, with the aim of provi-
ding better guidelines for therapy and prognosis. Until the
beginning of this century, the WHO1995 classification was
used worldwide (3). In 2003 the WHO1995 classification
was redefined (4) in order to allow better standardisation of
renal biopsies in lupus patients than before (4,5), in parti-
cular as it separates segmental and global lesions. The
importance of the latter was suggested by Najafi et al. in
2001 (6). These authors showed that patients with diffuse
proliferative lupus nephritis (LN) and segmental lesions
(n=24) were more likely to reach end-stage renal disease
(ESRD) than patients with diffuse proliferative LN and 
global lesions (n=35), although the number of patients 
entering remission and developing a renal flare was not 
different. 
In a search for a less toxic alternative for cyclophosphami-
de pulse therapy, the first Dutch lupus nephritis study star-
ted in 1995. In this study, 87 patients with biopsy-proven
proliferative LN were randomised to either cyclophospha-
mide pulse therapy, or to azathioprine combined with
methylprednisolone pulses (7). After two years a protocoli-
sed repeat renal biopsy was performed in 39 participants.
In order to evaluate the histomorphological lesions of these
biopsies in detail, a standardised scoring form was develop-
ed. Here we report the inter- and intraobserver agreement
among five specialised nephropathologists. We also compa-
re the WHO1995 classification with the ISN/RPS2003 classi-
fication for LN.
Material & Methods
Patient selection From September 1995 until September 2001,
87 patients with biopsy-proven proliferative LN were included
in the first Dutch lupus nephritis study (7). In this randomised
controlled trial, patients were treated with either azathiopri-
ne combined with methylprednisolone and prednisone, or
cyclophosphamide pulse therapy with oral prednisone during
two years. After two years, this regimen was followed by long-
term azathioprine and prednisone. All patients were followed
regularly, and clinical and laboratory parameters were collec-
ted according to the study protocol (7).
Inter- and intraobserver agreement of scoring
of histopathological characteristics and 
classification of lupus nephritis
Cecile Grootscholten, Ingeborg M. Bajema, Sandrine Florquin, Eric J. Steenbergen, Carine J. Peutz-Kootstra, Roel
Goldschmeding, Marc Bijl, E. Christiaan Hagen, Hans C. van Houwelingen, Ronald H.W.M. Derksen and Jo H.M. Berden, 
for the Dutch Working Party on SLE.
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Objective. The diversity of abnormalities in renal biopsies from patients with lupus nephritis (LN) is large, making
the assessment of renal biopsies and classification of LN a challenging task.
Methods. In this study five specialised nephropathologists scored 128 biopsies, among which 87 first and 39 repeat biop-
sies, from 87 patients with biopsy-proven proliferative LN, included in a randomised controlled trial. The inter- and
intraobserver agreement (expressed as intraclass correlation coefficients (ICC)) of the scored histopathological items was
calculated. Also, the WHO1995 and ISN/RPS2003 classification systems for LN were compared, with extra attention given
to the comparison between patients with diffuse proliferative LN with either segmental (IV-S) or global (IV-G) lesions. 
Results. There was a wide range of agreement. A good interobserver agreement (ICC >0.6) was present in 15%, and
a moderate interobserver agreement (ICC 0.4-0.6) in 31% of the scored items. The activity index for LN showed a
good (ICC 0.716) and the chronicity index a moderate (ICC 0.494) interobserver agreement. The intraobserver agree-
ment varied. Both classification systems showed low agreement, although consensus was easily reached. Patients
classified as IV-S (n=15) had more favourable clinical parameters at study entry than those with class IV-G (n=57).
Although suggested by others, we found no differences in outcome between these two subclasses.
Conclusion. This study shows that, although definitions were agreed upon beforehand, even specialised nephropatholo-
gists have difficulties with scoring histopathological characteristics of LN, particularly with the classification systems.
Histological studies performed in LN can therefore not easily be extrapolated, and should be interpreted cautiously.
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Renal biopsy All biopsies were performed and processed
locally. Before randomisation, all 87 inclusion biopsies were
reviewed and classified by at least one of three experienced
nephropathologists according to the WHO1995 criteria for
LN (3). The activity index (AI) and chronicity index (CI) were
calculated for each specimen as described previously (8),
with maximum scores of 24 for the AI and 12 for the CI.
After two years, all available patients were asked to have a
protocolised repeat renal biopsy performed for study purpo-
ses only. It was agreed that findings in these biopsies would
be anonymised and not used for therapeutic decisions. The
ethics committees of all participating hospitals approved
this pathology study, and it was conducted according to the
Declaration of Helsinki. After informed consent, 41 patients
underwent a repeat renal biopsy.
Scoring procedure
-Scoring form
Histological characteristics described in LN, together with their
definitions, were gathered from the literature. In three con-
sensus meetings with three specialised nephropathologists,
the list of items was reduced and a concept scoring form was
made. In a pilot study 10 biopsies were scored to solve discre-
pancies and problems. In a consensus meeting, these discre-
pancies were discussed and the scoring form was adjusted. In
another consensus meeting, the scoring form was again dis-
cussed and revised with five different, experienced nephropa-
thologists (I.B., S.F., E.S., C.P., R.G.) and a specialised nephropa-
thologist from abroad (dr. G.S. Hill, Department of Pathology,
Hôpital Europeen Georges Pompidou, Paris, France). With the
final version and after collecting the slides at a central office,
three scoring sessions followed. Each biopsy was scored by
three of five nephropathologists. For the intraobserver agree-
ment purposes an extra scoring session followed, in which
each nephropathologist scored 10 of the biopsies once more.
-Item selection & definitions
The first pathologist marked the section with the most glo-
meruli. For almost all assessments, silver-stained slides
were used (exceptions were predefined). Scoring the biopsy
was divided into several sections: glomerular, tubular, inter-
stitial and vascular. For definitions see the Appendix. For
each glomerulus, the presence of a variety of histopatholo-
gical items was counted. Vascular changes included items
described in the literature to be associated with antiphos-
pholipid syndrome (9-11).
The assessment was completed by filling out the WHO1995
and ISN/RPS2003 classification and activity and chronicity
indices for LN (3,4,8). To simplify the comparisons between
the two classification methods, membranous features were
mentioned as '+V'. After having scored the section, the
nephropathologist was asked to give an opinion on the
overall quality of the biopsy: either poor, reasonable or of
excellent quality. The quality was evaluated on both the
quality of the staining and the quality of the material. After
all scoring sessions were finished, the discrepancies in clas-
sification were discussed and a final joint judgment was
made, during three consensus meetings.
-Antiphospholipid antibodies
Antiphospholipid antibodies were measured in serum or
plasma samples at study entry at the Thrombosis and
Haemostasis Laboratory of the University Medical Centre
Utrecht. IgG anti-cardiolipin levels were measured using a
commercial kit (Varelisa®, Pharmacia Diagnostics,
Freiburg, Germany). The test was considered positive if >10
GPL-Units/ml. A home-made enzyme-linked immunosor-
bent assay was used for the assessment of IgG anti-β2-glyco-
protein-1 antibodies.
Statistical analysis All data were analysed by using SPSS 12.0.1
software. All continuous glomerular variables were expressed
as the percentage of the total number of non-sclerotic and
non-ischaemic glomeruli scored in the section. Intraclass
correlation coefficients (ICC) were used to evaluate both
interobserver and intraobserver readings for the entire set
of slides (12). The ICC is an index of concordance that indi-
cates the degree of agreement beyond that expected by
chance alone, and is appropriate when assessing agreement
between two or more raters. It is expressed in a score ran-
ging between 0 and 1: 0 indicating agreement by chance
and 1 total agreement. In general, values higher than 0.8
are considered excellent, values between 0.6 and 0.8 good,
values between 0.4 and 0.6 moderate and values below 0.4
poor concordance. The ICCs of both continuous, binominal
and ordinal variables can be computed, which also takes
into account the ranking order of the variables. The ICC was
favoured over the Cohen Kappa value since each of the five
observers scored only 3/5 of the biopsies. The scoring of the
biopsies was organised in such a way that an overlap of at
least one third of the slides existed between two nephropa-
thologists. To account for possible systematic differences
between nephropathologists, the nephropathologists were
added to the analyses as random effects. In doing so, the
found ICCs are comparable with the weighted Kappa.
Although the classification systems for LN are not actual
ordinal variables, for this analysis they were regarded to be
ordinal. Comparing the classes without their subcategories
would be too rough. For the descriptive parameters and the
comparisons only those histopathological characteristics
with an ICC >0.4 were used. The mean value of the scores of
the three pathologists who scored the biopsy was taken.
Non-parametric tests were used for the comparison between
patient subgroups. A p value <0.05 was regarded statistical-
ly significant.
Results
Biopsies In total 130 renal biopsies were performed in 87
patients. All patients underwent a biopsy at study entry, and
in two cases an extra biopsy was available, performed one
year before study entry. Forty one patients agreed to under-
go a repeat biopsy after two years of therapy. Of these 41
repeat biopsies, two did not contain glomeruli and were not
included. Therefore 128 biopsies were available for scoring.
Overall, the quality of the preparation of the biopsies was
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good: 55% were judged as excellent and 28% as reasonable.
However, in 17% of 128 biopsies either the staining or cut-
ting quality was judged as poor. A total of 9 out of 128 biop-
sies could not be classified. Reasons were: six or less glome-
ruli (n=7; 5 repeat biopsies and 2 taken at study entry), or
poor quality (n=2, both repeat biopsies).
Interobserver agreement The analyses were performed for
all 128 biopsies. A wide range of agreement for the diverse
characteristics was found. Good or excellent concordance
(ICC >0.6) was present in 15% of all 54 scored characte-
ristics. Agreement was moderate (ICC 0.4-06) in 31% and low
(ICC <0.4) in 54% of all scored characteristics.
The ICCs did not improve if the analyses were done after
exclusion of biopsies with six or less glomeruli or biopsies
of poor quality. The observed ICCs also did not change if
only the biopsies taken at study entry were analysed.
-Glomeruli
Excellent or good intraclass correlation coefficients were
found for the following items: total number of glomeruli
(ICC 0.950), percentage completely sclerosed glomeruli
(0.821), percentage endocapillary proliferation (0.646), per-
centage extracapillary proliferation (0.639) and percentage
spikes (0.629). For several items a moderate ICC was found.
In Table 1 the variables for which excellent, good or mode-
rate agreement existed are listed.
-Tubules and interstitium
Two tubular variables (tubular atrophy and casts) were sco-
red with moderate agreement. Interstitial infiltrate and
fibrosis showed acceptable ICCs, while disagreement
existed for oedema (ICC 0.294).
-Vascular changes
Vascular changes, including items related to antiphospholi-
pid antibodies, were not observed very often. Most frequent
were arteriolar hyalinisation, fibrous intimal hyperplasia,
thrombotic microangiopathy, focal cortical atrophy and
arteriolar thrombosis. Only for arterial fibrous intimal
hyperplasia and arterial thrombosis acceptable agreement
was observed (ICC 0.461 and 0.421, respectively).
Serum antiphospholipid antibodies and histological charac-
teristics of the antiphospholipid syndrome were rare. There
were no correlations between the presence of antiphospho-
lipid antibodies and any of the histopathological features.
The only observation was that patients with IgG anticardio-
lipin antibodies (n=5) surprisingly had a significantly lower
chronicity index (1.7 versus 2.7, p=0.022), but not a higher
activity index (9.7 versus 9.3, ns), compared with patients
that tested negative for these antibodies.
-Actvity and chronicity index
Good concordance was present for the AI (ICC 0.716) and
moderate concordance for the CI (ICC 0.494). However, the
separate components of the AI and CI showed inconsistent
ICCs, varying from 0.277 for fibrous crescents to 0.682 for
cellular crescents (data not shown).
Intraobserver agreement For the assessment of the intraob-
server agreement, each nephropathologist scored 10 of the
biopsies, taken at entry, twice. The agreement scores per
pathologist for the items with a moderate or high ICC in the
interobserver analysis are shown in Table 2.
WHO1995 classification and ISN/RPS2003 classification
Remarkably low ICCs (ICC<0.2) were found for the classifi-
cation systems, using both the WHO1995 and the
ISN/RPS2003 classification. If for the WHO1995 classifica-
tion the subclasses were excluded, and the classes II, III, IV,
V and VI were compared, the level of agreement slightly
improved (ICC improved from 0.108 to 0.368). And, if the
classes were divided into class II, III, IV-S, IV-G, V and VI
(ISN/RPS2003 classification) the ICC increased from 0.181 to
0.405. Table 3 shows how, after reaching consensus, all biop-
sies were classified. Membranous features were present in 3
(21%), in 6 (25%), and in 8 (10%) of the biopsies classified as
class II, III and IV, respectively. None of the repeat biopsies
were classified as pure membranous LN (class Va).
Segmental versus global diffuse proliferative lupus nephritis
In view of the assumed prognostic importance, patients
Table 1 Interobserver agreement: items for which agree-
ment was excellent (ICC >0.8), good (ICC 0.6-0.8) or modera-
te (ICC 0.4-0.6).
item ICC
GLOMERULAR
total number of glomeruli 0.950
percentage completely sclerosed glomeruli 0.821
percentage endocapillary proliferation 0.646
percentage extracapillary proliferation 0.639
percentage spikes 0.629
percentage synechia 0.522
percentage wire loops 0.498
percentage karyorrhexis 0.482
percentage ischaemic glomeruli 0.455
percentage loop necrosis 0.439
TUBULO-INTERSTITIAL
interstitial infiltrate 0.514
tubular atrophy 0.511
casts 0.458
interstitial fibrosis 0.418
INDICES
activity index 0.716
chronicity index 0.494
ICC: intraclass correlation coefficient
For the following items a poor interobserver agreement (ICC <0.4) was found:
percentage double contours, percentage normal glomeruli, percentage mesangi-
olysis, percentage mesangial proliferation, percentage glomerular infiltration
(both mononuclear and polynuclear), mesangial sclerosis (both segmental and
global), lumenal macrophages, tubular necrosis, interstitial oedema, WHO1995
classification, ISN/RPS2003 classification, and some subscores of the activity and
chronicity indices: cellular proliferation, fibrinoid necrosis/karyorrhexis, leukocy-
te infiltration, tubulointerstitial mononuclear infiltration, glomerular sclerosis,
fibrous crescents, interstitial fibrosis. The vascular items were not present often.
assessment of kidney biopsies in lupus nephritis
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with ISN/RPS2003 class IV-S and IV-G were assessed separa-
tely. At study entry, 15 biopsies were classified as class IV-S
and 57 as class IV-G. The clinical characteristics are summa-
rised in Table 4. Patients with segmental lesions had more
favourable characteristics: their renal function was better,
hypertension was less often present, and complement values
and haemoglobin were higher. A number of outcome para-
meters were not different between the two groups, namely
doubling of serum creatinine, frequency of relapses, and
serum creatinine and proteinuria at last follow-up. Actually,
more patients had doubling of serum creatinine in the IV-G
group (n=5) than in the IV-S group (n=0), after a median fol-
low-up of 77 months (interquartile range (IQR) 54-96), but
the differences were not statistically significant. Log rank
analysis of (time to) partial and complete remission did not
show differences between the two groups. Not unexpected-
ly, more endocapillary proliferation and higher scores for
wire loops were present in the biopsies categorised as class
IV-G. Also, the total activity index was lower in class IV-S
(7.7 versus 9.7), but this difference was not significant (see
Table 5 for the histological characteristics). To allow a com-
parison between the ISN/RPS2003 and the WHO1995 classi-
fication, the clinical and histopathological characteristics
were also evaluated for patients with WHO1995 class IVa or
IVb versus those classified as class IVc or IVd (data are added
to Tables 4 and 5). Of the 15 patients classified as ISN/RPS2003
class IV-S, only 2 were categorised as WHO1995 class IVa or
IVb and 13 as IVc or IVd. For the 57 patients classified as
ISN/RPS2003 class IV-G this was 15 and 42, respectively.
Discussion
This is the first time that the interobserver agreement for
many well-described histopathological characteristics of LN
was studied thoroughly, along with both the WHO1995 and
Table 3 WHO1995 and ISN/RPS2003 classification in 119 biop-
sies (2 biopsies before study entry, 85 biopsies at study entry,
and 32 repeat biopsies).
WHO1995 n ISN/RPS2003 n
I 0
IIa 11 II 11
IIb 3 II 3
IIIa 5 III-A 5
IIIb 7 III-A/C 7
IIIc 12 III-C 12
IVa 4 IV-G-A 4
IVb 13
IV-S-A 1
IV-S-A/C 1
IV-G-A 6
IV-G-A/C 5
IVc 58
IV-S-A/C 17
IV-G-A 2
IV-G-A/C 39
IVd 5
IV-S-C 2
IV-G-C 3
V 0
VI 1 VI 1
total 119
Table 2 Intraobserver agreement (10 biopsies each) for the items with excellent, good or moderate interobserver agreement
(see Table 1). Values expressed as ICC per nephropathologist (NP).
item NP1 NP2 NP3 NP4 NP5
GLOMERULAR
total number of glomeruli 0.781 0.986 0.957 0.948 0.981
% completely sclerosed glomeruli 0.753 0.900 0.812 0.874 0.937
% endocapillary proliferation 0.516 0.160 0.602 0.468 0.773
% extracapillary proliferation 0.713 0.764 0.618 0.906 0.610
% spikes 0.654 0.863 0.921 0.606 0.060
% synechia 0.301 0.835 0.637 0.845 0.160
% wire loops 0.074 0.389 0.830 0.146 0.541
% karyorrhexis 0.305 0.290 0.807 0.385 0.747
% ischaemic glomeruli 0.124 0.501 0.000 0.704 0.861
% loop necrosis 0.083 0.081 0.753 0.345 0.976
TUBULO-INTERSTITIAL
interstitial infiltrate 0.013 0.769 0.527 0.631 0.290
tubular atrophy 0.051 0.949 0.739 0.632 0.556
casts 0.632 0.561 0.143 0.385 1.000
interstitial fibrosis 0.083 0.483 0.739 0.632 0.656
INDICES
activity index 0.431 0.197 0.860 0.686 0.236
chronicity index 0.227 0.664 0.693 0.555 0.529
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Table 5 Histopathological characteristics of 72 patients with class IV lupus nephritis at study entry. Comparison of ISN/RPS2003
class IV-S and IV-G, and comparison of WHO1995 class IVa/IVb and IVc/IVd. Median with interquartile range, or number and
percentage are is given.
IV-S IV-G IVa or IVb IVc or IVd
n=15 n=57 p n=17 n=55 p
active lesions
% endocapillary proliferation 50 (37-77) 80 (67-96) 0.002 86 (68-93) 74 (52-92) ns
% extracapillary proliferation* 21 (5-34) 12 (2-31) ns 33 (13-41) 10 (2-28) 0.020
wire loop score ≥25% (n)(%) 1 (7) 27 (47) 0.004 8 (47) 20 (36) ns
activity index
- total score 7.7 (5.3-11.7) 9.7 (7.3-12.5) ns 10.7 (9.2-13.0) 9.3 (7.0-11.0) 0.036
- score ≥10 (n)(%) 5 (33) 28 (49) ns 12 (71) 21 (38) 0.019
chronic lesions
% completely sclerosed glomeruli 0 (0-5) 5 (0-9) ns 0 (0-1) 5 (0-11) 0.002
% synechia 27 (7-38) 16 (6-28) ns 10 (0-14) 23 (9-38) 0.01
tubular atrophy score ≥25% (n)(%) 1 (7) 6 (11) ns 0 (0) 7 (13) ns
interstitial fibrosis score ≥25% (n)(%) 1 (7) 3 (5) ns 0 (0) 4 (7) ns
chronicity index
- total score 2.3 (1.7-3.3) 2.7 (20-3.7) ns 2.0 (1.3-2.7) 3.0 (2.0-3.7) 0.000
- score ≥4 (n)(%) 1 (7) 8 (14) ns 0 (0) 9 (16) ns
* Fibrous crescents are chronic lesions, while cellular crescents are active lesions. Fibrous crescents were scored rarely.
Table 4 Clinical characteristics of 72 patients with class IV lupus nephritis at study entry. Comparison of ISN/RPS2003 class IV-S
and IV-G, and of WHO1995 class IVa/IVb and IVc/IVd. Number and percentage, or median with interquartile range is given.
IV-S IV-G IVa or IVb IVc or IVd
n=15 n=57 p n=17 n=55 p
clinical characteristics
CY/AZA (n) 9/6 35/22 ns 7/10 37/18 ns
age (year) 37 (28-47) 31 (24-41) ns 26 (21-34) 33 (24-44) 0.037
female (n)(%) 12 (80) 50 (88) ns 12 (71) 50 (91) 0.034
Caucasian (n)(%) 12 (87) 40 (70) ns 12 (71) 41 (75) ns
nephritis in past (n)(%) 3 (20) 12 (21) ns 1 (6) 14 (26) ns
hypertension (n)(%) 4 (27) 35 (61) 0.017 8 (47) 31 (56) ns
systolic blood pressure (mmHg) 140 (120-145) 140 (120-150) ns 140 (120-153) 140 (120-150) ns
diastolic blood pressure (mmHg) 80 (70-90) 80 (80-90) ns 80 (78-98) 80 (80-90) ns
disease duration (months) 2.5 (0.4-109) 22 (1-82) ns 2 (1-27) 22 (1-102) ns
SLEDAI 20 (14-26) 21 (16-24) ns 22 (17-27) 20 (14-24) ns
laboratory parameters
Screat (µmol/l) * 95 (72-121) 112 (87-154) 0.039 98 (84-139) 115 (85-152) ns
proteinuria (g/24h) 3.5 (1.8-6.5) 4.2 (2.7-6.6) ns 3.9 (2.8-6.2) 4.1 (2.2-6.7) ns
haemoglobin (mmol/l) 7.6 (7.0-8.3) 6.2 (5.6-7.2) 0.000 6.9 (5.6-7.6) 6.3 (5.6-7.5) ns
C3 (g/l) 0.54 (0.47-0.77) 0.43 (0.32-0.60) 0.012 0.45 (0.24-0.62) 0.49 (0.38-0.63) ns
C4 (g/l) 0.12 (0.10-0.22) 0.10 (0.07-0.12) 0.008 0.08 (0.07-0.14) 0.10 (0.08-0.14) ns
anti-dsDNA (IU/ml) 141 (37-558) 166 (18-553) ns 342 (93-807) 124 (22-502) ns
outcome parameters
follow-up (months) 78 (63-95) 76 (54-95) ns 93 (54-107) 75 (54-88) ns
Screatx2 (n)(%) ** 0 (0) 5 (9) ns 1 (6) 4 (7) ns
failure/relapse (n)(%) 2 (13) 10 (18) ns 2 (12) 10 (18) ns
complete remission (n)(%) 7 (53) 32 (56) ns 12 (71) 28 (51) ns
partial remission (n)(%) 13 (87) 54 (94) ns 16 (94) 51 (93) ns
Screat at last follow-up (µmol/l) 86 (71-94) 79 (73-108) ns 81 (63-111) 79 (72-104) ns
proteinuria at last follow-up (g/24h) 0.5 (0.1-1.4) 0.2 (0.1-0.8) ns 0.1 (0.1-0.5) 0.3 (0.1-1.1) ns
IV-S: class IV-segmental, IV-G: class IV-global, CY: patients treated with cyclophosphamide pulses, AZA: patients treated with azathioprine and methylpred-
nisolone pulses, SLEDAI: SLE disease activity index, Screat: serum creatinine, C3: complement C3, C4: complement C4, Screatx2: doubling of serum creatinine, 
* to convert serum creatinine to mg/dl divide by 88.4, ** primary study end point
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Figure 1 Several examples of histomorphological characteristics, which might explain why a low interobserver and intraob-
server agreement was found. For definitions see the Appendix. Furthermore, since the ISN/RPS2003 classification makes an
explicit distinction between segmental and global lesions, we would like to show you how difficult it can sometimes be to
make this distinction. For answers and considerations see text box on the following page.
(A) Is this a normal glomerulus?
(B) Glomerulus with mesangial changes, but is there endocapillary proliferation as well?
(C) Glomerulus with extensive mesangial proliferation, but is there a component of endocapillary proliferation as well?
(D) Glomerulus with a segmental proliferative lesion, but is it active or chronic?
(E) Glomerulus with mesangial sclerosis, but is it global or segmental? According to the definition, global mesangial sclerosis
involves more than 50% of the glomerular tuft, segmental mesangial sclerosis less than 50%.
(F) Glomerulus with minor inflammation, enough for a positive score? According to the definition, at least 5 inflammatory cells
should be present.
A
C
B
D
E F
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the ISN/RPS2003 classification for LN, among five speciali-
sed nephropathologists. Previous studies have hinted on
this subject, but either did not incorporate classification
data or used the histological characteristics for (prognostic)
regression analyses only. Analyses on why certain lesions
are associated with relatively high interobserver variation
have thusfar not been performed. The present study was
based on 128 renal biopsies of 87 patients with proliferati-
ve lupus nephritis in their initial biopsy, who were included
in a randomised controlled trial. We found a wide range of
agreement and disagreement, not only for the diverse histo-
logical characteristics but also for the WHO1995 and
ISN/RPS2003 classification, of which the latter was assumed
to be easily reproducible (5). A good interobserver agree-
ment was present in only 15% of the 54 scored characte-
ristics, and moderate in 31%. The intraobserver agreement
fluctuated from very poor to nearly perfect. The observation
that if more pathologists examine a biopsy, the disagree-
ment will increase, was described in many other pathology
studies (13-16), and is therefore not unique for LN. However,
since in lupus the variety of histological abnormalities is
huge as compared to other diseases, the problem of variable
interobserver agreement in lupus will probably be larger.
During the scoring sessions and the consensus meetings we
encountered several difficulties in interpreting the defini-
tions and slides. Although definitions for each item were
agreed upon beforehand, the nephropathologists may have
interpreted some of these definitions differently during the
scoring rounds. Most importantly, however, some of the
lesions seem to defy definition, of which we give a number
of examples in Figure 1. We were somewhat hampered by
the variable quality of the slides, caused by the fact that the
biopsies were taken, cut and stained locally. Unfortunately,
immunofluorescence slides were not available for this
study, which for several of the histomorphological items is
essential in order to evaluate them next to the light micro-
scopy findings. We developed a detailed scoring system for
our long-term follow-up study of which the biopsies came
from, but for daily use, this scoring system is too laborious
and unpractical.
Leaving the analysis of the separate parameters apart, the
agreement of the total score of AI and CI appeared to be
good to moderate (0.716 and 0.494, respectively). However,
the reproducibility fluctuated considerably. This is in line
with observations by others (17,18), but not with a study
that reported good inter- and intraobserver agreement
among three nephropathologists, from a single center (19).
Nevertheless, AI and CI scores are still regularly used both
in daily clinical practice and in research.
The disagreement on classification was striking: both for
the WHO1995 and ISN/RPS2003 classification low ICCs were
found (<0.2). Potential causes for these low levels of agree-
ment are smaller biopsies, biopsies in which around half of
the glomeruli were affected, affected glomeruli with both
segmental and global lesions, and the presence of the most
prominent proliferative lesions in the glomeruli at the edge
of the slide. According to the definition of total number of
glomeruli, the latter had to be disregarded, thereby hampe-
ring a proper classification. Finally, for a correct classifica-
tion, a minimum number of ten glomeruli is required (4),
and in several cases, our classification was made on less
than ten glomeruli. However, this did not explain the low
interobserver agreement, since ICCs did not change if the
data were analysed for biopsies with ten or more glomeruli
only. Strikingly, we found that during the consensus mee-
tings, consensus was often reached without difficulties.
Reports on the interobserver agreement of the WHO1995 or
ISN/RPS2003 classification are scarce (20,21). In most stu-
Considerations/answers to the questions (Figure 1):
(A) This is clearly not a normal glomerulus because it shows signs of ischaemia, namely wrinkling of GBM and irregular
Bowman’s capsule. However, it does not contain lupus-related lesions. In counting glomeruli with and without lupus-rela-
ted lesions, for instance to make a decision on a class III or class IV, this glomerulus would be on the ‘normal’ side, and was
categorised as such on the scoring form. 
(B) Next to mesangial changes this glomerulus shows chronic lesions, namely doubling of GBM and ischaemia. However, in a
number of capillary loops, endothelial cells are prominently present. However, leucocytes are absent and obliteration of capillary
loops due to proliferation hardly occurs. Three out of five pathologists scored this as segmental endocapillary proliferation.
However, the other two scored it as global endocapillary proliferation. It is certainly a case of A/C.
(C) The mesangial proliferation is dominant and most of the capillary loops surround the mesangial areas like a corona, without
apparent endocapillary proliferation. However, there seems to be endocapillary proliferation at 7 o’clock, and also at 9 o’clock,
to be scored as segmental.
(D) The mesangial changes in the background of the proliferative lesions are disregarded in making this decision. The prolife-
rative lesion next to the proximal tube has an element of chronicity, namely its adhesion to the capsule, and of activity, namely
its active endocapillary proliferation. Two pathologists scored it as a chronic lesion, letting the adhesion prevail on the decision.
The others chose for A/C.
(E) Mesangial sclerosis is most prominently present in the centre and on the right side of the glomerulus. To a lesser extent, it
is present on the left side and upper side as well. Does it reach an area of more than 50%? All pathologists decided it did.
(F) There seem to be 5 inflammatory cells present in capillary loops, so the answer is yes, and all pathologists agreed on this.
However, some inflammatory cells are difficult to recognise, and could easily be mistaken for endothelial cells. There are also
cells with apoptotic changes, of which it is uncertain whether they are inflammatory cells.
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dies on lupus nephritis only one nephropathologist classi-
fied the biopsies (22,23), or two nephropathologists classi-
fied the biopsies in consensus (6,24-27). An exception is a
report on the ISN/RPS2003 classification which described 60
Japanese patients with LN (20). The consensus between two
pathologists for the ISN/RPS2003 and WHO1995 classifica-
tion, was 98 and 83%, respectively. Another report on both
inter- and intraobserver agreement showed that the consen-
sus between two pathologists who studied 420 renal biop-
sies, was better for the ISN/RPS2003 classification than for
the WHO1995 classification (96 versus 87%), with also a
good intraobserver agreement (99 versus 92%) (28). Issues
regarding the distinction between segmental and global
lesions and outcome were not addressed in the latter study.
Very recently, Furness et al. reported a study on interobser-
ver variability of the classification systems throughout the
UK (21). Twenty renal biopsies, accompanied with clinical
information and immunofluorescence results, were sent to
(untrained) pathologists twice: the first time the pathologist
was asked to classify the biopsies according to the
WHO1995 classification, the second time according to the
ISN/RPS2003 classification. Calculated kappa values were
0.44 and 0.53 for the WHO1995 and ISN/RPS2003 classifica-
tion, respectively. Strikingly, with the ISN/RPS2003 classifi-
cation more biopsies were classified as class IV, mainly
because the new system allows two classes to be recorded,
for example IV+V. Disease activity (acute versus chronic ver-
sus acute and chronic) was poorly agreed upon (kappa 0.33).
They concluded that the ISN/RPS2003 classification is better
reproducible than the WHO1995 classification. In 1989,
Schwartz et al. showed that agreement between local patho-
logists and a committee consisting of three specialised nephro-
pathologists was good. A total of 85 renal biopsies were
assessed. For the three morphologic classifications used in
that study (segmental glomerulonephritis, diffuse glomeru-
lonephritis, and membranous glomerulonephritis with
superimposed severe focal segmental or diffuse glomerulo-
nephritis) the proportion of agreement between the local
pathologist and the central committee ranged from 0.85 to
0.96, while only one of the patients who was regarded eligi-
ble by the local pathologist was disqualified by the speciali-
sed nephropathologists (29). The major difference between
their study and ours was that only four options could be cho-
sen from (not eligible versus segmental, diffuse or membra-
nous glomerulonephritis) while all subclasses were conside-
red for our analyses, and also repeat biopsies were included
from patients treated for proliferative lupus nephritis.
Therefore, our study covered the whole spectrum of glome-
rular abnormalities in SLE.
Regarding the differences between class IV-S and IV-G, our
patients with IV-G had more active disease and worse clini-
cal parameters at study entry. The outcome between the IV-S
and IV-G group was not different, and none of the patients
who were classified as IV-S doubled their serum creatinine.
One of the reasons that we did not find differences in out-
come could be due to the fact that doubling of serum crea-
tinine did not occur often in our study (n=5), after a median
follow-up of 77 months. Like others (20,30,31), we could not
confirm the findings by Najafi et al. (6) that IV-S had a worse
prognosis than IV-G. All three above mentioned studies
(20,30,31) also found worse clinical and histopathological
characteristics in the IV-G patients. The chronicity index in
our population was lower than that in the study by Najafi et
al. (6), and higher than that found in the French study (31).
It is important to realise that the initial report described an
American population, while most of the recent studies,
including ours, were carried out in either European or Asian
patients. The comparison of patients with WHO1995 class
IVa or IVb with those classified as class IVc or IVd revealed
that IV-S and IV-G present as different clinical entities,
while IVa/b and IVc/d are histopathologically different.
Since for the patients with class III LN an impaired renal
function was obligatory for inclusion in our randomised
trial, a comparison between the patients with class IV-S and
IV-G with those with class III (n=11) is not meaningful.
We found no correlation between the presence of circula-
ting antiphospholipid antibodies and the histopathological
features. This could be explained by the small number of
patients who were antibody positive, and the small group of
biopsies with the described features present. But, it could
also partly be explained by the fact that the previously des-
cribed histopathological features (9-11) are not that specific
for the antiphospholipid syndrome.
In summary, although standardising the assessment of
renal biopsies in LN is needed both for clinical and research
purposes, and although the new ISN/RPS2003 classification
seems to be of help, our study shows that even specialised
nephropathologists disagree on quite some histopathologi-
cal characteristics. This disagreement is larger for the clas-
sification than for the activity and chronicity indices.
Our results do not weaken the importance of the classifica-
tion for LN, but they raise the question whether a further
subclassification is meaningful. Indeed, we did not find dif-
ferences in the outcome between the patients with class IV-S
or IV-G lesions, after a median follow-up of 77 months.
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APPENDIX  Definitions of histological features
item definition
GLOMERULAR
number of glomeruli - maximal number of glomeruli excluding those which are incomplete (e.g. at the edge)
normal glomeruli - number of normal glomeruli
completely sclerosed glomeruli - number of completely sclerosed glomeruli
ischaemic glomeruli - number of ischaemic but otherwise normal glomeruli (i.e. with wrinkling of all capillary
basement membranes)
mesangial proliferation - increase in cells in the mesangium, with or without an increase in mesangial matrix
endocapillary proliferation - increase in cellularity of the capillary walls
- on top of mesangial proliferation
- segmental or global (≤ or >50% of Bowman's space)
extracapillary proliferation - ≥3 cells between Bowman's capsule and capillary tuft
- circumferential or segmental (>or ≤50% of Bowman's space)
- cellular (purely cellular), fibrocellular (cellular with the addition of fibrillar material) or
fibrous (predominantly fibrotic (sclerotic) lesion with fibroblasts)
double contours - any duplication of glomerular basement membrane, or so called 'tram tracking'
spikes/vacuoles - extensions of glomerular basement membrane between deposits (egg racks)
- ≥50% of glomerulus
loop necrosis - disruption of glomerular basement membrane, with or without presence of fibrin-rich
material
mesangiolysis - detachment of the glomerular basement membrane from the mesangial matrix with for-
mation of microaneurysms
synechia - small fibrous adhesion of the flocculus with Bowman's capsule without proliferation or
sclerosis
mesangial sclerosis - diffuse mesangial accumulation of silver-positive material
- segmental or global (part or whole of glomerulus, within capillary tuft)
infiltration* - >4 inflammatory cells in the glomerulus
- polynuclear or mononuclear
karyorrhexis* - fragmentation of nuclei
wire loops* - thickened glomerular capillary walls that are deeply eosinophilic
TUBULAR
tubular atrophy* - reduction of the tubular cell height and increase of the tubular diameter
- absent, present but rare (<5-10%), 10-25%, 25-50%, >50%
tubular necrosis* - detachment and/or loss of nuclei of tubular epithelial cells
- present or absent
casts* - proteinaceous structures within the lumen of the tubules, which may contain cellular
debris; only scored when present in non-atrophic tubuli
- present or absent
lumenal macrophages* - macrophages in the tubular lumen
- present or absent
INTERSTITIAL
infiltration - inflammatory cells in the interstitium, in unscarred areas
- absent, present but rare (<5-10%), 10-25%, 25-50%, >50%
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fibrosis - interstitial collagen, and other extracellular material
- absent, present but rare (<5-10%), 10-25%, 25-50%, >50%
oedema - increased extracellular fluid in the interstitium resulting in increased spacing between
tubules; a pale and reticulated appearance with trichrome stains of the interstitium
- present or absent
VASCULAR
vasculitis** - marked vessel lesion with necrosis or necrosis and infiltrates
- present or absent
fibrinoid necrosis** - sharply demarcated, homogeneous, deeply eosinophilic areas of necrosis in the muscular
media
- present or absent
thrombosis** - total occlusion with fibrin
- present or absent
fibrous intimal hyperplasia - increase of fibrous and/or elastic matrix in the intima
- present or absent
- arteries only
hyalinisation - accumulation of glassy, refractile strongly PAS-positive material in the intima and/or
media
- present or absent
- arterioles only
ANTIPHOSPHOLIPID SYNDROME
thrombotic microangiopathy - fibrin thrombi in arterioles and/or glomeruli/(sub)total noninflammatory occlusion of the
vessel by intraluminal, subendothelial, or medial accumulation of fragmented red blood
cells, leukocytes, and eosinophilic material, and/or organised thrombi
- present or absent
cellular intimal hyperplasia - proliferation of myofibroblasts in intima with reduction of the lumen of small-calibre
arteries
- present or absent
focal cortical atrophy - subcapsular ischaemic cortical atrophy, sharply demarcated from normal
- present or absent, or cortex absent in section
* scored in PAS-staining, ** scored in both arteries and arterioles
The prognosis of patients with proliferative lupus nephritis
(LN) has improved considerably since corticosteroids are
combined with cytotoxic immunosuppressive drugs (1). Due
to this intensive treatment, however, also many side effects
occur (1). A tailor-made treatment that fits the individual
patient is therefore needed and searched for.
To identify those patients who are at risk for developing
end-stage renal disease (ESRD), clinical, biochemical and
histopathological predictors have been searched for.
Clinical and biochemical parameters included age (2), sex
(2,3), race (4-6), serum creatinine at presentation (4,7-11),
anti-SS-A antibodies (11), and the SLE disease activity index
(SLEDAI (12)) (9). Parameters in the renal biopsy which pre-
dicted worse outcome in many studies were predominantly
chronic lesions or the total chronicity index (2,4,5,8,10,13-
15). The activity index predicted outcome in some studies
(4,5,7,13,16). However, other studies did not find either of
the indices to be of prognostic value (6,17-21). Several stu-
dies in which repeat or serial renal biopsies were performed
have been published. In most of these studies repeat biop-
sies were obtained for clinical reasons, i.e. when clinical
renal parameters worsened (3,15,22-28). The transition in
LN WHO-class is the focus of most reports (23-25,29-31).
Others evaluated the effects of treatment and the change in
active and chronic lesions (20,32-38), or whether treatment
was changed based on the findings in the repeat biopsy (39).
The suggestion has been made that repeat biopsies are of
more prognostic importance than initial biopsies (21,40).
In a search for a less toxic alternative for cyclophosphami-
de pulse therapy, the first Dutch lupus nephritis study star-
ted in 1995. In this study, 87 patients with biopsy-proven
proliferative LN were randomised to either cyclophospha-
mide pulse therapy, or to azathioprine combined with
methylprednisolone pulses (41). After two years a protocoli-
sed repeat renal biopsy was performed in 39 participants. In
this pathology study, a standardised scoring form was used
to evaluate the changes in renal biopsy parameters and
WHO-class. The purpose of this study was to compare the
biopsy parameters at study entry and after two years, and to
analyse the differences between the two treatment arms.
Moreover, the predictive value of both laboratory and histo-
pathological parameters at study entry and after two years
of treatment were studied.
Cyclophosphamide delays the progression 
of chronic lesions more effectively than 
azathioprine/methylprednisolone in 
proliferative lupus nephritis
Cecile Grootscholten, Ingeborg M. Bajema, Sandrine Florquin, Eric J. Steenbergen, Carine J. Peutz-Kootstra, Roel
Goldschmeding, Marc Bijl, E. Christiaan Hagen, Hans C. van Houwelingen, Ronald H.W.M. Derksen and Jo H.M. Berden, 
for the Dutch Working Party on SLE
key words: outcome measures, lupus nephritis, prognostic factors, activity and chronicity indices, renal biopsies
Objective. To analyse the effect of treatment with either cyclophosphamide pulses (CY) or azathioprine combined
with methylprednisolone (AZA), in protocolised repeat biopsies in patients with proliferative lupus nephritis (LN).
To evaluate the predictive value of histopathological and clinical parameters with regard to disease outcome.
Methods. Biopsies were included from patients with proliferative LN, at study entry (T0) and after two years of the-
rapy (T2). The biopsies were scored according to a standardised scoring form.
Results. 39 of 87 included patients underwent a repeat biopsy. These patients were representative, both at T0 and
T2. The activity index changed from 8.0 to 2.7 (no differences between the treatment groups). In the AZA group the
increase of the chronicity index (from 2.7 to 3.8) was larger than in the CY group (from 2.7 to 3.0)(p=0.050). With
multivariate analyses renal function at T0 and T2 was the best predictor of renal function at last visit, while none
of the histopathological variables (either at T0 or T2) added to this prediction. Comparing patients with a transition
to class II with those who remained to have proliferative LN, showed no differences between CY and AZA (at T0 or
T2), or clinical differences at T2. However, a higher serum creatinine at T0 and more proteinuria at last visit were
characteristic of patients with proliferative LN at T2. 
Conclusion. Although both CY and AZA were effective in reducing active lesions, progression of chronic lesions was
more effectively halted by CY. Repeat biopsy variables did not predict clinical outcome.
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Methods
Patient selection From September 1995 until September
2001, 87 patients with biopsy-proven proliferative LN were
included in the first Dutch lupus nephritis study. In this
randomised controlled trial patients were treated with
either cyclophosphamide pulse therapy with oral predniso-
ne (CY), or azathioprine combined with methylprednisolo-
ne and prednisone (AZA) during two years. After two years
all patients received long-term azathioprine and predniso-
ne. All patients were followed regularly, and clinical and
laboratory parameters were collected according to the
study protocol (41). For this survey, serum creatinine, esti-
mated glomerular filtration rate (GFR) (42), proteinuria,
complement C3, complement C4 and anti-dsDNA titres at
the time of the biopsy were used. The events complete
remission, doubling of serum creatinine and treatment fai-
lure or relapse, and serum creatinine and proteinuria at last
visit were used as outcome measures.
Renal biopsy Before randomisation, all 87 biopsies were
reviewed and classified, according to the WHO1995 criteria
for LN (43). After two years, all available patients were asked
to undergo a repeat renal biopsy for study purposes only,
the results of which would be anonymised  and not used for
therapeutic decisions. The ethics committees of all partici-
pating hospitals approved this pathology study. After
having given their informed consent, 41 patients under-
went a repeat biopsy. Two of these repeat biopsies were
excluded since they did not contain any glomeruli. Thus, for
this study 126 biopsies were used. All biopsies were perfor-
med and processed locally. For this study, they were scored
for several glomerular, tubulointerstitial and vascular items
(see Appendix A) by five nephropathologists. Both the acti-
vity index (AI) and chronicity index (CI) for LN was estima-
ted (13), and both the initial and repeat biopsies were clas-
sified according to the WHO1995 classification.
Definitions For the definitions of the histopathological fea-
tures see Appendix A. The following clinical definitions were
used. Primary study end point: (not necessarily sustained)
doubling of serum creatinine at any time point during fol-
low-up (Screatx2). Primary treatment failure: doubling of
baseline serum creatinine, evaluated at week 12. Relapse
(from week 12 onwards): doubling of the lowest obtained
serum creatinine so far and/or development of either a
nephrotic syndrome (proteinuria >3.5 g/day and serum
albumin <30 g/l), while the lowest protein excretion so far
had been ≤ 2.0 g/day repeatedly, or proteinuria >1.5 g/day
without other causes, in a previously non-proteinuric
patient. Complete remission: serum creatinine <130% of
the lowest serum creatinine since start of treatment, protei-
nuria <0.5 g/day, and <10 erythrocytes/hpf.
Statistical analysis All data were analysed using SPSS 12.0.1
software. All patients were followed for the intention-to-
treat analysis. Descriptive statistics included frequency 
tables of the histopathological and patients' characteristics.
Glomerular parameters were expressed as the percentage of
the total number of non-sclerotic and non-ischaemic glome-
ruli present in the slide. Comparisons and correlations were
studied with non-parametric tests. Intraclass correlation
coefficients (ICC) were calculated (44), using all available
biopsies. In general, values higher than 0.8 were considered
excellent, values between 0.6 and 0.8 good, values between
0.4 and 0.6 moderate, and values below 0.4 poor concordan-
ce. For the analyses of the changes in time between biopsy
at study entry and after two years of therapy, and for the
analyses of the prognostic value of histopathological items,
only those parameters which were frequently present and
showed an ICC >0.4 were used. These are summarised in
Appendix B. Each biopsy was scored by three of the five
nephropathologists and the mean value of the scores was
used for the analyses. Differences between the two treat-
ment groups with regard to histopathological changes be-
tween first and second biopsy was studied with repeated
measurements mixed model tests. The occurrence of the
events 'doubling of serum creatinine', 'failure or relapse'
and 'complete remission' was studied by stepwise logistic
regression and expressed as Nagelkerke R2 (45). The 'time
to' these events was studied using Cox regression analysis.
With stepwise multivariate regression methods the outco-
me variables 'serum creatinine at last visit' and 'proteinuria
at last visit' were analysed. Since there was no normal distri-
bution, these parameters were transformed (log or square
root), before entering the equation. Predictive models are
expressed as adjusted R2. The last observation was carried
forward, except for those patients who were lost to follow-
up during the first two years (n=2). All other patients, inclu-
ding those who experienced a renal relapse, were conside-
red because of the intention-to-treat analysis. For the inde-
pendent histopathological and clinical variables, the p value
to enter the diverse regression analyses was set at <0.05,
and the p value to remain at <0.10. Moreover, to study the
possible effect of the two treatment regimens, treatment
was added to all analyses, as an independent parameter. A
p value ≤ 0.05 was regarded statistically significant. To 
correct for the effect of multiple comparisons, correction
according to Bonferroni was applied to correlation coeffi-
cients, and as a consequence a p value <0.01 was regarded
statistically significant. The uncorrected p values are menti-
oned in the tables.
Results
Clinical data At the beginning of 2006, the median follow-up
was 77 months (interquartile range (IQR) 54-96). Nine
patients reached the primary study end point (non-sustai-
ned doubling of serum creatinine), and this occurred more
often in the AZA group than in the CY group (RR 5.2, 95%CI
1.1-25.2, p=0.040). Primary treatment failure was observed
in one patient who started with haemodialysis at week 12,
and died 9 years later due to intracerebral abscesses after
renal transplantation, without showing any sign of lupus
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activity. Renal relapses occurred in 17 patients. Eight of
these relapses occurred during the first two years of treat-
ment. In the azathioprine-treated patients renal relapses
occurred significantly more frequent (RR 4.9, 95%CI 1.6-15.0,
p=0.006). Seven patients died, and five were lost to follow-
up. The median serum creatinine at last follow-up was 82
µmol/l (IQR 74-108) and median proteinuria at last follow-up
was 0.30 g/24h (IQR 0.10-0.72) (no differences between the
two treatment arms). At last visit most patients were still
using low doses of azathioprine and prednisone (65%). The
other immunosuppressive regimens were: azathioprine
alone (4%), prednisone alone (20%), or mycophenolate mofetil
combined with prednisone (8%), while 4% had discontinued
all immunosuppressive drugs. At the time of last visit 22% of
the patients used statins. The median systolic and diastolic
blood pressure at last visit were 120 (IQR 110-130) and 80
mmHg (IQR 70-83), respectively. The majority of patients
(70%) were using ACE inhibitors (ACEi) or angiotensin-recep-
tor blockers (ARB), and 39% used other or additional antihy-
pertensive drugs. The mean number of antihypertensive
drugs (including ACEi and ARB) was 1.3 (SD 1.1). There were
no differences between the CY and AZA group. 
Characteristics at study entry The histopathological charac-
teristics at study entry are summarised in Table 1.
Extracapillary proliferation was present in a median of 13%
of the glomeruli. It was more often segmental than circum-
ferential (85% versus 15%). Fibrous crescents were rarely
seen. The median activity and chronicity index was 9.3 and
2.7, respectively. There were no differences in histological
items between the two treatment groups, except that endo-
capillary proliferation (especially global) and interstitial
fibrosis were more frequent in the CY group (p=0.012 and
p=0.008, respectively) (data not shown). Although the
patients who presented with LN as their first symptom of
SLE (n=36) had less chronic changes in the biopsy, their
serum creatinine was higher than in patients who had been
diagnosed with SLE previously (p=0.03). Also, karyorrhexis
was more prevalent in patients newly diagnosed with SLE
(p=0.004). Histopathological parameters, which were more
often seen in patients with worse renal function at presen-
tation (GFR <70 ml/min), were mainly tubulointerstitial
lesions: interstitial infiltration, interstitial fibrosis, and
tubular atrophy. Complement factor C3 was negatively asso-
ciated with several active lesions (karyorrhexis, R=-0.389,
p<0.01, and endocapillary proliferation, R=-0.317, p <0.01),
and positively with the total CI (R=0.340, p<0.01). Anti-
all patients patients with 
repeat biopsy
characteristic n=87 n=39 pa
histological characteristics in first biopsy
total number of glomeruli 11 (8-18) 10 (7-18) ns
active lesions
% endocapillary proliferation 71 (47-89) 77 (53-92) ns
% extracapillary proliferationb 13 (3-33) 10 (0-26) ns
% spikesc 0 (0-12) 0 (0-12) ns
% loop necrosis 5 (0-19) 3 (0-22) ns
casts (%) 46 33 ns
wire loop ≥25% (%) 33 41 ns
interstitial infiltrate ≥25% (%) 5 5 ns
activity index
- total score 9.3 (6.7-11.7) 8.0 (6.0-12.0) ns
- score ≥10 (%) 44 41 ns
chronic lesions
% completely sclerosed glomeruli 4 (0-9) 5 (0-11) ns
% ischaemic glomeruli 0 (0-5) 0 (0-2) 0.02
% synechia 16 (6-29) 16 (3-27) ns
interstitial fibrosis ≥25% (%) 8 10 ns
tubular atrophy ≥25% (%) 13 10 ns
chronicity index
- total score 2.7 (2.0-3.7) 2.7 (2.0-3.3) ns
- score ≥4 (%) 16 16 ns
classification
III/IVd 11/72 2/34 ns
clinical and laboratory characteristics at time of 1st biopsy
CY/AZA 50/37 19/20 ns
female (%) 86 82 ns
Caucasian (%) 76 69 ns
age (years) 33 (25-43) 31 (25-36) ns
nephritis in past (%) 21 31 ns
hypertension (%) 58 54 ns
LN presenting symptom (%) 41 46 ns
failure/relapse in first 2 years (%) 10 5 ns
serum creatinine (µmol/l)e 111 (85-156) 98 (84-130) ns
proteinuria (g/24h) 3.9 (2.1-6.5) 3.6 (2.6-7.1) ns
C3 (g/l)f 0.50 (0.37-0.64) 0.50 (0.34-0.63) ns
C4 (g/l)g 0.10 (0.08-0.15) 0.10 (0.05-0.16) ns
anti-dsDNA (IU/ml) 158 (26-545) 68 (23-340) ns
laboratory characteristics at time of 2nd biopsy
n=78 n=39
serum creatinine (µmol/l)e 85 (74-97) 84 (74-95) ns
proteinuria (g/24h) 0.3 (0.03-0.85) 0.2 (0.1-1.2) ns
C3 (g/l) 0.88 (0.72-1.06) 0.84 (0.72-1.06) ns
C4 (g/l) 0.17 (0.12-0.23) 0.16 (0.12-0.23) ns
anti-dsDNA (IU/ml) 12 (0-37) 9 (0-20) ns
Table 1 Histopathological and clinical characteristics of all
included patients and of the patients who underwent a repeat
biopsy. Only items with a moderate to excellent interobserver
agreement (ICC>0.4) were used for the analyses. Nine patients
were no longer available after two years of treatment.
Percentages or median and interquartile ranges are given. 
a p value applies to the comparison of patients who did and those who did
not undergo a repeat biopsy, b fibrous crescents are scored in the chronicity
index, while cellular extracapillary proliferation is a component of the activi-
ty index, c note: spikes were only scored if they covered >50% of the glome-
rular area. d not all biopsies comprised enough glomeruli to be classified, and
two were not classified as proliferative LN, e to convert values of creatinine to
milligrams per decilitre, divide by 88.4, f C3: serum complement C3, g C4:
serum complement C4
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dsDNA autoantibodies were positively correlated with the
total AI (R=0.351, p<0.01), extracapillary proliferation
(R=0.443, p<0.01) and loop necrosis (R=0.354, p<0.01), but
also negatively with karyorrhexis (R=-0.389, p<0.01). If
patients with a high CI (CI≥4, n=14) were compared with
patients with a low CI (CI<4, n=73), they more frequently
had hypertension (p=0.018). Worse renal function was also
seen in patients with a high CI (p=0.045), while no signifi-
cant differences were present for proteinuria. Apart from
the separate components of the CI, patients with a high CI
also more frequently had synechia (p=0.001), another
chronic damage parameter. Patients with a high AI (AI≥10,
n=38) more frequently had an active urine sediment
(p=0.012) and higher anti-dsDNA titres (p=0.01) than
patients with a low AI (AI<10, n=49). There were no diffe-
rences for proteinuria or for renal function between the
high and low AI group. Next to the separate components
of the AI, more loop necrosis was present in biopsies with
a high AI (p=0.000). Also a lower percentage of sclerosed
glomeruli was encountered in patients with a high AI, but
the differences were not statistically significant (p=0.054).
Characteristics of patients who underwent repeat biopsies At
study entry and after two years of therapy, there were no dif-
ferences in clinical characteristics between the subgroup of
patients who underwent a repeat biopsy and those who did
not (see Table 1). Apart from a significantly, but only slightly
lower percentage of ischaemic glomeruli in the patient group
that underwent a repeat biopsy, no differences in histopatho-
logical characteristics at baseline were present (see Table 1).
Moreover, the frequency of primary treatment failure or
renal relapse during the first two years of treatment did not
differ between the group with or without repeat biopsy.
Histopathological changes during treatment At repeat renal
biopsy, a decrease in active lesions was seen, with an in-
crease of chronic damage (Table 2): the AI decreased from
Table 2 Change in histopathological characteristics after two
years of therapy in 39 patients. Only items with a moderate to
excellent interobserver agreement were used for the analyses.
Medians and interquartile ranges or percentages are given.
at inclusion after 2 years
characteristic n=39 n=39 p
active lesions
% endocapillary proliferationa 77 (53-92) 8 (0-27) 0.000
% extracapillary proliferationb 10 (0-26) 0 (0-0) 0.000
% spikes 0 (0-12) 6 (0-39) ns
% wire loopsa 17 (0-36) 0 (0-0) 0.000
% karyorrhexisa 20 (10-47) 0 (0-8) 0.000
% loop necrosis 3 (0-3) 0 (0-0) 0.000
casts (%) 33 49 ns
interstitial infiltrate ≥25% (%)a 5 8 ns
activity index 8.0 (6.0-12.0) 2.7 (2.0-3.3) 0.000
chronic lesions
% completely sclerosed glomerulic 5 (0-11) 10 (6-33) 0.000d
% ischaemic glomeruli 0 (0-2) 2 (0-7) 0.026
% synechiac 16 (3-27) 14 (5-29) ns
tubular atrophy score ≥25% (%)c 10 28 0.009d
interstitial fibrosis >25% (%)c 10 18 0.012
chronicity index 2.7 (2.0-3.3) 3.3 (2.7-4.7) 0.000d
a component of the activity index, b fibrous crescents are scored in the chroni-
city index, while cellular extracapillary proliferation is a component of the acti-
vity index. Fibrous crescent were rare, therefore extracapillary proliferation is
included in the active lesions section of this table, c component of the chroni-
city index, d for these parameters the differences between the first and second
biopsy between the two treatment groups were statistically significant
Table 3 Comparison of patients with persistent proliferative
lesions at repeat biopsy versus those with a transition 
to non-proliferative lesions (class II). One patient had a 
transition to class VI and was excluded from this analysis; the
remaining 7 biopsies could not be classified because they did
not comprise enough glomeruli (n=5) or because of poor
quality of the slides (n=2). Laboratory and histological 
characteristics at study entry as well as at repeat biopsy, and
outcome parameters are given (expressed as medians and
interquartile ranges or percentages).
proliferative non-proliferative
n=19 n=12 p
at study entry
laboratory characteristics
Screat (µmol/l)* 109 (95-146) 86 (83-101) 0.028
proteinuria (g/24h) 3.2 (2.0-5.7) 4.7 (2.0-7.3) ns
histological characteristics
% extracapillary proliferation 21 (5-42) 1 (0-15) 0.025
activity index 9.3 (7.0-13.3) 7.7 (5.4-12.5) ns
% completely sclerosed glomeruli 7 (0-11) 0 (0-2) 0.006
% synechia 17 (1-35) 5 (1-15) ns
tubular atrophy score ≥25% (%) 11 0 ns
chronicity index 2.7 (2.0-3.7) 2.0 (1.1-2.7) 0.014
at second biopsy
laboratory characteristics
Screat (µmol/l)* 83 (74-102) 89 (76-94) ns
proteinuria (g/24h) 0.5 (0.1-1.3) 0.15 (0.07-0.30) ns
C3 (g/l) 0.83 0.97 ns
(0.72-1.06) (0.81-1.30)
anti-dsDNA (IU/ml) 7 (2-14) 9 (0-20) ns
histological characteristics
% extracapillary proliferation 0 (0-2) 0 (0-0) ns
activity index 3.3 (2.5-5.0) 2.0 (1.3-2.6) 0.001
% completely sclerosed glomeruli 10 (6-20) 0 (6-37) ns
% synechia 26 (12-41) 4 (0-13) 0.000
tubular atrophy score ≥25% (%) 32 0 0.037
chronicity index 3.3 (3.0-4.7) 2.7 (2.3-3.5) 0.028
outcome parameters
Screat at last follow-up (µmol/l)* 92 (74-107) 77 (68-82) ns
proteinuria at last follow-up (g/24h)0.50 0.16 0.005
(0.30-1.20) (0.09-0.20)
* Screat: serum creatinine (mmol/l). To convert values of creatinine to 
milligrams per decilitre, divide by 88.4
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8.0 to 2.7 (p<0.001) and the CI increased from 2.7 to 3.3
(p<0.001). In Figure 1 the changes in both the activity and
chronicity index are depicted. The effect of treatment was
significantly different with regard to the extent of comple-
tely sclerosed glomeruli, tubular atrophy, and the CI
(p=0.042, 0.007 and 0.050, respectively). These differences
were all in favour of the cyclophosphamide-treatment. The
CI increased from 2.7 to 3.0 in the CY group, while it in-
creased from 2.7 to 3.8 in the AZA group. The (median) per-
centage of completely sclerosed glomeruli increased from 2
to 9 in the CY group and from 7 to 14 in the AZA group. In
the repeat biopsies, the percentage of biopsies with tubular
atrophy covering ≥25%, was 16% and 40% in the CY and AZA
group, respectively. The extent of the decrease of the AI or
its components was not different between the two treat-
ment arms.
Change in class Of the 39 repeat biopsies, 5 did not compri-
se enough glomeruli to be classified. Two repeat biopsies
could not be classified because of a poor quality of the slides,
leaving 32 biopsies for evaluation. In most biopsies a transi-
tion was seen: 12 (38%) changed from proliferative lupus
nephritis to class II, and 13 (41%) changed from class IV to
class III. The transitions are summarised in Figure 2.
Although more CY patients changed to class II (n=8) as com-
pared with the AZA patients (n=4), and more patients in the
AZA group still had proliferative LN after two years (12 ver-
sus 7 patients), the distribution of these changes between
the two treatment arms was not significantly different
(p=0.149). With the ISN/RPS2003 classification for LN (46)
an equal distribution of the subtypes segmental and global
was also present for the treatment arms, both in the first
and second biopsies. If patients with persistent proliferati-
ve lesions at repeat biopsy (n=19) were compared with
those who changed to class II (n=12), we found no differen-
ces in clinical characteristics at study entry. Although
patients with persistent proliferative LN had a higher
serum creatinine at study entry, both their serum creatini-
ne at repeat biopsy and at last visit were not different. The
patients with persistent proliferative lesions had higher
proteinuria at last visit (0.16 versus 0.05 g/24h), but not at
the other time points. Some of the laboratory and histolo-
gical characteristics are summarised in Table 3.
Association between outcome and clinical or biopsy parameters
-Doubling of serum creatinine and failure or relapse
Neither doubling of serum creatinine, nor failure or relapse
were predicted by clinical or biopsy parameters at study
entry. The treatment with azathioprine/methylprednisolo-
ne, however, was strongly associated with these events
(Nagelkerke R2 for Screatx2: 0.207, p=0.025, and for failure
or relapse: 0.226, p=0.003). Also, for the time to doubling of
serum creatinine and failure or relapse, treatment was the
only predictive factor. At the time of the repeat biopsy none
of the two-year-parameters, including treatment, could pre-
dict the occurrence of doubling of serum creatinine or fai-
lure or relapse, or the time to these events.
-Complete remission
During the first two years, treatment in the two groups was
different. To evaluate a difference in the efficacy of the ini-
tial treatment, remission was defined for this period only.
Thus, for these analyses, only the first biopsy was used.
Reaching complete remission was associated with the per-
centage of completely sclerosed glomeruli (Nagelkerke R2:
0.140, p=0.029). Of the clinical parameters only proteinuria
was associated with reaching complete remission, which is
not surprising since proteinuria (<0.5 g/24h) was one of the
criteria of complete remission. The time to enter complete
remission was also associated with the percentage of sclero-
sed glomeruli. Remission parameters were not predicted by
treatment with azathioprine or cyclophosphamide.
-Parameters at last visit
With regard to the clinical and histopathological parame-
ters at study entry, the combination of renal function, the
percentage of completely sclerosed glomeruli, and the
amount of extracapillary proliferation (adjusted R2 for
these three parameters: 0.248) could predict serum creatinine
at last visit. Serum creatinine at the time of repeat biopsy
predicted serum creatinine at last follow-up. The presence
of tubular casts in the repeat biopsies was also a significant
predictor of serum creatinine at last visit, although the
association was less strong (adjusted R2 for these two para-
meters: 0.410). Neither clinical parameters nor histopatho-
logical parameters in the repeat biopsy could predict protei-
nuria at last visit. The percentage of completely sclerosed
glomeruli and tubular casts present in the first biopsy,
however were significant predictors of the degree of
proteinuria at last visit (adjusted R2 for the two parameters:
0.216). Type of treatment was not a predictor for the out-
come parameters serum creatinine or proteinuria at last
visit. Putting renal function at study entry, renal function at
repeat biopsy, treatment, percentage of sclerosed glomeruli
in the first biopsy and crescents in the first biopsy in a pre-
dictive model the findings were as follows: serum creati-
nine at last visit was best predicted by the combination of
serum creatinine at two years and the percentage of sclero-
sed glomeruli in the first biopsy (adjusted R2 for this com-
bination: 0.585, for serum creatinine at second biopsy
alone: 0.546). Treatment did not add to this equation.
Discussion
In our representative cohort of patients with proliferative
LN who underwent a repeat biopsy after two years of induc-
tion therapy, a significant decrease of the AI and a signifi-
cant increase of the CI was observed, both in patients trea-
ted with cyclophosphamide and those treated with azathio-
prine/methylprednisolone. The increase in chronic changes
was, however, significantly greater in the AZA group. This
means that treatment during 24 months with 13 pulses of
cyclophosphamide is better in tempering the progression of
chronic lesions than a two-year-treatment with azathiopri-
ne and 9 pulses of methylprednisolone. If the cyclophospha-
mide group had not started off with more interstitial fibro-
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Figure 1 Change in activity and chronicity index in 39 patients with proliferative lupus nephritis in whom a repeat biopsy was
performed. (A) Activity index (median and interquartile range), (B) Chronicity index (median and interquartile range), (C)
Change in activity index per patient in the CY group, (D) Change in activity index per patient in the AZA group, (E) Change in
chronicity index per patient in the CY group and (F) Change in chronicity index per patient in the AZA group.
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sis, the observed significant differences with regard to the
chronicity index would probably have been larger, empha-
sising the superior efficacy of cyclophosphamide. This is
also reflected by the lower incidence of relapses and doub-
ling of serum creatinine in the cyclophosphamide group.
Whether azathioprine is also less effective than a short
course of cyclophosphamide, low doses of cyclophosphami-
de, or mycophenolate mofetil remains to be investigated.
Moreover, another relevant question is whether cyclophos-
phamide pulses during 24 months are more effective than
treatment with mycophenolate mofetil. We believe that,
although cyclophosphamide during two years is more effec-
tive both with regard to renal relapses and the effect on
chronic lesions, for selected patients with proliferative LN
who want to avoid the gonadal toxicity of cyclophosphami-
de, treatment with azathioprine/methylprednisolone can
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be an alternative, since so far long-term renal function is
comparable with cyclophosphamide.
In Figure 3 the change in CI between first and repeat biopsy
is depicted, as was observed in our population and found by
other investigators in adults with LN in whom protocolised
repeat biopsies were performed. The solid lines represent
our patient groups, while the dotted lines represent the
other studies (20,32-37). The design of the different studies
is described in the upper panel of Figure 3. Since the CI was
introduced in 1984, all studies published before this date
were not considered. It has to be noted that comparison of
the studies is hampered by the fact that not all studied
patients were diagnosed with proliferative LN, different treat-
ment regimens were given, and either means or medians
were described in these publications. A difference in ethni-
city could also play a role in the observed differences.
Moreover, not all studies on protocolised repeat biopsies
could be included in the figure, since the data were incom-
plete. Performing a genuine meta-analysis on these data
was therefore impossible. Nevertheless, the figure gives an
impression of the observed change in CI during or after
induction treatment. As can be seen the change in CI in our
study population was quite small as compared to others. In
two studies it was found that persistent lower complement
levels were associated with a larger increase of CI and/or
worse renal outcome (14,38). By studying our data, we could
not find a correlation between the depression of C3, the
duration of suppression of C3 and the (change in) CI.
In our population, fourteen (36%) repeat biopsies showed an
AI higher than 3, and none of the biopsies were inactive
(AI=0). Of the patients in whom a repeat biopsy was perfor-
med, one fulfilled the clinical criteria for a renal relapse at
the time of biopsy and was therefore treated with reinduc-
tion therapy, as was prescribed by the study protocol. The
AI and CI in the second biopsy of this particular patient
were 7.7 and 5.7, respectively. All the other patients had cli-
nically silent disease. This discrepancy between clinical
quiescent disease and the presence of active lesions in the
biopsy has been observed by others. Favre et al. found a
mean AI of 3.6±0.5 in 26 repeat biopsies of patients with LN
(WHO-class varying from II to V) after 18-24 months of treat-
ment with cyclosporin A and prednisone (47). Nevertheless,
in general a decline in AI was found, since improvement of
AI was observed in 71% of patients (38), as well as a median
AI of 2.0 (33), in two-year-biopsies.
Many reports were published with regard to the transition in
WHO-class in repeat biopsies in patients with LN, either in
case of clinical deterioration (3,22,27,39), or in protocolised
repeat biopsies to study the results of treatment (34,35,48). Of
our patients in whom a repeat biopsy was performed a chan-
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Figure 2 Transition in WHO1995 class after two years of treatment. Membranous features were present in 5 biopsies at start,
and 6 biopsies after 2 years of therapy. Two repeat biopsies could not be classified due to poor quality of the slides. The remai-
ning five biopsies did not contain enough glomeruli to be classified.
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ge to a less active class was regularly seen, although still 59%
were classified as proliferative LN, predominantly class III.
This is in concordance with most other reports.
The percentage of sclerotic glomeruli in the biopsy at pre-
sentation was the best prognostic factor for the course of the
disease, i.e. reaching complete remission, time to reach com-
plete remission, and serum creatinine and proteinuria at last
visit. This is in line with previous studies (49). Remarkably,
there was no correlation between the percentage of comple-
tely sclerosed glomeruli and renal function at the time of biop-
sy (r=-0.182 for GFR and r =0.175 for serum creatinine). This
could best be explained by hyperfiltration of the remaining
non-inflamed glomeruli. Notably, both the activity and chro-
nicity index failed to predict renal outcome. As many others,
we found that renal function was predictive of outcome
(4,5,7,50). Moreover, renal function after immunosuppressive
treatment for proliferative LN was previously shown to prog-
nosticate long-term renal function (37,51). In contrast to our
data, several authors reported that repeat biopsies were pre-
dictive of outcome (21,33,52). In 1993 Esdaile et al. showed
that subepithelial and subendothelial deposits in repeat biop-
sies were associated with both renal outcome and SLE-related
mortality. Light microscopic characteristics however, were
not significantly associated with outcome, although a trend
was present for the activity and the tubulointerstitial index
and renal outcome (33). Hill et al. studied repeat biopsies in
71 patients after six months of intravenous cyclophosphami-
de, of whom 18 patients had doubled their serum creatinine
after a mean follow-up of 7 years (21). They showed that
patients who had reversible interstitial fibrosis and segmen-
tal glomerular scarring had a better prognosis (52). The main
differences between this study population and ours were that
less of our patients were non-Caucasian (44% versus 24%) and
that our patients were treated with long-term maintenance
treatment. Data on treatment after six months were not
mentioned in the articles by Hill et al. In other studies repeat
biopsies were also predictive of renal outcome, but these had
been obtained for clinical reasons, thereby introducing a
selection bias (3,15). Interestingly, although the increase in
the CI was larger in the AZA group, the CI itself could not pre-
dict outcome, neither at study entry nor in the repeat biopsy.
This could be explained by the overlap of the chronicity
index values in both treatment groups, or by the follow-up of
77 months, which might be too short to find differences in
renal outcome.
Figure 3 Change in chronicity index in protocolised repeat
biopsies in LN as published in the literature, and in our popu-
lation. The lines refer to the following references: (A1) Balow et
al. 1984, corticosteroids only (32), (A2) Balow 1984 et al., cyto-
toxic drug(s) (32), (B) Esdaile et al. 1993 (33), (C) Valeri et al. 1994
(20), (D) Tam et al. 1998 (34), (E) Gunnarsson et al. 2002 (35), (F)
Ding et al. 2004 (36), (G1) Houssiau et al. 2004, high dose intra-
venous cyclophosphamide (37), (G2) Houssiau et al. 2004, low
dose intravenous cyclophosphamide (37), (H1) this study: CY
group (solid line) and (H2) this study: AZA group (solid line). 
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In conclusion, our study showed that treatment with cyclo-
phosphamide pulses during 24 months delays the increase in
chronicity better than azathioprine, and better than in most
studies reported. Whether newer therapies, like mycopheno-
late mofetil, are better in retarding chronic lesions remains
to be determined. The protocolised repeat renal biopsy after
two years of treatment, the results of which did not influen-
ce treatment decisions, did not provide additional informa-
tion with regard to the outcome at last follow-up. Both renal
function at entry and after two years were better predictors
of renal outcome than the histopathological features in the
repeat biopsy. Thus, clinical parameters are more informati-
ve in patients with LN than the findings in the repeat renal
biopsy. Protocolised repeat biopsies should only be perfor-
med in randomised controlled trials, to compare the effect of
the treatment regimens. In our opinion performing a proto-
colised repeat biopsy in individual patients with proliferative
LN does not provide prognostic information.
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APPENDIX A Definitions of histological features
item definition
GLOMERULAR
number of glomeruli - maximal number of glomeruli excluding those which are incomplete (e.g. at the edge)
normal glomeruli - number of normal glomeruli
completely sclerosed glomeruli - number of completely sclerosed glomeruli
ischaemic glomeruli - number of ischaemic but otherwise normal glomeruli (i.e. with wrinkling of all capillary
basement membranes)
mesangial proliferation - increase in cells in the mesangium, with or without an increase in mesangial matrix
endocapillary proliferation - increase in cellularity of the capillary walls
- on top of mesangial proliferation
- segmental or global (≤ or >50% of Bowman's space)
extracapillary proliferation - ≥3 cells between Bowman's capsule and capillary tuft
- circumferential or segmental (>or ≤50% of Bowman's space)
- cellular (purely cellular), fibrocellular (cellular with the addition of fibrillar material) 
or fibrous (predominantly fibrotic (sclerotic) lesion with fibroblasts)
double contours - any duplication of glomerular basement membrane, or so called 'tram tracking'
spikes/vacuoles - extensions of glomerular basement membrane between deposits (egg racks)
- ≥50% of glomerulus
loop necrosis - disruption of glomerular basement membrane, with or without presence of fibrin-rich
material
mesangiolysis - detachment of the glomerular basement membrane from the mesangial matrix with 
formation of microaneurysms
synechia - small fibrous adhesion of the flocculus with Bowman's capsule without proliferation 
or sclerosis
mesangial sclerosis - diffuse mesangial accumulation of silver-positive material
- segmental or global (part or whole of glomerulus, within capillary tuft)
infiltration* - >4 inflammatory cells in the glomerulus
- polynuclear or mononuclear
karyorrhexis* - fragmentation of nuclei
wire loops* - thickened glomerular capillary walls that are deeply eosinophilic
TUBULAR
tubular atrophy* - reduction of the tubular cell height and increase of the tubular diameter
- absent, present but rare (<5-10%), 10-25%, 25-50%, >50%
tubular necrosis* - detachment and/or loss of nuclei of tubular epithelial cells
- present or absent
casts* - proteinaceous structures within the lumen of the tubules, which may contain cellular
debris; only scored when present in non-atrophic tubuli
- present or absent
lumenal macrophages* - macrophages in the tubular lumen
- present or absent
INTERSTITIAL
infiltration - inflammatory cells in the interstitium, in unscarred areas
- absent, present but rare (<5-10%), 10-25%, 25-50%, >50%
fibrosis - interstitial collagen, and other extracellular material
- absent, present but rare (<5-10%), 10-25%, 25-50%, >50%
92
oedema - increased extracellular fluid in the interstitium resulting in increased spacing between
tubules; a pale and reticulated appearance with trichrome stains of the interstitium
- present or absent
VASCULAR
vasculitis** - marked vessel lesion with necrosis or necrosis and infiltrates
- present or absent
fibrinoid necrosis** - sharply demarcated, homogeneous, deeply eosinophilic areas of necrosis in the muscular
media
- present or absent
thrombosis** - total occlusion with fibrin
- present or absent
fibrous intimal hyperplasia - increase of fibrous and/or elastic matrix in the intima
- present or absent
- arteries only
hyalinisation - accumulation of glassy, refractile strongly PAS-positive material in the intima and/or
media
- present or absent
- arterioles only
ANTIPHOSPHOLIPID SYNDROME
thrombotic microangiopathy - fibrin thrombi in arterioles and/or glomeruli/(sub)total noninflammatory occlusion of the
vessel by intraluminal, subendothelial, or medial accumulation of fragmented red blood
cells, leukocytes, and eosinophilic material, and/or organised thrombi
- present or absent
cellular intimal hyperplasia - proliferation of myofibroblasts in intima with reduction of the lumen of small-calibre
arteries
- present or absent
focal cortical atrophy - subcapsular ischaemic cortical atrophy, sharply demarcated from normal
- present or absent, or cortex absent in section
* scored in PAS-staining, ** scored in both arteries and arterioles
APPENDIX  B Histopathological items for which agreement between five nephropathologists was good
(ICC >0.6) or moderate (ICC 0.4-0.6).
characteristic ICC
GLOMERULAR
% total glomeruli 0.950
% completely sclerosed glomeruli 0.821
% endocapilllary proliferation 0.646
% extracapillary proliferation 0.639
% spikes* 0.629
% synechia 0.522
% wire loops 0.498
% karyorrhexis 0.482
% ischaemic glomeruli 0.455
% loop necrosis 0.439
TUBULAR
tubular atrophy 0.511
casts 0.458
INTERSTITIAL
interstitial infiltrate 0.514
interstitial fibrosis 0.418
INDICES
activity index 0.716
chronicity index 0.494
ICC: intraclass correlation coefficient
* spikes were only scored if they covered >50% of the glomerular area.
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In this thesis a kaleidoscopic spectrum of aspects regarding
SLE, in particular lupus nephritis, are described. SLE has
manifestations throughout the body, with variable severity
and is characterised by remissions and exacerbations. Thus,
collaboration and a broad view by physicians and resear-
chers is required. Furthermore, the disease and its therapy
have a great impact on the lives of the patients, which
should be taken into account while caring for lupus
patients. This thesis deals with several wide-ranging
questions: (i) What is the role of nucleosomes in the patho-
genesis of SLE/lupus nephritis and can anti-chromatin auto-
antibodies be helpful in the detection and follow-up of
patients with the disease?; (ii) Which treatment is optimal
for proliferative lupus nephritis, with regard to both renal
parameters and therapy-related morbidity and quality of
life?; (iii) Is it possible to stop immunosuppressive therapy,
and if so, in which patients with proliferative lupus nephri-
tis?; (iv) Do renal biopsies give information on the course of
the disease, and do they help to identify patients at greatest
risk of therapy failure and eventual renal outcome?
Although the prognosis of patients with proliferative lupus
nephritis has improved considerably over the last decades,
morbidity should not be underestimated. Whereas in the
seventies survival was the first target of treatment, the
focus has changed to a better balance between both effica-
cy and side effects. The accepted treatment approach for
proliferative lupus nephritis nowadays is to combine corti-
costeroids with a cytotoxic immunosuppressive drug. For a
long time cyclophosphamide combined with corticoste-
roids was regarded first choice of therapy. However, since
cyclophosphamide has substantial side effects, less toxic
regimens are searched for. The most important side effect
of cyclophosphamide is premature ovarian failure.
Therefore, we conducted a randomised controlled trial in
patients with proliferative lupus nephritis to study a regi-
men with and a regimen without cyclophosphamide. Not
only the effect on renal function, but also the effect on auto-
antibodies involved in the development of lupus nephritis
and on quality of life was evaluated.
Part I Pathogenesis
Nucleosomes play a pivotal role in the pathogenesis of
lupus nephritis. The current opinion on the hypothesis of a
disturbed removal of apoptotic cells and its consequences
are given in Chapter II. In the past, nucleosomes and histo-
nes were shown to be present in deposits in the glomerular
basement membrane (GBM) of patients with lupus nephri-
tis. The binding to the GBM of autoantibody/antigen com-
plexes seems to occur through the negatively charged hepa-
ran sulfate. Heparan sulfate is present in basement mem-
branes throughout the body. To study the presence of nucle-
osome/anti-chromatin complexes in the (easily reachable)
epidermal basement membrane, we studied biopsies of
non-lesional skin from patients with active proliferative
lupus nephritis and from patients with inactive SLE. These
were compared with skin biopsies from patients with insu-
lin-dependent diabetes mellitus (non-autoimmune disease
controls), and from patients with parapemphigus (disease
controls with IgG deposits in the dermal basement mem-
brane). In Chapter III we show that indeed histones were pre-
sent in the epidermal basement membrane of patients with
active proliferative lupus nephritis, whereas this was not
the case in skin biopsies from inactive SLE patients and dia-
betic patients and only in a few biopsies from patients with
parapemphigus. Using monoclonal anti-nucleosome antibo-
dies the only positive staining was found in the patients
with active proliferative lupus nephritis (7%). From these
data it can be concluded that nucleosome-mediated binding
to basement membranes in patients with lupus nephritis
does not only occur in the kidney, but also at other sites. In
the next study, Chapter IV, we evaluated the effect of treat-
ment on autoantibody profiles in serial plasma samples
from patients included in the first Dutch lupus nephritis
study. Anti-chromatin responses, including anti-dsDNA,
anti-histone and anti-nucleosome autoantibodies were stu-
died. Moreover, anti-C1q autoantibodies and mannose bin-
ding lectin concentrations were analysed. We found that at
study entry most patients were positive for anti-dsDNA
autoantibodies (96%), anti-nucleosome autoantibodies (81%)
and anti-C1q autoantibodies (62%), whereas anti-histone
autoantibodies were present in only 23% of the patients.
During treatment the autoantibody levels decreased signifi-
cantly and similarly during cyclophosphamide and azathio-
prine/methylprednisolone treatment. The levels of anti-
histone autoantibodies did not change during treatment.
Renal relapses were not preceded by an increase in autoan-
tibody levels. The anti-chromatin autoantibodies correlated
with each other, but not with anti-C1q autoantibodies con-
firming that they arise by different antigenic stimulation.
Patient characteristics and the course of the disease were
only slightly different for the diverse autoantibody entities.
Summary & conclusions
Cecile Grootscholten
key words: thesis, lupus nephritis, apoptosis, autoantibodies, histopathology, classification, randomised controlled trial, 
immunosuppression, future
Chapter XI Considerations
correspondence: Cecile Grootscholten, MD, Division of Nephrology (464),
Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB
NIJMEGEN, The Netherlands, m.grootscholten@aig.umcn.nl
submitted: 29 September 2006; accepted: 25 October 2006
94
Mannose binding lectin concentrations were not related to
disease activity. Mannose binding lectin concentrations did
not change during treatment suggesting that mannose bin-
ding lectin is not significantly consumed during active di–
sease. In conclusion: anti-chromatin autoantibodies and
anti-C1q autoantibodies were present in most patients with
active lupus nephritis and their levels decreased during tre-
atment. However, since they were not associated with disea-
se course or renal outcome, they seem not to be helpful for
monitoring patients during treatment.
With the findings from the studies in the first part of this
thesis it is not possible to determine the exact role which
nucleosomes play in the pathogenesis in lupus nephritis.
However, previous studies from our laboratory underline the
importance of nucleosomes for the induction of SLE and the
evolution of renal and other disease manifestations (1). Direct
intrarenal perfusion of nucleosome/autoantibody complexes
led to a clear binding in the glomerular capillary wall in
contrast to isolated nucleosomes, purified autoantibodies
free from nucleosomal material, or nucleosomes and sub-
class-specific control antibodies. Removal of heparan sulfate
by heparitinase prior to perfusion prevented this GBM bin-
ding, pointing to the pivotal role of heparan sulfate as target
ligand in the GBM. These in vivo perfusion experiments were
confirmed by i) the masking of heparan sulfate in the GBM
by nucleosome/Ig complexes in both murine and human
lupus nephritis; ii) the deposition of histones in the base-
ment membrane of the kidney and the skin (this thesis) of
patients with active lupus; iii) the prevention of nucleoso-
me/Ig complexes in the GBM in murine lupus by treatment
with 'heparan sulfate lookalikes', like heparin and non-coa-
gulant heparinoids. Recently, these findings were supported
by the research group of Dr. Rekvig. With meticulous and
laborious co-localisation electron microscopy techniques
they found that in murine lupus, IgG was targeted to chro-
matin in the GBM and not to other putative cross-reactive
intrinsic GBM ligands, like laminin and alpha-actinin (2). In
yet unpublished findings they also documented this in
human lupus nephritis. Given this important role of nucleoso-
mes, why did we not find a better correlation between anti-
chromatin autoantibodies and lupus nephritis? First, so far
nucleosomes isolated from normal cells have been used as
antigens. Based on our hypothesis, the use of nucleosomes
from apoptotic cells might be better, since these will contain
putative apoptosis-induced modifications. Second, from
reports studying the importance of anti-dsDNA for disease
flares, it has become clear that frequent, monthly sampling
is necessary. Last, in time course studies in mouse lupus
models, we found that evolution of renal disease was accom-
panied by lower levels of anti-nucleosome antibodies. The
nephritogenic antibodies apparently disappeared from the
circulation as they were targeted to the kidney (3). Our cur-
rent techniques and sampling protocols showed an associa-
tion between autoantibody profiles and the presence of
overt renal disease, but did not allow us to support an impor-
tant role of these autoantibodies in the occurrence of renal
flares. Since this is the first analysis in which autoantibodies
were measured prospectively, more studies are needed.
Part II Clinical aspects
As outlined before, in the first Dutch lupus nephritis study,
patients were randomised to either cyclophosphamide pul-
ses or to azathioprine combined with methylprednisolone
pulses. Of the enrolled 87 patients, 50 were randomised to
cyclophosphamide pulses during two years, while 37 were
allocated to treatment with azathioprine/methylprednisolo-
ne. Both groups also received oral prednisone. At start of
the study it was expected that, after five years of follow-up,
30% of the patients in the cyclophosphamide group would
have doubled their serum creatinine, while a maximum of
50% was regarded acceptable in the azathioprine group.
Unfortunately, we did not manage to include the required
number of 100 patients which caused a loss of power. In
Chapter V we report the results after a median follow-up of
5.7 years (interquartile range 3.9-6.6). Noticeably, less than
the expected 30% of all patients had doubled their serum
creatinine. This doubling of serum creatinine did hardly
ever lead to renal insufficiency. At least in part this may be
due to the fact that in the definitions we used in our study,
a doubling of serum creatinine did not have to be sustained.
As treatment was rapidly adjusted, as prescribed by the pro-
tocol, renal function and proteinuria improved in most
patients. However, more renal failures and relapses occur-
red in the azathioprine group, which suggests that azathio-
prine/methylprednisolone is less potent in silencing the
disease. In Table 1 the occurrence of renal relapses in diffe-
rent time periods during follow-up is given. The frequency
is normalised per 100 patient years to allow a proper com-
parison (see also Table 1 of Chapter VIII). The course of labo-
ratory parameters and the number of patients reaching par-
tial or complete remission, and the time to do so, did not
differ between the two treatment arms. Regarding side
Table 1 Renal relapse rate, expressed as number of relapses
per 100 patient years during various periods of follow-up in
the first Dutch lupus nephritis study population.
renal relapse rate 
(number/100 patient years)
study period (years) n total CY AZA
during first 2 years of treatment 87 6.0 2.1 11.0
from 2 to 5 years of follow-up* 82 4.4 2.3 7.1
after a minimum follow-up of 5 years** 61 3.4 1.4 5.5
CY: patients randomised to treatment with cyclophosphamide pulses, AZA:
patients randomised to treatment with azathioprine and methylprednisolone
pulses, * after two years of therapy the treatment was identical in both treatment
groups (azathioprine 2 mg/kg/day combined with prednisone 10 mg/day).
After four years after study entry, this regimen was tapered over the period of
one year to: azathioprine 1 mg/kg/day and prednisone 10 mg every other day,
** after five years of therapy low doses of azathioprine (1 mg/kg/day) and
prednisone (10 mg every other day) were continued until at least seven years
after study entry (or after reinduction therapy for a renal relapse).
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effects, an equal amount of pregnancies and patients with
premature ovarian failure was seen in both groups.
Unexpectedly, more infections, especially herpes zoster
virus infections, were observed in the azathioprine group.
The absence of a difference in gonadal toxicity might be due
to the fact that the most important reason for patients not
to participate in the study was a strong wish to conceive.
The higher frequency of herpes zoster virus infections in
the azathioprine/methylprednisolone group might be
explained by the larger dosage of corticosteroids these
patients were given. The number of hospital admissions for
infections was not different between the two treatment
groups. From these data we can conclude that, although
during azathioprine/methylprednisolone treatment more
relapses and infections occurred, this regimen may be an
alternative for cyclophosphamide for some patients with
proliferative lupus nephritis. Until now, 80% of our patients
did not develop a doubling of their serum creatinine. And,
so far 80% of the patients who were randomised to treat-
ment with azathioprine/methylprednisolone could avoid
cyclophosphamide. Most importantly, at last follow-up
serum creatinine and proteinuria did not differ between the
two treatment arms. Long-term follow-up is needed to
detect assumed differences in renal function, especially in
those patients who experience a renal relapse. Patients who
consider a treatment with azathioprine/methylprednisolo-
ne need to be informed that the risk for relapses or treat-
ment failures and infection is increased, and that long-term
follow-up is needed to draw final conclusions for both pre-
servation of renal function and fertility.
Although generic quality of life measures are valuable in
patients with SLE, disease-specific questionnaires can provi-
de important additional information. Therefore, a new SLE-
specific questionnaire, the SLE Symptom Checklist (SSC),
was developed. In Chapter VI analyses with the SSC and
other quality of life instruments are described. In lupus
patients with stable disease and patients with active lupus
nephritis who were treated with cyclophosphamide, it was
shown that the SSC had a high internal consistency, was
reproducible and was able to detect changes. While signifi-
cant correlations were found between the SSC and the
other quality of life instruments and also the patient's visual
analogue scale (VAS), no correlation was found with disease
activity measured with the SLE disease activity index (SLEDAI)
and the physician's VAS. This indicates that experiencing
symptoms of disease and therapy, and the impact of disease
on daily life, are other aspects of SLE than disease activity
as measured by the treating physicians. Therefore, next to
the physical and laboratory findings, specific attention
should be paid to patient's complaints. It is concluded that
the SSC can be used in clinical and research settings. The
effect of both treatment regimens on quality of life is discussed
in Chapter VII. Although it was anticipated that during treat-
ment the number of side effects and the total burden of
both disease-related and treatment-related side effects
would be less in the azathioprine group, no differences
were found between the two treatment groups. In both
groups the domains of the various quality of life scales
improved similarly. Despite therapy, still subnormal values
for most of the domains of a general and often used quality
of life instrument, MOS-SF36, were present after two years.
This shows that suffering from proliferative lupus nephritis
has a great impact on daily life. The mentioned experienced
treatment burden was larger in cyclophosphamide-treated
patients. The patient's VAS increased only slightly but did
not further increase after one year of treatment. This phe-
nomenon of 'coping' has also been found in other patients
with chronic diseases: due to the changes in physical health
a cognitive adaptation occurs. In Chapter VIII an overview 
is given of studies on relapse frequency in patients with 
proliferative lupus nephritis in whom immunosuppressive
drugs were minimised or discontinued. The number of studies
in which it was attempted to discontinue all drugs is limited.
Since in a considerable number of patients a relapse occurs,
which indicates a higher chance of permanent loss of renal
function, one should be very careful. However, the positive
impact on side effects, for example osteoporosis and lipids,
should also be taken into account. Only in those patients
who have been treated for at least five years and who are both
clinically and serologically in remission, it can be considered to
attempt tapering the immunosuppressive drugs. This should
always be done at slow pace and under strict surveillance.
The studies in this thesis dealing with the clinical issues in
patients with lupus nephritis implicate that the search for
the optimal treatment regimen in terms of effect on renal
function and to lessen the burden of disease and treatment
should continue. To answer the most interesting question
(What is the renal function after a long follow-up of 10 to 15
years?), a conscientious follow-up of our patients is needed.
Beside the treatment regimens chosen for this randomised
controlled trial, other alternatives for long-term cyclophos-
phamide pulse therapy should be investigated. Shorter and
lower doses of cyclophosphamide (4,5) and mycophenolate
mofetil (MMF) (6-8) are currently studied in clinical trials.
Especially MMF shows favourable results in establishing
remission, not only in Caucasian but also in Afro-American
and Asian patients. However, long-term follow-up is also
needed for this drug, since long-term studies are currently
lacking. Newer therapies, for example anti-B cell therapy
with anti-CD20, have been studied in small groups, mainly
in patients with lupus resistant to cyclophosphamide. It
should be noted that these therapies are very expensive,
whereas both cyclophosphamide and azathioprine are not.
Future studies should include a comparison in patients with
different backgrounds, and these studies should have
enough power and a long follow-up. To enable this, (inter-
national) collaboration of both rheumatologists and nephro-
logists from many centres is needed. An important issue
which should be taken into consideration when studying dif-
ferent treatment options, is the impact of the disease and
side effects of treatment on daily life. As in time a patient
learns to deal with having a chronic disease, also the burden
of the experienced symptoms changes. It could not be
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demonstrated that azathioprine/ methylprednisolone resul-
ted in a better quality of life than cyclophosphamide, as was
measured with both generic and disease-specific questionnai-
res. In the future more SLE patient groups should be studied
to show the value of the SSC. Since over the years the prog-
nosis of patients with lupus nephritis has improved, the
focus on induction treatment could partially shift to main-
tenance therapy. Studies should be undertaken in which
not only the choice of maintenance drug treatment, but
also the dosage and duration of maintenance therapy are
considered. Since treatment has considerable side effects, it
should be limited as much as possible. However, since each
renal flare is associated with (some) loss of glomeruli, main-
tenance therapy with low doses of drugs might result in a
better (renal) outcome than discontinuing all drugs.
Prospective studies are needed to answer the question in
whom, when and how the maintenance treatment should
be given and in whom and when immunosuppressive drugs
can be discontinued.
Part III Renal histopathology
Renal biopsies were performed in all patients before study
entry. After two years of therapy protocolised repeat renal
biopsies were available from 39 patients. Since in other
diseases it was shown that the agreement among patholo-
gists varies considerably and the diversity of changes descri-
bed in lupus nephritis is large, we wanted to study the
agreement among Dutch specialised nephropathologists. As
is described in Chapter IX a scoring form was developed. Five
nephropathologists systematically judged and scored all
biopsies. A wide range of agreement was found. It was low
for the WHO1995 and ISN/RPS2003 classification systems.
For the often used activity index and chronicity index for
lupus nephritis the agreement was good and moderate, res-
pectively. However, the individual parameters of these indi-
ces also showed variable agreement. This implies that the
pathologists had a similar 'overall feeling' of chronicity or
activity, instead of interpreting the separate definitions
similarly. Furthermore, we focused on the subclasses seg-
mental and global diffuse proliferative lupus nephritis (IV-S
and IV-G). Although at study entry several laboratory diffe-
rences were found, the suggested differences in outcome
between these two groups could not be confirmed. On the
contrary, although not statistically different, none of the
patients classified as IV-S had doubled their serum creatini-
ne after a median follow-up of 77 months. From our data it is
concluded that making subclassifications in lupus nephritis
is not consequential for daily clinical practice (i.e. treat-
ment options are the same) and that histological studies in
lupus nephritis should be interpreted with caution. To
study the effects of the two treatments with regard to the
histopathological parameters, as described in Chapter IX, we
compared the findings in the biopsies taken at study entry
with those obtained after two years of therapy. In Chapter X
these data are presented. The patients who underwent a
repeat biopsy were representative of the total group of
patients. After two years of therapy a decrease in active
lesions and an increase in chronic lesions was observed. By
comparing the two treatment groups, it was shown that the
increase of several chronic lesions and the (composite) chro-
nicity index was significantly larger in the azathioprine
group than in the cyclophosphamide group. However, by
comparing our data with other studies in which protocoli-
sed repeat renal biopsies were performed, the increase in
both groups was relatively small. 
In the past, others have searched for predictive parameters
for (renal) outcome and course of disease. We studied the
predictive value of both clinical, laboratory and histopatho-
logical parameters at study entry and after two years of the-
rapy. Treatment was the only predictor of experiencing a
renal relapse, while renal function both at study entry and
after two years was a better predictor of serum creatinine at
last visit than the biopsy parameters. Although several
histopathological parameters in the first biopsy added to
the prediction of serum creatinine at last visit, neither the
chronicity index nor the activity index in the repeat biopsy
predicted renal outcome. Therefore, it is concluded that cli-
nical parameters are more helpful for daily clinical practice
than performing a repeat renal biopsy.
The chapters in the final part of this thesis show that asses-
sing a renal biopsy from a patient with lupus nephritis is not
a simple task, and that it is subject to considerable inter- and
intraobserver variation. International training and forums
might improve the agreement among nephropathologists.
Subclassifying diffuse proliferative lupus nephritis into seg-
mental or global should be used for research purposes only,
until it has proven its value for clinical practice. Based on
our analyses and those in the literature, it may be questio-
ned whether the classification of lupus nephritis should be
simplified. In our opinion a division into membranous,
mesangial, proliferative and sclerosing lupus nephritis is
sufficient, if also overall activity and chronicity is scored
with the NIH activity and chronicity indices. In the future,
protocolised repeat biopsies obtained from different rando-
mised controlled trials could help to answer the question
whether or not the treatment schedules are able to prevent
an increase in chronic lesions, and whether these lesions
affect the final renal outcome of the lupus patients. The
search for prognostic histopathological factors should con-
tinue, and since short-term treatment efficacy has impro-
ved, long-term studies are needed.
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In dit proefschrift komt een caleidoscopisch spectrum van
aspecten van systemische lupus erythematosus (SLE) aan
bod, met de nadruk op lupusnefritis. SLE komt in het gehe-
le lichaam voor, varieert in ernst en wordt gekarakteriseerd
door remissies en exacerbaties. Samenwerking en een brede
blik van artsen en onderzoekers is derhalve vereist.
Daarnaast heeft zowel de ziekte zelf als ook de behandeling
een grote impact op het dagelijks leven van de patiënt. Dit
moet worden meegenomen bij de behandeling van lupuspa-
tiënten. Meerdere vragen komen in dit proefschrift aan de
orde: (i) Wat is de rol van nucleosomen in de pathogenese
van SLE/lupusnefritis, en zouden anti-chromatine-autoanti-
stoffen nuttig kunnen zijn bij het vaststellen van de ziekte en
het monitoren van de behandeling? (ii) Welke behandeling
is optimaal voor patiënten met proliferatieve lupusnefritis,
zowel wat betreft renale parameters als therapie-gerelateer-
de morbiditeit en kwaliteit van leven?; (iii) Is het bij patiën-
ten met lupusnefritis mogelijk om de immuunsuppressie te
stoppen, en zo ja, bij wie dan?; (iv) Geven nierbiopten infor-
matie over het beloop van de ziekte, en kunnen nierbiopten
behulpzaam zijn bij het identificeren van patiënten met de
grootste kans op therapiefalen en de uiteindelijke nierfunctie?
Alhoewel in de afgelopen decennia de prognose van patiën-
ten met proliferatieve lupusnefritis verbeterd is, moet de
morbiditeit niet worden onderschat. Terwijl in de zeventi-
ger jaren overleven het belangrijkste doel van de behande-
ling was, is de focus nu verschoven naar een betere balans
tussen effectiviteit en bijwerkingen. De huidige, geaccep-
teerde behandelingsaanpak van proliferatieve lupusnefritis
is om corticosteroïden te combineren met een cytotoxisch
immuunsuppressivum. Lange tijd is de combinatiebehande-
ling van cyclofosfamide met corticosteroïden als eerste
keuze beschouwd. Echter, aangezien cyclofosfamide aan-
zienlijke bijwerkingen kent, wordt er gezocht naar minder
toxische regimes. De belangrijkste bijwerking van cyclofos-
famide is het optreden van een vroegtijdige menopauze.
Wij zijn een gerandomiseerde, gecontroleerde studie
gestart, om bij patiënten met proliferatieve lupusnefritis
een behandeling met en een behandeling zonder cyclofos-
famide te onderzoeken. In deze studie zijn, naast het effect
op de nierfunctie, het effect op autoantistoffen die samen-
hangen met het ontstaan van lupusnefritis en het effect op
de kwaliteit van leven bestudeerd.
Samenvatting
trefwoorden: proefschrift, lupusnefritis, apoptose, autoantistoffen, histopathologie, classificatie, gerandomiseerde studie,
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Deel I Pathogenese
Nucleosomen spelen een cruciale rol in de pathogenese van
lupusnefritis. De huidige opvattingen met betrekking tot de
hypothese van een stoornis in het opruimen van apoptoti-
sche cellen en de gevolgen hiervan worden beschreven in
Hoofdstuk II. In het verleden is aangetoond dat nucleosomen
en histonen aanwezig zijn in deposities in de glomerulaire
basaalmembraan (GBM) van patiënten met lupusnefritis.
Het aan de GBM binden van antigeen/autoantistofcom-
plexen lijkt via het negatiefgeladen heparansulfaat plaats te
vinden. Heparansulfaat is aanwezig in basaalmembranen in
het gehele lichaam. Om de aanwezigheid van nucleosoom/
anti-chromatinecomplexen in de (eenvoudig bereikbare)
epidermale basaalmembraan te bestuderen, hebben wij
huidbiopten van niet-aangedane huid van patiënten met
actieve proliferatieve lupusnefritis en van patiënten met
inactieve SLE bekeken. Deze werden vergeleken met huid-
biopten van patiënten met insuline-afhankelijke diabetes
mellitus (controlegroep zonder immuunglobulinedeposities)
en van patiënten met parapemphigus (controlegroep met
immuunglobulinedeposities in de dermale basaalmem-
braan). In Hoofdstuk III hebben wij aangetoond dat er inder-
daad histonen aanwezig waren in de epidermale basaal-
membraan van patiënten met actieve proliferatieve lupus-
nefritis, terwijl dit niet het geval was in de huidbiopten van
patiënten met inactieve SLE en diabetespatiënten, en slechts
in een klein aantal biopten van patiënten met parapemphigus.
Met monoklonale anti-nucleosoomantistoffen kleurden
alleen huidbiopten van patiënten met actieve proliferatieve
lupusnefritis aan (7%). Hieruit kan geconcludeerd worden
dat nucleosoom-gemedieerde binding aan basaalmembranen
in patiënten met lupusnefritis niet alleen in de nier maar
ook op andere plaatsen in het lichaam voorkomt, zoals in
de huid. In de volgende studie (Hoofdstuk IV) hebben wij het
effect onderzocht van twee behandelingsregimes op ver-
schillende autoantistofprofielen in plasmamonsters van
patiënten, die in de eerste Nederlandse lupusnefritisstudie
waren ingesloten. De volgende anti-chromatine-antistoffen
werden bestudeerd: anti-dsDNA-, anti-histon- en anti-nucleo-
soomautoantistoffen. Daarnaast werden anti-C1q-autoanti-
stoffen en 'mannose binding lectin' (MBL)-concentraties geana-
lyseerd. Bij start van de studie waren de meeste patiënten
positief voor anti-dsDNA-autoantistoffen (96%), anti-nucleo-
soomautoantistoffen (81%) en anti-C1q-autoantistoffen (62%),
terwijl anti-histonautoantistoffen slechts in 23% van de patiën-
ten aanwezig waren. Tijdens de behandeling met cyclofosfa-
mide en azathioprine/ methylprednisolon namen de autoanti-
stoftiters significant af. Er waren geen verschillen tussen de
twee behandelingsgroepen. De titers van anti-histonautoanti-
stoffen veranderden niet tijdens behandeling. Renale reci-
dieven werden niet voorafgegaan door een toename van auto-
antistoftiters. De anti-chromatine-autoantistoffen correleer-
den met elkaar, maar niet met anti-C1q-autoantistoffen,
hetgeen bevestigt dat deze autoantistoffen ontstaan door
verschillende autoantigeenstimulatie. Patiënten karakteris-
tieken en het beloop van de ziekte waren slechts minimaal
verschillend voor de diverse autoantistofentiteiten. MBL-
concentraties veranderden niet tijdens behandeling, pas-
send bij het feit dat MBL niet significant verbruikt wordt 
tijdens actieve ziekte. Geconcludeerd kan worden dat anti-
chromatine-autoantistoffen en anti-C1q-autoantistoffen 
in de meeste patiënten met actieve lupusnefritis werden
gevonden en dat de concentraties tijdens behandeling afnamen.
Echter, aangezien er geen verband met ziektebeloop of
renale uitkomstmaten werd gevonden, lijkt het bepalen
van de autoantistoftiters wel belangrijk voor het stellen van
de diagnose, maar niet nuttig om het effect van de behan-
deling te volgen.
Met de bevindingen van de studies uit het eerste deel van
dit proefschrift is het niet mogelijk om de exacte rol, die
nucleosomen spelen in de pathogenese van lupusnefritis,
vast te stellen. Eerdere studies van ons laboratorium onder-
strepen echter wel het belang van nucleosomen bij de
inductie van SLE en de ontwikkeling van renale en andere
ziektemanifestaties (1). Directe intrarenale perfusie van
nucleosoom/autoantistofcomplexen leidde tot een duide-
lijke binding aan de glomerulaire capillaire wand. Dit in
tegenstelling tot geïsoleerde nucleosomen, gezuiverde auto-
antistoffen zonder gebonden nucleosomaal materiaal of
nucleosomen met identieke subklasse-specifieke antistoffen.
Verwijdering van heparansulfaat met heparitinase vooraf-
gaand aan perfusie voorkwam deze GBM-binding, hetgeen
duidt op de cruciale rol van heparansulfaat als 'doelwit' in
de GBM. Deze in vivo perfusie-experimenten werden
bevestigd door i) het maskeren van heparansulfaat in de
GBM door nucleosoom/Ig-complexen in zowel muizen- als
humane lupusnefritis; ii) de depositie van histonen in de
basaalmembraan van de nier en de huid (dit proefschrift)
van patiënten met actieve lupus; iii) het voorkomen van
binding van nucleosoom/Ig-complexen in de GBM in muizen-
lupus door behandeling met 'heparansulfaat lookalikes',
zoals heparine en niet-stollingsactieve heparinoïden.
Recent werden deze bevindingen ondersteund door de
onderzoeksgroep van Dr. Rekvig. Met nauwkeurige en tijd-
rovende colocalisatie-electronmicroscopietechnieken toonde
zij aan dat in muizenlupus IgG bindt aan chromatine in de
GBM en niet aan andere kruisreactieve intrinsieke GBM-
bestanddelen, zoals laminine en alfa-actinine (2). Ook in
humane lupusnefritis toonde zij dit aan (nog niet-gepubliceerde
onderzoeksresultaten). Gegeven het feit dat nucleosomen
een belangrijke rol spelen, hoe kan het dan dat wij geen
betere correlatie vonden tussen anti-chromatine-autoanti-
stoffen en lupusnefritis? Allereerst, totnogtoe zijn alleen
nucleosomen die geïsoleerd waren uit normale cellen als
antigeen gebruikt. Het gebruik van nucleosomen afkomstig
van apoptotische cellen zou beter kunnen zijn, aangezien
die waarschijnlijk apoptose-geïnduceerde modificaties
bevatten. Ten tweede, eerdere studies die het belang van
anti-dsDNA voor exacerbaties hebben bestudeerd, hebben
aangetoond dat frequente, maandelijkse monsterafname
noodzakelijk is. Tenslotte, in lupusmuismodelstudies hebben
wij aangetoond dat het ontstaan van renale ziekte samen-
ging met lagere anti-nucleosoomautoantistofconcentraties.
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De nefritogene antistoffen verdwenen blijkbaar uit de circulatie
omdat zij in de nier werden gebonden (3). Met onze huidige
technieken en monsterafnameprotocollen lieten wij een relatie
zien tussen autoantistofprofielen en de aanwezigheid van
manifestatie van SLE in de nier. Een belangrijke rol van
deze autoantistoffen bij het optreden van renale recidieven
kon echter niet worden bevestigd. Aangezien dit de eerste
analyse is waarin deze autoantistoffen prospectief zijn
gemeten, zijn meer studies noodzakelijk.
Deel II Klinische aspecten
In de eerste landelijke lupusnefritisstudie werden patiënten
via loting ingedeeld voor een behandeling met ofwel cyclo-
fosfamide-infusen ofwel azathioprine gecombineerd met
methylprednisoloninfusen. Van de 87 ingesloten patiënten,
lootten 50 patiënten voor cyclofosfamide-infusen en 37
voor behandeling met azathioprine/methylprednisolon.
Beide groepen werd ook oraal prednison voorgeschreven. In
1995, de start van de studie, werd ingeschat dat, na een
periode van 5 jaar, 30% van de patiënten in de cyclofosfami-
de-groep een 'verdubbeling van het serumkreatinine' zou
hebben bereikt. Maximaal 50% werd acceptabel geacht voor
de azathioprinegroep. Helaas werd het berekende benodig-
de aantal van 100 patiënten niet bereikt waardoor enig ver-
lies van statistische bewijskracht optrad. In Hoofdstuk V
staan de resultaten beschreven na een mediane observatie-
periode van 5.7 jaar (interkwartiele bereik 3.9-6.6).
Opvallend was dat bij minder dan de verwachte 30% van
alle patiënten een 'verdubbeling van het serumkreatinine'
optrad. Deze verdubbeling van serumkreatinine leidde
bijna nooit tot nierinsufficiëntie. Dit kan (in ieder geval ten
dele) worden toegeschreven aan de definities die wij in de
studie hebben gebruikt: een 'verdubbeling van serumkrea-
tinine' hoefde niet permanent te zijn. De nierfunctie en pro-
teïnurie verbeterden bij de meeste patiënten doordat de
behandeling snel werd aangepast, zoals voorgeschreven
door het studieprotocol. Echter, in de azathioprinegroep
kwamen vaker therapiefalen en renale recidieven voor, het-
geen suggereert dat azathioprine/methylprednisolon min-
der goed in staat is om de ziekte te onderdrukken. In Tabel
1 is het voorkomen van renale recidieven in diverse tijdspe-
rioden weergegeven. De frequentie is genormaliseerd per
100 patiëntenjaren om een vergelijking met andere studies
mogelijk te maken (zie ook Tabel 1 van Hoofdstuk VIII). Het
beloop van laboratoriumparameters en het aantal patiën-
ten dat partiële of complete remissie bereikte, en de tijd tot
het bereiken van partiële of complete remissie, waren niet
verschillend tussen de twee behandelingsgroepen. Wat
betreft bijwerkingen: evenveel zwangerschappen traden op
in beide groepen en evenveel vrouwen ontwikkelden een
vroegtijdige menopauze. Een onverwacht groter aantal
infecties, met name herpeszostervirusinfecties werd vastge-
steld in de azathioprinegroep. Een verklaring voor het uit-
blijven van een verschil in gonadale toxiciteit kan gezocht
worden in het feit dat een sterke zwangerschapswens de
belangrijkste reden voor patiënten was om niet deel te
nemen aan de studie. Het vaker voorkomen van herpes-
zostervirusinfecties in de azathioprine/methylprednisolon-
groep zou verklaard kunnen worden door de hogere doses
corticosteroïden die aan deze groep werd voorgeschreven.
Het aantal ziekenhuisopnames voor infecties verschilde
echter niet tussen de twee behandelingsgroepen.
Geconcludeerd kan worden dat, ondanks het feit dat meer
recidieven en infecties optraden in de patiëntengroep die
behandeld werd met azathioprine/methylprednisolon, dit
regime een alternatief voor cyclofosfamide kan zijn voor
bepaalde patiënten met proliferatieve lupusnefritis.
Totnogtoe trad bij 80% van de patiënten geen 'verdubbeling
van serumkreatinine' op. En, 80% van de patiënten uit de
azathioprine/methylprednisolongroep kon het gebruik van
cyclofosfamide vermijden. Nog belangrijker is de bevinding
dat bij het laatste bezoek er geen verschil in serumkreatinine
en proteïnurie bestond. Een lange follow-upperiode is nodig
om eventuele verschillen in nierfunctie aan te tonen, met
name in die patiënten die een recidief krijgen. Patiënten die
behandeling met azathioprine/methylprednisolon overwegen,
moeten worden geïnformeerd over het verhoogde risico op
een renaal recidief, therapiefalen en infecties, en dat een
langere follow-up nodig is om definitieve conclusies over
zowel behoud van nierfunctie als van fertiliteit te kunnen
trekken. Alhoewel generieke meetinstrumenten voor het
meten van de 'kwaliteit van leven' bij patiënten met SLE
hun waarde hebben bewezen, kunnen ziekte-specifieke
vragenlijsten belangrijke aanvullende informatie opleveren.
Derhalve werd een nieuwe, SLE-specifieke vragenlijst, de
zogenaamde 'SLE Symptom Checklist' (SSC), ontwikkeld. In
Hoofdstuk VI worden de eerste analyses met de SSC en andere
'kwaliteit van leven'-instrumenten beschreven. Bij patiënten
met inactieve SLE en patiënten met actieve lupusnefritis,
behandeld met cyclofosfamide, werd aangetoond dat de
SSC een goede interne consistentie had, reproduceerbaar
was en in staat was om verschillen op te sporen. Er werden
significante correlaties gevonden tussen de SSC en de andere
'kwaliteit van leven'-instrumenten en tussen de SSC en de
patiënt-'visual analogue scale' (VAS). Daarentegen werd
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Tabel 1 Renaal recidieffrequentie, uitgedrukt als aantal
recidieven per 100 patiëntjaren, gedurende diverse tijds-
perioden in de eerste landelijke lupusnefritisstudiepopulatie.
renaal recidieffrequentie
(aantal/100 patiëntjaren)
studieperiode (jaren) n total CY AZA
ged. de eerste 2 jaar van behandeling 87 6.0 2.1 11.0
van 2 tot 5 jaar* 82 4.4 2.3 7.1
na een min. follow-upduur van 5 jaar** 61 3.4 1.4 5.5
CY: patiënten in cyclofosfamidegroep, AZA: patiënten in azathioprine/methyl-
prednisolongroep, * na 2 jaar was de behandeling in beide behandelingsgroepen
identiek (azathioprine 2 mg/kg/dag gecombineerd met prednison 10 mg/dag). Na
4 jaar werd dit regime over de periode van een jaar afgebouwd tot: azathiopri-
ne 1 mg/kg/dag en prednison 10 mg om de dag, ** na 5 jaar werden lage doses
azathioprine (1 mg/kg/dag) en prednison (10 mg om de dag) gecontinueerd tot
minimaal 7 jaar na start van de studie (of na reïnductiebehandeling voor een
renaal recidief).
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geen correlatie gevonden tussen de SSC en de ziekteacti-
viteit, gemeten met de 'SLE disease activity index' (SLEDAI),
en de artsen-VAS. Deze resultaten geven aan dat het ervaren
van symptomen van ziekte en therapie en de impact van
ziekte op het dagelijks leven, andere aspecten van SLE zijn
dan de ziekteactiviteit zoals artsen die meten. Het is daar-
om van belang, dat naast klinische en laboratoriumbevin-
dingen, specifieke aandacht wordt geschonken aan de
klachten van de patiënt. Geconcludeerd kan worden dat de
SSC gebruikt kan worden voor klinische en onderzoeks-
doeleinden. Het effect van beide behandelingsregimes op
de 'kwaliteit van leven' wordt beschreven in Hoofdstuk VII.
Tevoren hadden wij verwacht dat tijdens behandeling met
azathioprine het aantal bijwerkingen en de ervaren last van
zowel ziekte-gerelateerde als behandelingsgerelateerde bij-
werkingen minder zouden zijn dan tijdens behandeling
met cyclofosfamide. Dit bleek echter niet het geval te zijn:
er waren geen verschillen tussen de twee behandelingsvormen.
In beide groepen verbeterden de domeinen van de diverse
'kwaliteit van leven'-schalen vergelijkbaar. Ondanks behan-
deling werden na twee jaar nog altijd subnormale waarden
voor de meeste domeinen van een generiek en veelgebruikt
'kwaliteit van leven'-instrument, de MOS-SF36, gevonden.
Dit geeft aan dat het hebben van proliferatieve lupusnefritis
een grote invloed heeft op het dagelijkse leven. De ervaren
behandelingslast was groter in de cyclofosfamidegroep. De
patiënt-VAS verbeterde slechts in geringe mate, en nam niet
verder toe na het eerste jaar behandeling. Dit fenomeen van
aanpassing ('coping') wordt ook in andere patiëntengroepen
met een chronische ziekte beschreven: patiënten zijn
geneigd zich cognitief aan te passen aan de veranderingen
in de lichamelijke gezondheid. In Hoofdstuk VIII wordt een
overzicht gegeven van studies die bestudeerd hebben wat
de recidieffrequentie is in patiënten met proliferatieve
lupusnefritis, bij wie de immuunsuppressie werd verminderd
of gestaakt. Het aantal onderzoeken, waarin geprobeerd is
om alle medicatie te stoppen, is beperkt. Aangezien bij een
behoorlijk aantal patiënten een recidief optreedt, hetgeen
een grotere kans op permanent verlies van nierfunctie met zich
meebrengt, moet men voorzichtig zijn. Met het verminderen
of stoppen van de medicatie moet echter ook de positieve
invloed op bijwerkingen zoals osteoporose en afwijkende
lipiden worden meegewogen. De overweging om te proberen
de immuunsuppressiva af te bouwen, kan alleen gemaakt
worden in die patiënten die minimaal vijf jaar behandeld
zijn en die zowel klinisch als serologisch in remissie zijn.
Afbouwen moet altijd langzaam en onder strikte controle
geschieden.
De studies in dit proefschrift over de klinische aspecten van
lupusnefritis geven aan dat de zoektocht naar het optimale
behandelingsregime met betrekking tot het effect op de
nierfunctie én het verminderen van de last van ziekte en
behandeling, moet worden voortgezet. Om de meest interes-
sante vraag (Wat is de nierfunctie na een follow-upduur van 10
tot 15 jaar?) te beantwoorden is het nauwgezet volgen van
onze patiënten noodzakelijk. Naast de behandelingsregimes
zoals die voor deze studie waren gekozen, moeten ook
andere alternatieven voor langdurige cyclofosfamide-
behandeling worden bestudeerd. Korterdurende en lagere
doses cyclofosfamide (4,5) en mycofenolaatmofetil (MMF)
(6-8) worden momenteel onderzocht in klinische studies.
Vooral MMF laat veelbelovende resultaten zien wat betreft het
bereiken van remissie, niet alleen in Caucasische patiënten,
maar ook in Afro-Amerikaanse en Aziatische patiënten.
Aangezien er nog geen langetermijnstudies met MMF
bestaan, moet een langere follow-up worden afgewacht.
Nieuwere behandelingen, bijvoorbeeld anti-B-celbehande-
ling met anti-CD20, zijn bestudeerd in kleinere groepen
patiënten, met name in patiënten met cyclofosfamide-
resistente lupus. Van belang is zich te realiseren dat deze
nieuwere behandelingen erg duur zijn, terwijl dit niet het
geval is voor cyclofosfamide en azathioprine. Toekomstige studies
zouden een vergelijking moeten maken in patiëntengroepen
van verschillende etniciteit, en deze studies behoren een
voldoende statistische 'power' te hebben en een lange follow-
upduur. Om dat mogelijk te maken is (internationale)
samenwerking tussen reumatologen en nefrologen uit vele
centra een vereiste.
Bij het bestuderen van verschillende behandelingsopties
voor patiënten met lupusnefritis moeten de impact van de
ziekte en de bijwerkingen van behandeling op het dagelijks
leven worden meegewogen. In de tijd leert een patiënt om
te gaan met het feit dat hij/zij een chronische ziekte heeft
en ook de last van de ervaren klachten verandert. Noch
generieke, noch ziekte-specifieke vragenlijsten konden aan-
tonen dat behandeling met azathioprine/methylprednisolon
tot een betere 'kwaliteit van leven' leidde dan behandeling
met cyclofosfamide. In de toekomst moeten meer groepen
van patiënten met SLE worden onderzocht om de waarde
van de SSC aan te tonen.
Aangezien de afgelopen decennia de prognose van patiën-
ten met lupusnefritis verbeterd is, zou de focus op inductie-
therapie gedeeltelijk kunnen gaan verschuiven naar expli-
cietere aandacht voor onderhoudsbehandeling. Er moeten
studies worden verricht waarbij niet alleen de keuze van de
onderhoudsmedicamenten van belang is, maar waarin ook
de dosis en de duur van de onderhoudsbehandeling wordt
meegenomen. Aangezien behandeling met medicijnen bij-
werkingen met zich meebrengt, moet deze zoveel mogelijk
worden teruggebracht. Echter, het zou zo kunnen zijn dat
onderhoudsbehandeling met lage doses medicijnen tot een
betere (renale) uitkomst leidt dan het stoppen met alle
medicijnen, omdat iedere renale exacerbatie gepaard gaat
met (enig) verlies van glomeruli. Prospectieve studies zijn
nodig om de vraag te beantwoorden bij wie, wanneer en
hoe de onderhoudsbehandeling moet worden gegeven en
bij wie en wanneer de immuunsuppressieve behandeling
kan worden gestopt.
Deel III Renale histopathologie
Voorafgaand aan deelname aan de studie werd een nier-
biopt verricht bij alle patiënten. Na twee jaar behandeling
waren 39 protocollaire nierbiopten beschikbaar. Omdat in
andere ziekten is aangetoond dat de overeenstemming tus-
sen pathologen behoorlijk schommelt, en omdat de diver-
siteit aan in lupusnefritis beschreven afwijkingen groot is,
wilden wij de overeenstemming tussen Nederlandse gespe-
cialiseerde nefropathologen bestuderen. Zoals in Hoofdstuk
IX is beschreven werd een scoreformulier ontwikkeld. Vijf
nefropathologen beoordeelden en scoorden alle biopten
aan de hand van dit formulier. Een grote variatie in overeen-
stemming werd gevonden. De overeenstemming was laag
voor de WHO1995- en de ISN/RPS2003-classificatiesystemen
voor lupusnefritis. Voor de vaak gebruikte activiteits- en
chroniciteitsindex voor lupusnefritis was de overeenstem-
ming respectievelijk goed en redelijk. De afzonderlijke
parameters van deze indices echter lieten een variabele
overeenstemming zien. Dit houdt in dat de nefropathologen
een vergelijkbaar 'overall' gevoel van chroniciteit en activiteit
hadden, in plaats van dat zij alle vijf de afzonderlijke definities
hetzelfde interpreteerden. Ook werden de subklassen seg-
mentale en globale diffuse proliferatieve lupusnefritis (IV-S
en IV-G) vergeleken. Bij inclusie bestonden verschillen tussen
IV-S en IV-G wat betreft een aantal laboratoriumparameters.
Het gesuggereerde verschil in klinische uitkomst tussen
deze twee groepen werd echter niet gevonden. Integendeel,
na een mediane follow-upduur van 77 maanden bleek geen
van de patiënten die geclassificeerd waren als IV-S een ver-
dubbeling van het serumkreatinine te hebben (echter het
verschil met IV-G was statistisch niet-significant).
Geconcludeerd werd dat het indelen van lupusnefritis in
subklassen geen consequenties heeft voor de dagelijkse
praktijk (dat wil zeggen: de behandelingsopties zijn hetzelfde)
en dat histologische studies in lupusnefritis behoedzaam
moeten worden geïnterpreteerd. Om de effecten van de
twee behandelingsregimes op de histopathologische para-
meters, zoals beschreven in Hoofdstuk IX, te bestuderen,
werden de bevindingen van de biopten die afgenomen
waren bij inclusie vergeleken met de herhalingsbiopten,
afgenomen na twee jaar. In Hoofdstuk X worden deze data
gepresenteerd. De patiënten die een herhalingsbiopt onder-
gingen waren representatief voor de gehele groep. Na twee
jaar behandeling werd een afname van actieve laesies en
een toename van chronische laesies gezien. Als de twee
behandelingsgroepen met elkaar vergeleken werden, bleek
dat de toename van chronische laesies en de (samengestelde)
chroniciteitsindex significant groter was in de azathioprine-
groep dan in de cyclofosfamidegroep. Als deze data echter
vergeleken werden met gegevens uit andere studies waarin
protocollaire herhalingsbiopten werden verricht, dan was
de toename in onze twee patiëntengroepen relatief klein. Al
eerder werd door andere studiegroepen gezocht naar voor-
spellende parameters voor (renale) uitkomst en het beloop
van de ziekte. Wij bestudeerden de voorspellende waarde
van klinische, histopathologische en laboratoriumparameters,
zowel bij inclusie als na twee jaar behandeling.
Behandeling bleek de enige voorspellende factor voor het
krijgen van een renale exacerbatie te zijn, terwijl de nier-
functie, zowel bij inclusie als na twee jaar, een betere voor-
spellende parameter van serumkreatinine bij het laatste
bezoek was dan biopsieparameters. Een aantal histopatholo-
gische parameters van het eerste biopt droeg bij aan het voor-
spellen van het serumkreatinine bij het laatste bezoek. Dit
gold echter niet voor de chroniciteits- of de activiteitsindex.
Uit deze gegevens werd gededuceerd dat klinische parameters
bruikbaarder zijn voor de dagelijkse praktijk dan het ver-
richten van een herhalingsnierbiopt.
Deze hoofdstukken in het laatste deel van dit proefschrift
tonen aan dat het beoordelen van een nierbiopt van een
patiënt met lupusnefritis geen eenvoudige opgave is, en dat
het onderhevig is aan behoorlijke variatie tussen en binnen
beoordelaars. Mogelijk verbetert de overeenstemming 
tussen nefropathologen als internationale trainingen en
forums worden georganiseerd. Het splitsen van diffuse 
proliferatieve lupusnefritis in segmentaal en globaal moet
alleen voor onderzoeksdoeleinden worden gebruikt, totdat
het zijn waarde voor de klinische praktijk heeft bewezen.
Gebaseerd op onze analyses en die uit de literatuur, kan
men zich afvragen of de classificatie voor lupusnefritis zou
moeten worden vereenvoudigd. Volgens ons zou kunnen
worden volstaan met een indeling in membraneuze, mesan-
giale, proliferatieve en scleroserende lupusnefritis, zolang
ook de activiteits- en chroniciteitsindex worden gescoord.
Protocollaire herhalingsbiopten uit verschillende gerando-
miseerde studies zouden de vraag kunnen beantwoorden of
de gekozen behandelingsschema's de toename van chronische
schade kunnen voorkomen, én of deze chronische schade
tot een slechtere uiteindelijke nierfunctie leidt. De zoek-
tocht naar prognostische histopathologische parameters
moet worden voortgezet. En, nu de effectiviteit van de
behandeling op de korte termijn blijkt te zijn toegenomen,
zijn langetermijnstudies noodzakelijk. 
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Dankwoord
trefwoorden: samen, bedankt, super, AGIKO, opleiding, promotie, proefschrift, klaar
Dit proefschrift had ik nooit kunnen schrijven zonder de hulp
van velen. Allereerst dankzij alle mensen die mijn sluimerend
vuur voor onderzoek hebben aangewakkerd. Vervolgens werd
mij de mogelijkheid geboden om in de vorm van een AGIKO-
constructie in Nijmegen te komen werken. En uiteraard
waren er veel mensen betrokken bij het promotietraject zelf.
Tot slot al de mensen om mij heen die mijn leven maken tot
wat het is. Het zal niet mogelijk zijn iedereen bij naam te
noemen. Desondanks hoop ik dat ik een ieder die ik dank
verschuldigd ben, op een of andere manier duidelijk (heb)
(ge)maak(t) dat ik hem/haar zeer erkentelijk ben!
Het voortraject Allereerst ben ik alle medewerkers van de
afdeling Nucleaire Geneeskunde van het Academisch
Ziekenhuis Leiden, met name Jan-Willem Arndt, Marcel
Stokkel en Tilly Hagendoorn, dankbaar voor het bieden van
een reuzegezellig 'thuishonk'. De artsen en verpleegkundigen
van de afdeling 'Gastroenterology' uit Oxford, en mijn referent
uit Leiden, professor Lamers: bedankt voor het creëren van
allerlei mogelijkheden. De internisten van het Ziekenhuis
Leyenburg staan aan de basis van mijn carrière als arts:
bedankt voor de prettige leerperiode. De stage op de afdeling
Hematologie maakte mijn AGNIO-tijd compleet. Hans Haak,
Pièrre Wijermans, Wim Gerrits en Cecile Idink: bedankt voor de
aangename werksfeer, vooral de woensdagmiddagen en de
mogelijkheid onderzoek te doen. De periode bij Joep Lange
van het NATEC in Amsterdam heeft mij veel leerzame momen-
ten opgeleverd, vooral op statistiek en logistiek niveau.
De AGIKO-constructie Het combineren van de opleiding tot
internist met onderzoek is in Nijmegen goed georganiseerd.
Jos van der Meer, Paul Stuyt en Jacqueline de Graaf bedankt
voor het maken van alle ingewikkelde roosters en voor jullie
enthousiasme over en de aandacht voor de vorderingen van
mijn onderzoek. Ook de andere internisten en specialisten
van de subspecialismen, en de collega's internisten-in-
opleiding bedankt voor de geboden mogelijkheden en de
goede opleidingssfeer.
Het promotietraject Zonder patiënten geen promotie:
bedankt dat u al die jaren bereid bent geweest extra vragen
te beantwoorden, extra bloed af te staan en zelfs extra nier-
biopten te ondergaan om de kennis op het gebied van lupus-
nefritis te doen toenemen. 
Jo Berden, jaren geleden ondernam jij stappen om de eerste
landelijke lupusnefritisstudie werkelijkheid te laten worden.
Nu, ruim 11 jaar nadat de eerste patiënt in de studie werd
ingesloten, begint de verwachte 'spin-off' eindelijk waarheid
te worden. Bedankt voor je pro-actieve inzet, het feit dat je
altijd tijd voor me maakt en al je complimenten. Ik heb veel
van je geleerd, vooral het feit dat discussie een artikel alleen
maar beter zal maken.
Ron Derksen, jij als mede-hoofdonderzoeker hebt op enige
afstand de vorderingen van mijn artikelen gevolgd. Als een
van de eersten reageerde je altijd op mijn e-mails en je com-
mentaar en opmerkingen waren altijd opbouwend. Bedankt
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voor je bijna niet te stuiten enthousiasme!
De bekendheid van de studie zou zonder de coördinatie van Gerry
Ligtenberg niet zo groot zijn geweest. De vele inspanningen die jij
hebt geleverd zijn met recht groots te noemen. Bedankt voor alle
organisatorische en medisch inhoudelijke inzet. 
Veel dank ben ik verschuldigd aan Hans van Houwelingen.
Keer op keer ging ik naar Leiden om met je te overleggen over
de statistische aanpak. En iedere keer kwam ik vol enthousi-
asme en met nieuw opgedane kennis terug in Nijmegen. 
De artsen uit de diverse deelnemende centra wil ik bedanken
voor hun inzet en het begeleiden van de patiënten. Deze
specialisten zijn:
Academische centra
AMC, Amsterdam J.W. de Glas-Vos
VUmc, Amsterdam A.E. Voskuijl
UMCG, Groningen H. Bootsma, M. Bijl, C.G.M. Kallenberg
LUMC, Leiden C.A. Verburgh, Y.W.J. Sijpkens, T.W.J. Huizinga
AzM, Maastricht J.N.M. Barendregt, J.P. Kooman, F.M. van der Sande
UMC St Radboud, Nijmegen J.H.M. Berden, F.H.J. van den Hoogen
EMC, Rotterdam A.L. Zanen, R. Zietse
UMCU, Utrecht G. Ligtenberg, R.H.W.M. Derksen
Perifere centra:
Medisch Centrum Alkmaar, Alkmaar W. Bronsveld
Flevoziekenhuis, Almere E.P.M. van Steenberge
Meander Medisch Centrum, Amersfoort E.C. Hagen
OLVG, Amsterdam J. Silberbusch, J.O. Groeneveld
Jeroen Bosch Ziekenhuis, Den Bosch A.A.M.J. Hollander
Bronovo Ziekenhuis, Den Haag M.L. Westedt
HAGA ziekenhuis, Den Haag W. Geerlings, R.M. Valentijn
Gelderse Vallei Ziekenhuis, Ede G.W. Feith, M. den Hartog
Medisch Spectrum Twente, Enschede G.J. Haagsma, W. Koning-
Mulder, H.S. Brink
Catharina Ziekenhuis, Eindhoven P. van Paassen, P. Douwes-Draaijer
St Jansdal Ziekenhuis, Harderwijk M.J. van der Veen
Atrium Medisch Centrum, Heerlen J. Wolters
Spaarne Ziekenhuis, Heemstede K.D. van de Stadt
Medisch Centrum Leeuwarden, Leeuwarden P.M. Houtman
Medisch Centrum Rotterdam Zuid, Rotterdam A.C.M. Romme
Twee Steden Ziekenhuis, Tilburg P.F.M.J. Spooren
Diakonessen Ziekenhuis, Utrecht J.B.L. Hoekstra
Máxima Medisch Centrum, Veldhoven A.W.L. van den Wall Bake
University Hospital, Tromsø, Noorwegen J.C. Nossent
De vele medeauteurs van de diverse artikelen geven wel aan
dat veel mensen betrokken zijn geweest bij de studie. Naast
leden van de SLE-werkgroep, betrof dit ook andere onder-
zoekers. Onder andere Frank Snoek heeft veel bijgedragen
aan de artikelen over kwaliteit van leven, Elke de Jong aan
het artikel over de huidbiopten, en met Idske Hovinga Kremer
en Marije Koopmans volgt nog een publicatie. De medewer-
kers van de afdeling nierziekten van het LUMC wil ik bedan-
ken voor het bepalen van de autoantistoffen en 'mannose
binding lectin'-concentraties in onze monsters.
Bij naam wil ik nog graag noemen de pathologen die veel
werk verzet hebben: Jan Weening, Jan-Anthonie Bruijn, Karel
Assmann, Ingeborg Bajema, Sandrine Florquin, Eric
Steenbergen, Carine Peutz-Kootstra en Roel Goldschmeding,
en daarnaast ook pathologen-in-opleiding Tri Nguyen en
Joris Roelofs. Bedankt voor alle bijeenkomsten, de consen-
susmiddagen en de 'score'sessies. Dankzij jullie inzet heeft
de studie meerwaarde gekregen en hebben we een aantal
mooie artikelen kunnen schrijven. Ingeborg, bedankt voor de
brainstormmomenten/-dagen! Eric, ik zie me nog met mijn
kussentje onder mijn arm over de gang lopen om bij jou de
biopten te gaan scoren. Ook bedankt voor het maken van de
foto's voor de introductie.
De staf nierziekten van het UMC St Radboud wil ik bedanken
voor het bieden van een leerzaam & gezellig onderzoekskli-
maat. De medewerkers van het laboratorium nierziekten voor
hun gastvrijheid en geduldige uitleg. Vooral Jürgen Dieker en
Johan van der Vlag voor de goede samenwerking, en ook Mieke
van Bruggen voor al het voorwerk en Marinka Bakker voor het
maken van de foto's met behulp van de confocale microscoop.
Familie & vrienden Lieve ouders, zussen, zwagers, neefjes en
nichtje: jullie hebben mij gemaakt tot wie ik ben! En lieve
vrienden, van alle windstreken, ontmoet dichtbij huis, of
overzees, al langgeleden of pas kort, golfend of niet: jullie
geven alles extra kleur. Allemaal bedankt voor het me regel-
matig voorhouden van de spiegel en de kostbare momenten
samen! En, Tilly en Patrick, bedankt dat jullie naast vrienden
ook mijn paranimfen willen zijn.
Tot slot In de inleiding gaf ik al aan dat het onmogelijk is ieder-
een in dit dankwoord persoonlijk te bedanken. Toch realiseer ik
me terdege dat een studie en artikelen alleen tot stand kunnen
komen met hulp van velen. Iedereen die op een of andere
manier heeft bijgedragen ben ik erkentelijk. Zo ook Willem
Teunissen voor het grafisch ontwerp van dit proefschrift, mijn
zus Eleonore voor het ontwerpen van de omslag en Jos van der
Meer voor het creëren van de cartoons. Dankzij subsidies van
Zon-MW/NWO, de Nierstichting en het Reumafonds was het
mogelijk de diverse studies uit te voeren. Uiteraard bedank ik
de manuscriptcommissieleden en de leden van de promotie-
commissie voor hun beoordeling en aanwezigheid. Tot slot
dank aan alle medewerkers van de afdeling medische oncolo-
gie, waar kortgeleden mijn toekomst begonnen is!
dankwoord
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Cecile Grootscholten werd geboren op 9 november 1971 in
Monster. Na het behalen van het diploma ongedeeld VWO
met Latijn aan het Sint Janscollege in Den Haag, startte zij in
1990 met de studie Biomedische Wetenschappen aan de
Rijksuniversiteit Leiden. Na het behalen van het propedeu-
tisch examen, werd per 1991 de overstap gemaakt naar de
studie Geneeskunde aan dezelfde universiteit. In de zomer
van 1993 liep ze in het kader van een uitwisselingsprogram-
ma een klinische stage op de afdeling 'Plastische und
Wiederherstellungschirurgie' van het RWTH Klinikum in
Aachen, Duitsland. Ter afsluiting van de 1e studiefase ver-
richtte zij onderzoek van januari 1994 tot februari 1995 bij de
afdeling 'Nucleaire Geneeskunde' van het Academisch
Ziekenhuis Leiden (thans Leids Universitair Medisch Centrum)
(begeleider dr J.W. Arndt). Na het behalen van het doctoraal-
examen volgde een onderzoeksstage op de afdeling 'Gastro-
enterology' van de Radcliffe Infirmary te Oxford, Groot-
Brittannië (begeleiders dr J. Satsangi en dr D.P. Jewell), waar-
na werd gestart met de co-schappen. Het artsexamen (cum
laude) werd behaald op 18 april 1997. Van 1 mei 1997 tot 1
januari 1998 werkte Cecile als assistent-geneeskundige-niet-
in-opleiding (AGNIO) op de afdeling 'Interne Geneeskunde'
van het Ziekenhuis Leyenburg te Den Haag (opleider dr J.C.M.
van der Vijver), gevolgd door 10 maanden op de afdeling
'Hematologie' van datzelfde ziekenhuis (opleider dr H.L.
Haak). Van november 1998 tot september 1999 werkte zij als
arts-onderzoeker bij het NATEC (National AIDS Therapy
Evaluation Centre) te Amsterdam (begeleiders prof.dr J. Lange
en dr R.H. Kauffmann). Sinds september 1999 werkt zij in het
Academisch Ziekenhuis Nijmegen (thans UMC St Radboud). In
het kader van een NWO-AGIKO-constructie combineerde zij
de opleiding tot internist (opleider prof.dr J.W.M. van der
Meer) met het onderzoek beschreven in dit proefschrift. Op 15
oktober 2005 vond registratie als internist plaats, en op 1
januari 2007 is Cecile gestart met de subspecialisatie tot
medisch oncoloog (opleider prof.dr P.H.M. de Mulder).
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